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Urethral dysfunction is a common complication of many conditions including diabetes mellitus, 
spinal cord injury, vaginal childbirth, and pelvic trauma.  Stress urinary incontinence (SUI) is the 
involuntary loss of urine due to the inability of the urethral sphincter to maintain a tight seal 
during the storage phase and is a condition that physically and emotionally affects millions of 
women.  Currently treatments for SUI show limited effectiveness and/or complications.  
Regenerative medicine techniques may improve function and support of the diseased urethra.  
We hypothesized that exposure of bone marrow progenitor cells to mechanical stimuli would 
differentiate these cells to a contractile smooth muscle cell phenotype.  This hypothesis was 
tested with the use of a bioreactor to aid in the differentiation via mechanical and/or chemical 
stimulation.  In addition, an animal model of SUI was used to assess how the structural, 
functional and mechanical properties of the urethra were affected by placement of the tissue 
engineered urethral wrap (TEUW) around the native urethra. 
 Our results indicate that bioreactor culture caused an up-regulation of myosin heavy 
chain, a contractile smooth muscle cell marker, with the highest expression seen after 10 days of 
culture with transforming growth factor beta (TGF-β).  While some differentiation was observed, 
bioreactor conditions were not sufficient to create a fully functional TEUW.  Exploration of 
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 v 
stimulation regimens similar to what is seen by the urethra may cause further differentiation of 
these cells towards a smooth muscle phenotype.  No differences between in-vivo groups were 
observed in leak point pressure results, but mechanical and pharmacological assessments 
indicated that the TEUW provided support to the urethra with responses more similar to controls 
than to SUI animals.  Although ex-vivo results are promising, placement of the TEUW as a full 
wrap required separation of the urethra from the vagina, which appeared to cause remodeling and 
possibly scar formation.  This separation may have contributed to the discrepancies seen between 
our in-vivo and ex-vivo data.  Continued exploration of the benefits of the TEUW could include 
an animal model which receives the TEUW as only a partial wrap, attached to only the dorsal 
urethra, negating the need for tissue separation. 
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1.0  INTRODUCTION 
Urethral dysfunction is a common complication of diabetes mellitus, spinal cord injury, vaginal 
childbirth and pelvic trauma.  The most common urethral dysfunction is urinary incontinence, 
where there is an involuntary loss of urine.  Stress urinary incontinence (SUI) [1] is the most 
common type of urinary incontinence.  It is defined as an involuntary loss of urine due to the 
inability of the urethral sphincter to maintain a tight seal during the storage phase and is a 
condition that physically and emotionally affects 25 million American women annually [2].  This 
condition is emotionally draining and may cause social isolation. 
1.1 LOWER URINARY TRACT ANATOMY AND PHYSIOLOGY 
The lower urinary tract, consisting of the bladder and urethra (Figure 1.1), function over three 
phases: continence, transition, and urination, where the forces of continence and urination are 
believed to oppose each other [3].  The filling and emptying of the bladder is the result of 
reverse-order pressure in the bladder and urethra.  That is, the urinary (bladder) pressure is low 
and the urethral pressure is high during bladder filling, which reverses when the bladder empties 
[4].  The bladder acts as a reservoir for urine storage and as a pump for micturition.  Once the 
bladder reaches capacity, stretch receptors within the detrusor muscle are activated and initiate a 
voiding reflex.  Voiding occurs as the urethra relaxes and the detrusor muscle contracts, allowing 
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urine to flow out of the body [5].  The urethra maintains a tight seal during bladder filling and 
relaxes during micturition.  The following sections describe the anatomy and neural control of 
the bladder and urethra. 
 
 
 
 
 
 
 
Figure 1.1 The lower urinary tract anatomy.  Reproduced from Drake et al., (2005) [6]. 
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1.1.1 Urinary Bladder 
The urinary bladder is a hollow organ composed mainly of smooth muscle layers and an inner 
lining of epithelial cells.  The main function of the bladder is to store urine as it is transported 
from the kidney to the bladder by the ureters.  The maximum volume of the bladder is 700-800 
mL [7].  The bladder can be divided into 3 main portions: the urothelium, the detrusor and the 
trigone (Figure 1.1).  The urothelium (Figure 1.2) is a stratified epithelium consisting of a layer 
of umbrella cells and an underlying basal layer.  There may be several layers of transitional cells 
between the two main layers [8].  The human detrusor (Figure 1.2) is composed of three layers 
of bundles of smooth muscle organized in alternating longitudinally and circumferentially 
oriented layers and is responsible for contraction of the bladder during voiding [9].  The trigone 
is a triangular area formed by the ureters and urethra at the base of the bladder and is responsible 
for maintaining continence during filling and for opening the urethra during voiding [10]. 
The bladder is autonomically controlled by both parasympathetic and sympathetic nerves 
(see Section 1.1.3).  Parasympathetic signals travel between the bladder and the sacral portion of 
the spinal cord via the pelvic nerve.  Sympathetic signals travel between the bladder and 
thoracic-lumbar portion of the spinal cord via the hypogastric nerves [11]. 
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Figure 1.2 Movat’s pentachrome staining of a cross-section of a female, Sprague-Dawley rat bladder.  Tissue 
section courtesy of Silvia Wognum-Enders. 
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1.1.2 Urethra 
The human urethra is approximately 6 mm in diameter with a length of 4 cm in females and 20 
cm in males, with the main purpose of preventing urine leakage during bladder filling [12, 13].  
It is composed of several layers and cell types contained in a dense connective tissue (Figure 
1.3). 
 
 
 
 
 
 
Figure 1.3 Cross-section of the human urethra.  Reproduced from Brading et al., (2001) [14]. 
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The inner most layer of the urethra consists of a lumen covered with urothelial cells, which is 
continuous with the bladder urothelium and whose main function is to protect the underlying 
layers from urine.  The next layer, the lamina propria, is composed of both mucosal and 
submucosal layers.  The submucosal layer contains numerous blood vessels, longitudinally-
oriented smooth muscle cells and elastic fibers and contributes to the tight seal of the urethra 
during contraction.  The mucosal layer contains glands, whose secretions most likely contribute 
to coaptation and continence.  Surrounding the lamina propria is a layer of longitudinally-
oriented smooth muscle, whose role is unclear but whose contraction may aid in urethral 
shortening and funneling of the urethra during voiding.  Surrounding the longitudinal smooth 
muscle is a layer of circumferentially-oriented smooth muscle, which aids in the maintenance of 
urethral pressure during storage and contributes to the resting tone of the urethra.  The outermost 
layer of the urethra is composed of a layer of striated muscle cells, which is believed to be 
responsible for continuous urethral pressuring during bladder filling and increased contractions 
during increases in bladder pressure [15].  The urethra contains two sphincters - the internal 
(located at the bladder neck and composed of mostly smooth muscle) and external (located at the 
external meatus and composed of mostly striated muscle) - which are responsible for maintaining 
involuntary and voluntary urethral control, respectively [12].  The urethra also contains a large 
amount of extracellular matrix (ECM).  The main ECM component in the urethra is collagen, 
which is circumferentially-oriented and provides structural support to the tissue [16].  The 
urethra also contains some longitudinally-oriented elastin, which is generally localized around 
the muscle fibers, but whose role in the continence mechanism remains unclear [17]. 
The urethra’s ability to maintain continence is composed of several mechanisms.  One 
mechanism is the support of the surrounding structures including the pelvic floor muscles and the 
 7 
surrounding organs (the vagina in the female and the prostate in the male) during increased 
abdominal pressure by pressing the urethra closed (Figure 1.4) [15].  There is also a large degree 
of innervation by both the autonomic and somatic nervous systems which control the activity of 
the internal and external urethral sphincters [13]. 
 
 
 
 
 
 
 
Figure 1.4 Female urethral support structures.  Reproduced from DeLancey(1994) [18]. 
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The urethra is innervated by parasympathetic, sympathetic and somatic nerves (Figure 
1.5).  Sympathetic signals via the hypogastric nerve innervate the proximal urethra and bladder 
neck through α1-adrenergic and β-adrenergic receptors, respectively.  Parasympathetic signals 
via the pelvic nerve innervate the urethral smooth muscle (both circumferential and longitudinal) 
through cholinergic, peptidergic and nitrergic receptors, as well as the bladder smooth muscle via 
muscarinic receptors [19-21].  The pudendal nerve (somatic) innervates the striated muscle of the 
external urethral sphincter, providing voluntary urethral continence [22]. 
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Figure 1.5 Innervation of the bladder and urethra.  Reproduced from Wein (2007) [8] 
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1.1.3 Storage and Voiding Reflex 
Storage and micturition are dependent on both the bladder and urethra.  The storage and voiding 
reflex of the bladder (smooth muscle) and urethra (smooth and striated muscle) is under neural 
control by both the autonomic and somatic nervous systems (Figure 1.5).  Three main pathways 
control these organs.  The sacral parasympathetic pathway provides contraction of the bladder 
and relaxation of the urethra and serves as the primary activator of storage and micturition 
reflexes in the sacral spinal cord.  The thoracolumbar sympathetic and sacral somatic pathways 
provide contraction of the urethra [23].  
During storage, as urine is transported to the bladder, pressure within the bladder 
increases.  During this process continence is maintained by excitatory inputs from sacral afferent 
pathways activating the sympathetic and somatic efferent nerves to the urethra, while 
parasympathetic input to the bladder is dormant [23].  Storage is maintained by sympathetic 
inhibition of parasympathetic ganglion efferent signaling and sympathetic stimulation of β-
adrenergic receptors in the bladder (relaxation) and α-adrenergic receptors in the urethra 
(contraction).  Afferent input from the bladder signals the pudendal nerve to contract the striated 
sphincter to maintain urethral closure [24]. 
As bladder filling progresses, eventually a threshold is reached and stretch receptors 
activate voiding by sending afferent signals via the pelvic nerve to the sacral portion of the spinal 
cord [11].  During micturition, the pontine micturition center (PMC), located in the rostral 
brainstem, activates the parasympathetic excitatory input to the bladder via the pelvic nerve and 
inhibits the sympathetic and somatic signals to the urethra via the hypogastric and pudendal 
nerves, respectively [23, 24].  The PMC is responsible for bladder emptying via sustained 
contraction of the detrusor and relaxation of the striated sphincter [24].  The PMC receives input 
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from the cerebellum which synchronizes contraction of the bladder with relaxation of the striated 
sphincter [24].  First, bladder contraction is activated by parasympathetic activation of 
cholinergic receptors in the detrusor.  Simultaneously, the sympathetic and somatic innervation 
of the urethra is inhibited creating an open conduit to the outside of the body [24]. 
1.2 STRESS URINARY INCONTINENCE 
Continence is maintained by a coordinated response between the bladder, urethra, pelvic muscles 
and connective tissues.  Urinary incontinence is the result of a disturbance in the storage and or 
micturition functions of the lower urinary tract [25].  Stress urinary incontinence [1] is the 
involuntary leakage of urine with increases in abdominal pressure caused from laughing, 
sneezing, and coughing but in the absence of a bladder contraction.  Although SUI affects both 
men and women, it is more common in the female population.  SUI is the most common type of 
urinary incontinence [26] costing the US more than $26 billion annually [27].  It affects women 
not only physically, but psychologically as well.  Due to the embarrassing nature of SUI (causing 
odor, wetness, and discomfort), many sufferers experience decreased self-esteem, and avoid 
social settings and discussing the problem with their physician [28]. 
1.2.1 Pathophysiology of SUI and Diagnosis 
SUI occurs when abdominal pressures exceed the urethral closure pressure, resulting in urine 
leakage [29].  Urethral pressure is influenced by many things including the surrounding 
structures such as the vagina and the pelvic floor, the urethral smooth and striated muscle, and 
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neural and vascular innervation of the urethra [29].  The main factors contributing to SUI are 
thought to be urethral hypermobility, where the urethra is lacking support from its surrounding 
structures and unable to withstand high intravescicle pressures [30], and intrinsic sphincter 
deficiency (ISD), where a weak urethral sphincter is incapable of preventing urine flow with 
increased abdominal pressures [31].  Stress incontinence can be classified as one of three types: 
1.) urethral hypermobility; 2.) intermediate; 3.) ISD, with severity increasing from type 1-3.  
Major causes of SUI include pelvic nerve damage, muscle weakness or damage, or damage to 
the supporting structures of the bladder and urethra, which can be a result of natural childbirth, 
hormonal deficiency, increased age and obesity [32, 33]. 
Vaginal delivery is the most common risk factor of SUI.  Anatomically, the female 
urethra lies directly on top of the vagina, making it susceptible to injury during vaginal delivery.  
It is believed that during this process, neural, muscular and connective tissue injury occurs.  It 
has previously been shown that urethral closure pressure decreases as an effect of damage to the 
pelvic and/or pudendal nerves during vaginal delivery [34].  Since it is common for SUI to 
develop later in life following vaginal delivery, it is thought to be related to ischemia and 
decreased blood flow, which has been confirmed in an animal model [35].  It has also been 
shown that changes in hormone levels, following menopause can lead to an increased risk of SUI 
[36].  Estrogen has been shown to maintain neuronal stability.  As estrogen levels decrease 
following menopause, nerves that were damaged by vaginal distension may no longer be able to 
remain stable and could therefore contribute to the late onset of SUI [37]. 
Urethral hypermobility is due to a decreased support of the proximal portion of the 
urethra.  This lack of support alters the transmission of pressure to the urethra and results in 
incontinence.  These alterations in pressure transmission are thought to be due to a change in the 
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anatomical position of the urethra and/or a loss of integrity of the pubourethral ligament and 
endopelvic fascia, which compose the connective tissue support of the urethra [38].  
Hypermobility is detected by a Q-tip test in which a cotton swab is inserted into the urethra and 
the patient is asked to strain.  The angular change in the Q-tip between rest and strain is used to 
determine the degree of hypermobility of the urethra [39].  If it is determined that hypermobility 
is present, a support device may be implanted to provide structural support to aid the urethra in 
maintaining continence [40]. 
ISD is the most severe form of incontinence, where the urethra is unable to maintain its 
seal and leakage occurs.  ISD can accompany urethral hypermobility, but can be present without 
it [38].  The simplest test for ISD is that for Valsalva leak point pressure.  This test is performed 
with the patient in the vertical position by first inserting a 10-Fr microtip pressure transducer 
catheter to measure bladder pressure and an anal probe to measure abdominal pressure.  The 
bladder is then filled to half of capacity (~200 mL) with saline or a contrast agent, and the patient 
is then asked to make an expulsive effort against a closed glottis until leakage is observed.  This 
is repeated several times and the lowest pressure is taken as the Valsalva leak point pressure.  
Values of 60 cmH2O or less indicate ISD, while values near 90 cmH2O are associated with 
urethral hypermobility [41]. 
 In addition to the above mentioned detection methods for hypermobility and ISD, SUI 
can be diagnosed in several other ways.  Some physicians rely solely on a questionnaire or diary 
and a cough stress test in the office.  This requires the patient to keep detailed records of such 
things as liquid consumption, voiding volumes and number of accidents.  Further evaluation can 
include urodynamics, which allows measurement of urethra and bladder physiologic functions 
simultaneously during filling and emptying [29].  Numerous studies have been performed on the 
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validity and reproducibility of the different ways to diagnose SUI, but there is no gold standard 
at this time. 
1.2.2 Current Treatments for SUI 
Currently there are several options for the treatment of SUI.  These options include non-invasive, 
surgical or pharmacological treatments.  Although there is no preferred treatment of SUI, each 
available treatment has both benefits and limitations. 
Non-invasive treatments rely heavily on patient compliance.  Such treatments include 
keeping a diary of fluid intake and voiding, behavioral changes such as weight loss, monitoring 
fluid intake and developing a regular voiding schedule.  Other non-invasive treatments include 
strengthening of the pelvic floor muscles with Kegel exercises.  Pelvic floor training can increase 
the likeliness of being cured of SUI by a factor of seven.  Many women, however, either do not 
perform the exercises correctly or do not adhere to the strict regimen required to see results [25].  
These non-invasive treatments are generally used as a first measure of treatment, but due to 
patient non-compliance, additional treatment is generally required [25, 29, 42]. 
There are over 160,000 surgical treatments for SUI performed in the United States [43].  
The most common surgical treatments for SUI include the injection of a bulking agent, 
colposuspension or sling placement. Injection of a bulking agent into the urethra is the least 
invasive of the surgical treatments available.  An agent such as collagen, fat or silicone is 
injected into the periurethral tissue at the proximal urethra to provide support to the urethra and 
aid in maintenance of closure. Success rates for bulking agents are 75% with a cure rate of 50%.  
These agents, however, tend to dissipate over time requiring additional procedures [25, 38, 42]. 
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Retropubic urethropexy (colposuspension) is thought of as the optimal surgical treatment 
for SUI with the most long-term results [25].  The colposuspension lifts the bladder neck by 
suturing it either to the Cooper’s ligament or the peristeum of the pubic symphysis via a 
suprapubic incision.  These procedures have a reputable cure rate up to 8 years (90%), but this 
decreases to 55-69% by 10 years [25].  There is also a relatively high (~25%) rate of 
complication with this procedure. Pubovaginal sling procedures require placement of a strip of 
polymer or tissue under the urethra to hold it up.  The ends of the strip are then anchored in the 
body, generally to the pubic symphysis.  Slings have similar success and complication rates to 
the colposuspension with less long-term data [25].  Although a range of materials have been used 
for the slings, naturally occurring materials have a greater success rate.  Synthetic materials tend 
to have an increased rate of complications, such as erosion of the urethra and/or vagina [25].  It is 
thought that complication rates are high due to overtightening of the sling or overlifting of the 
bladder neck in these procedures causing retention and other complications.  Although these 
surgical treatments have decent success rates, they are limited in that they only focus on treating 
urethral hypermobility. 
There are several pharmacological treatments prescribed for SUI.  Alpha-adrenergic 
agonists, such as ephedrine and midodrine, can act on α-adrenergic receptors at the bladder neck 
and proximal urethra to increase smooth muscle contraction.  Tricyclic antidepressants, such as 
doxepin and imipramine hydrochloride, have been shown to increase urethral resistance and 
decrease bladder contractility, although the exact mechanism is unknown.  Beta-adrenergic 
antagonists, such as propranolol, amplify an α-adrenergic response.  Serotonin and 
norepinephrine reuptake inhibitors, such as duloxetine hydrochloride, subdue parasympathetic 
activity and enhance both sympathetic and somatic activity increasing bladder relaxation and 
 16 
urethral resistance [44, 45].  Although early studies indicate that such drugs would be beneficial 
to those with SUI, systemic effects and lack of long-term data have prevented any drug from 
receiving FDA approval for SUI. 
1.2.3 Animal Models of SUI 
SUI can develop as a result of various bodily changes or traumas including obesity, nerve 
damage, vaginal child birth and age.  In order to identify the mechanism of how each factor 
contributes to SUI and assess possible treatments for it, a reproducible animal model is 
necessary.  As there are many factors that can lead to SUI, independently or collaboratively with 
others, various models of SUI are needed.  There are several SUI models regularly used to assess 
how specific factors contribute to the onset of SUI, each with its own limitations.  The most 
common models include vaginal distension, hormone deficiency and neurogenic models. 
1.2.3.1 Vaginal distension 
Vaginal delivery is one of the most common risk factors for SUI.  As a baby is delivered through 
the vaginal canal, the surrounding organs, structures and nerves are distorted and serious trauma 
occurs [35, 46].  As the urethra lies on top of the vagina and is connected to it via connective 
tissue, nerves and blood vessels, it could be at risk for hypoxia and loss of innervation during the 
trauma of child birth.  This trauma contributes to both an acute and delayed onset of SUI in a rat 
model, with the risk of SUI increasing with increased vaginal deliveries [36].  Therefore, a model 
of vaginal distension (VD) has been implemented for animal studies to determine the mechanism 
of the development of SUI [47-49].  Models that simulate the mechanical trauma of childbirth 
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include intravaginal balloon inflation with [49, 50] and without [32, 35, 46, 51] ovariectomy to 
address how hormonal changes affect damage caused by VD (see Section 1.2.3.3). 
VD is performed on anesthetized animals by first inserting a balloon catheter into the 
vagina of the animal.  The balloon is then inflated to a volume representative of the size of a pup 
from the desired model.  The catheter is generally left in place for at least 4 hours [35, 46].  
Models including ovariectomy with VD better simulate what happens in humans.  In this 
procedure, anesthetized animals are subjected to ligation of the fallopian tubes and the ovarian 
branch of the uterine artery, followed by removal of the ovaries (see Section 1.2.3.3).  Three 
days post ovariectomy, animals are subjected to vaginal distension [50].  Animals have been 
assessed at various time points, from hours to days to weeks, following VD.  From these studies, 
it has been established that VD in a rat model causes an acute decrease in urethral resistance [32, 
46, 48, 49, 51], which tends to return to normal over time [47], decreased mid-urethral 
innervation [46, 52] and bloodflow [35], and increased smooth muscle hypoxia [35] and urethral 
compliance [53, 54]. 
VD studies have shown that the severity of SUI is dependent on both the duration and 
degree of distension.  Numerous studies have shown that VD decreases leak point pressure in a 
rat model [48, 51].  It has also been shown that VD has a large effect on the striated sphincter, 
decreasing urethral response to sneeze [48] and causing hypoxia of the urethral cells [35].  
Longer durations of VD in a rat model caused a lower leak point pressure and more muscular 
damage than shorter durations [51].  It has also been demonstrated that VD causes striated 
sphincter necrosis as well as decreased ganglion and nitric oxide synthase in the vaginal neural 
plexus [32].  Although these models can produce SUI by vaginal birth simulation, they are only 
accurate for acute studies due to the rapid healing of this model [55]. 
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1.2.3.2 Neurogenic models 
The urethra is a highly innervated structure (see Sections 1.1.2 and 1.1.3) and the maintenance of 
continence is a controlled by complex circuitry allowing communication between the bladder, 
urethra and spinal cord.  Thus, damage to any of these nerves could lead to incontinence.  It is 
known that the pudendal nerve, innervating the striated sphincter of the urethra, is damaged 
during childbirth and that this nerve trauma can lead to SUI [56].  It has been reported that 
women with SUI tend to have some degree of denervation of the pelvic floor muscles as well as 
pudendal nerve neuropathy [57].  Thus, neurogenic models of SUI are important to assess to 
determine how denervation of various nerves contributes to SUI.  There are several neurogenic 
models including pelvic nerve transection and pudendal nerve crush [46, 47, 56] or transection 
[43, 47, 58]. 
Transection of the pelvic nerves, which innervate the bladder and proximal urethra, 
creates an SUI model by abolishing tonic urethral continence mechanisms activated in the 
afferent pathways of the pelvic nerve [59].  However, micturition signals are also mediated by 
the efferent pathways of the hypogastric and pudendal nerves [60].  Hence this is a somewhat 
incomplete model of SUI. 
Pudendal nerve crush or transection (the chosen model for this work) [46, 47, 56] was 
developed as a model of SUI based on a report that women with SUI may also have pudendal 
nerve damage possibly caused by vaginal distension during childbirth [46].  Direct damage to the 
pudendal nerve has been shown to significantly decrease leak point pressure [56, 61] with 
decreased amplitude of urethral contraction, voided volume and atrophy of the striated muscle 
[61].  Models in which the external urethral sphincter is denervated in order to create an SUI 
model have been used to test slings [62, 63] and stem cell injections [64, 65], which were placed 
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proximal to the denervated portion of the urethra.  It has also been shown that transection of the 
sciatic nerve proximal to its branching into the pudendal nerve causes proximal urethral atrophy 
with decreased smooth muscle cell (SMC) contractility and abolished striated muscle 
contractility [64].  The pudendal nerve transection model results in a weakened proximal urethra 
while simulating the nerve injury that may occur with childbirth (one of the primary contributors 
to SUI).  Neurogenic models are able to supply a more chronic model of SUI, but do not portray 
any of the pathophysiology that accompanies most cases of SUI. 
1.2.3.3 Ovariectomy model 
Although the trauma of vaginal delivery significantly contributes to the development of 
SUI, it is generally not evident until many years later.  In fact, symptoms of SUI do not appear 
until years later, generally following menopause [36].  It has been reported that over 50% of 
women over the age of 60 are afflicted with urinary incontinence [66], with SUI being the 
second leading cause of bladder overactivity in causes of urinary leakage in elderly females [36].  
During menopause there is a permanent loss of ovarian follicular activity [67].  This means that a 
woman’s menstrual cycle ceases and there is a decrease in levels of estrogen and progesterone 
[67].  There is a strong belief that this hormone deficiency contributes to the severity and 
emergence of SUI. An ovariectomy (Ov) animal model was developed to simulate menopause. 
In this model, animals are subjected to bilateral removal of the ovaries and are studied at various 
time points following the procedure [36].  It is common to assess this model in the presence of 
other procedures such as VD or pudendal nerve crush to better simulate the conditions of the 
population most affected by SUI [47].  Although previous studies have not shown a strong effect 
of Ov on continence rates, it has increased incontinence when used in conjunction with VD [47]. 
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1.2.4 ECM Changes in SUI 
The urethral ECM is composed of collagen (types I and III) and elastin [68].  The ECM provides 
resistance to increased tension and structural recovery from the tension.  Collagen, which 
provides structural resistance to the tissue, comprises ~30% of the urethral ECM and is produced 
mainly by fibroblasts [52].  Globally, the collagen fibers are circumferentially oriented.  Elastin 
allows the urethra to undergo elastic deformation and helps it to retain its shape during 
micturition [68], but is present in smaller quantities than collagen [17].  Elastin is oriented 
longitudinally in the urethra and is localized to muscle fibers [17, 69].  There have been 
contradicting reports on how SUI affects the ECM content of the urethra and periurethral tissues.  
One study reports that nulliparous, incontinent females had significantly less collagen in 
periurethral tissue [70], while another reports that incontinent women at reproductive age had 
~30% more collagen in periurethral tissues [71].  A study in rats showed that following natural 
childbirth and/or simulated childbirth, there was an immediate, significant increase in collagen 
compared to controls [68].  These studies did not assess the degree of incontinence in these 
animals.  Another study showed that VD caused a decrease in collagen content of the middle 
urethra and increase in whole-urethra elastin content in a rat model of SUI [53].  Although the 
results of these studies are inconsistent, it is clear that there is an alteration in the remodeling of 
the urethra and its surrounding structures during SUI.  These alterations in the structural proteins 
of the urethra may be one of the main contributors to the inability of the urethra to maintain a 
tight seal.  Therefore, a urethral treatment which provides both structural support and a 
foundation for cell growth and ECM production, such as the TEUW, may provide more directed 
remodeling, and a more effective treatment. 
 21 
1.3 TISSUE ENGINEERING FOR THE URETHRA 
Although the exact definition of tissue engineering may have changed over the years, it is 
basically the application of both engineering and life science principles to the development of 
biologically-based replacements for the repair, maintenance or enhancement of normal tissue or 
organ function [72].  Tissue engineering includes the use of cells and/or scaffolds [73]. 
The cells used in tissue engineering can be divided into two main types: adult or 
terminally differentiated cells and stem or progenitor cells [73].  Adult cells are generally 
isolated from a small tissue biopsy and grown in culture.  However, adults cells tend to grow 
slowly and if they are isolated from the area needing repair, could yield only diseased cells [74].  
Stem cells can be isolated from various areas (bone marrow, blood, the embryo), grow quickly 
and have the ability to differentiate into various cell types [72, 75].  Both types of cells can come 
from various sources such as: from the person they are to be used on (autologous), from a donor 
of the same species (allogenic), from a genetically identical donor (syngeneic) or from a different 
species (xenogenic) [72]. 
The scaffold is used to serve as an artificial ECM, providing a 3-D environment for the 
cells to adhere, grow and organize a new tissue [74].  Just as there are numerous types and 
sources of cells, the same applies for scaffolds.  Scaffolds are generally divided into those that 
are biologically or synthetically derived [74].  Biological scaffolds, such as collagen, fibrin and 
ECM, provide natural, inherently friendly environments for the cells and degrade into natural bi-
products that can easily be processed in the body [72, 74, 76].  Synthetic scaffolds for tissue 
engineering can be developed from a variety of polymers and are generally divided into 
degradable, degrade into naturally occuring monomers, which can be processed by the body, or 
non-degradable.  The choice of a degradable or non-degradable polymer with or without cells, 
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generally depends on the body area of interest and its naturally occurring mechanical and 
functional properties [72]. 
1.3.1 Progenitor Cells in Urethral Tissue Engineering 
Although several reviews of urologic tissue engineering give an overview of the potentials of 
stem cell usage [77-79] there have been no reports, to our knowledge, of constructs seeded with 
them for urethral augmentation.  A small number of previous studies have been performed on the 
use of progenitor cells for treatment of urethral dysfunction [80, 81]. 
Several groups have performed studies to investigate the abilities of stem cell injections 
to augment the in-vivo function of the lower urinary tract [64, 65, 81-85].  In one series of 
studies, muscle derived stem cells (MDSCs) were injected into the lateral walls of the mid-
urethra in ISD [81] and SUI [65] Sprague-Dawley rat models.  In the ISD study [81], rats were 
divided into three groups: those undergoing urethral cauterization and injection of MDSCs a 
week later, those undergoing cauterization and injection of saline a week later, and a sham group 
where the urethra was exposed but not cauterized.  Cystometry, leak point pressure (LPP), H&E, 
fast myosin heavy chain, anti-protein gene product (PGP), and LacZ were assessed at 2, 4, and 6 
weeks post-injection. Cystometry showed that cauterization did not damage bladder function.  
LPP results revealed an improved urethral closure function for the MDSC-injected group when 
compared to the saline-injected controls, returning to a baseline by 6 weeks.  Histology showed 
that the saline-injected urethra had disruptions in the striated muscle layer, while those receiving 
MDSCs did not.  β-galactodidase was expressed within the wall of the MDSC-injected urethras, 
suggesting the injected cells remained at the site of injury.  PGP staining revealed more nerves in 
this group than the saline-injected urethras, suggesting increased innervation to the tissue. 
 23 
In the SUI study [65], three experimental groups were again utilized: a sham, an SUI (via 
urethral sciatic nerve transaction) group with saline injection, and an SUI group with MDSC 
injection.  LPP measurements and H&E were performed at 1 and 4 weeks post-injection.  At 4 
weeks, MDSC-injected cells demonstrated increased dorsolateral skeletal muscle masses with 
variable orientation at the injection site, while the saline-injected group became atrophic.  LPP 
measurements showed improved urethral closing function in the MDSC-injected urethras 
compared to the saline-injected and even the sham controls at both time points.  A short term 
study was also performed in which the time points were 14 days, and these results match those of 
the long term study [64]. 
While intriguing, this method of urethral augmentation is still under development and is 
unproven.  For example, cell fate following injection, in terms of remaining localized to the point 
of injection and their terminal differentiation status, remains unclear. 
1.3.2 Previous Approaches in Urethral Tissue Engineering 
The concept of a tissue engineered urethra (TEU) is one that has gained recent interest.  
Unfortunately, several common limitations have persisted that have hampered progress of this 
technology.  The earliest forms of tissue engineering applications for the urethra were based on 
the use of native tissues, including genital and extragenital skin flaps, mucosal grafts generated 
from both bladder and buccal sub-mucosa, tunica vaginalis, and peritoneal grafts [86].  Due to 
the high rate of complications resulting from the use of these native tissue materials such as hair 
growth, graft shrinkage, stricture and stone formation in addition to donor site morbidity, pain, 
immobilization of the lower abdominal incision, bladder spasm, hematuria, and post-operative 
voiding frequency [86-88], the focus was turned toward the use of synthetic materials.  Silicone 
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grafts were the most common early synthetic prosthesis for urethral use [78], followed soon after 
by Teflon and Dacron [86].  These early synthetic materials were generally accompanied by 
erosion, dislodgement, fistula, stenosis, extravasation, and calcification [86]. 
Collagen has served as a scaffold for urethral reconstruction quite successfully in animal 
models over the years [89-92].  It has excellent biocompatibility and is amenable to cellular 
remodeling.  Collagen is however, limited by its mechanical strength [78].  Non-seeded materials 
may be adequate for repair of small areas.  However, if total urethral replacement is required, 
seeding the material with urothelial and SMCs may be necessary to prevent graft contraction and 
shrinkage [87, 93].  In one study, acellular collagen was isolated from donor porcine bladder to 
be used in an onlay fashion as a urethral replacement in a hypospadias model.  The study 
revealed that cell infiltration and angiogenesis was present within two weeks of the onlay 
placement.  Within two months of the onlay, muscle fibers were present in the construct and 
there were no incidences of scarring, stricture or shrinkage out to six months.  It was observed, 
however, that an unseeded construct was only beneficial in an onlay fashion over a small area 
and that a larger replacement, such as a tubular segment of the urethra, requires seeding of the 
construct to initiate infiltration of native urethral cells and to prevent contracture of the construct 
[86, 90, 92]. 
In addition to naturally occurring biomaterials, several biocompatible polymers have 
been developed for urologic applications [74].  For example, a polyglycolic acid polymer 
scaffold coated with poly-L-lactic acid and seeded with chondrocytes has been shown to be 
elastic and capable of withstanding high pressures [77].  Additionally, a non-woven mesh of 
polyglycolic acid demonstrated re-epithelialization of the implantation site and degradation of 
the polymer after 14 days with no complications to voiding or structure [92].  Furthermore, the 
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development of a polyglactin-fiber mesh tubes coated with polyhydroxybutyric acid and 
hyaluronan benzyl ester have shown complete regeneration of the urethral epithelium and of the 
adjacent connective tissue [86]. 
While promising, all of these studies have been tested in a male animal model.  The male 
urethra is divided into three portions: (1) the prostatic urethra, which begins at the urinary 
bladder and is the continence maintaining portion of the male urethra, (2) the membranous 
urethra, which passes through the pelvic floor muscles, and (3) the spongy urethra, which passes 
through the penis to the urethral orifice [7].  The above approaches have focused on regeneration 
of the conduit and non-functional (membranous and spongy) portions of the male urethra, 
providing no evidence that they are capable of contributing to continence. 
1.4 FIBRIN AS A SCAFFOLD MATERIAL 
Fibrin is a natural biomaterial that is a main component of blood clots and aids in the regulation 
of wound healing.  Fibrin forms as part of the coagulation cascade when fibrinogen comes into 
contact with thrombin [76].  Fibrin naturally contains binding sites for both smooth muscle and 
endothelial cells [94] as well as several important growth factors (e.g., FGF-2 and VEGF) 
allowing cells to maintain cell function and contribute to tissue remodeling [76] and myogenesis 
[95].  Fibrin also supports cell migration, proliferation and extracellular matrix (ECM) 
production [95].  Since fibrin is naturally formed within the body, it can be formed from 
autologous fibrinogen, which can be isolated from the blood and therefore avoid a potential 
allergic reaction from animal sources like collagen [96]. 
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In tissue engineering, fibrin is generally utilized in a cell entrapment technique in which 
constructs are created by suspending cells within a fibrinogen solution, adding thrombin and 
gelling the mixture within a mold [94].  This produces a highly efficient seeding density and 
homogeneous cell distribution [94].  Concentrations of fibrinogen, thrombin, calcium and 
clotting time all contribute to the structure of fibrin and its mechanical properties [76].  For 
example, Rowe, et al., reported that fibrin fiber diameter, construct compaction, material 
modulus and tensile strength all increased with decreasing thrombin concentration [76].  Its 
degradation and hence remodeling can be controlled by aprotinin or aminohexanoic acid, which 
are fibrinolytic inhibitors [94].  However, they have been reported to alter mechanical strength 
and vascular reactivity [96]. 
Fibrin has been used in numerous tissue engineering applications, specifically for 
vascular applications [94, 97-100].  Ross et al., performed studies in which smooth muscle cells 
were seeded into fibrin constructs and cultured.  They found that as the fibrin was degraded, 
collagen and elastin fibers replaced it.  They also showed increased mechanical properties with 
increased culture duration as collagen and elastin were replacing the fibrin [100].  Yao et al., 
performed studies in which they implanted fibrin constructs into the jugular vein of lambs with 
patency up to 15 weeks.  These constructs were highly remodeled and had adequate mechanical 
strength due to the presence of large amounts of collagen and elastin [94]. 
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1.5  GUIDED DIFFERENTIATION OF PROGENITOR CELLS TO SMOOTH 
MUSCLE CELLS 
As described in Section 1.2, there is damage to both the muscular and ECM components of the 
urethra in urethral dysfunctions such as SUI.  Due to the alterations seen in the urethral tone and 
compliance of the proximal urethra in SUI [53, 54, 101], a therapy which targets the contractile 
deficiency of the smooth muscle in that portion may increase urethral resistance and eliminate 
incontinence.  A cell-based therapy is therefore a logical treatment for SUI.  Since cells are a 
product of their environmental cues [102], smooth muscle cells for urethral therapy should be 
isolated from the lower urinary tract.  However, utilizing a biopsy from an already damaged area 
may not produce the most effective treatment [74].  Therefore, the use of stem cells is an 
attractive option.  Stem cells allow for an autologous therapy, while providing a cell type that is 
capable of differentiating into a variety of other cell types [72, 75] with mechanical and/or 
chemical cues similar to the environment in which they will be placed. 
1.5.1 Mechanical Stimulation 
The role of biomechanical forces in progenitor cell differentiation has been largely ignored.  
Therefore, the powerful potential of this stimulus may have gone underutilized in the field of 
urologic tissue engineering.  There are several reports evaluating the effect of biomechanical 
forces on progenitor cell differentiation to smooth muscle cells in-vitro [103-105].   
Our laboratory previously reported that rat BMPCs in monolayer were responsive to 
cyclic uniaxial strain, suggesting that cyclic uniaxial strain guides BMPC differentiation to a 
SMC lineage [103].  Decreased proliferation, increased alignment perpendicular to the direction 
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of strain and expression of both α-SMA and h1-calponin resulted from exposure to 10% strain at 
1 Hz for 7 days [103].  Other studies published at approximately the same times, showed similar 
results [104, 105]. 
Park et al. exposed mesenchymal stem cells (MSCs) to both uniaxial and equiaxial strain.  
They reported increased α-SMA and collagen production and cell alignment perpendicular to the 
direction of strain when exposed to uniaxial strain (10%, 1Hz), and decreased α-SMA when 
exposed to equiaxial strain (10%, 1Hz) [104].  Kobayashi et al. exposed BMPCs to cyclic shear 
stress (0.6/1.2 L/min at a pressure of 10mmHg), cyclic hydrostatic pressure (120/60mmHg, at a 
flow of 0.1L/min), and the combination of both shear and pressure stimulation.  They reported 
that pressure or combined stimulation upregulated smooth muscle α-actin and smooth muscle 
myosin heavy chain [105]. 
Additional reports include a study by Huang et al., which found that seeding of 
embryonic stem cells onto a segmented polyurethane matrix and culturing them in a perfusion 
system under pulsatile conditions produced differentiation of the cells lining the lumen to 
endothelial cells with those deeper in the matrix to cells expressing smooth muscle actin [106].  
Also, a study on mouse embryonic fibroblasts by Kim-Kaneyama et al., found that uni-axial 
stretch causes Hic-5 to relocalize to stress fibers, regulating the contractile ability of cells within 
the stress fibers [107]. 
Additional studies by our laboratory show that rat BMPCs, obtained from the Tulane 
Center for Genetics (utilized in the work described in Chapters 2.0  - 7.0 ), stimulated in 
monolayer with cyclic uniaxial stretch (10%, 1Hz) for 5 days express  smooth muscle alpha 
actin, calponin, and myosin heavy chain (MHC) while unstrained control cells remained negative 
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for these markers.  Our laboratory also noted that these cells are positive for Flk-1, a homologue 
of vascular endothelial growth factor receptor 2 (VEGFR2) [108-111]. 
Three-dimensional studies, utilizing a FlexcellTM Tissue-TrainTM and the same Tulane 
BMPCs, showed that exposure to 10% longitudinal cyclic stretch at 1Hz for 6 days increased 
stress filament area per cell and caused alignment of cells parallel to the direction of the 
stress/strain over static and constrained (but not cyclically stretched) controls [102].  An 
increased expression of SMA and calponin was seen in both the constrained and cyclically 
stretched samples [102].  These studies clearly highlight the important potential of mechanical 
stimulation in guiding progenitor cell differentiation to SMCs. 
1.5.2 Chemical Stimulation 
As our knowledge of growth factors, cytokines and other bioactive molecules that mediate cell 
phenotype in-vivo has increased, conditions have been identified that can be utilized to guide the 
in-vitro differentiation of progenitor cells to various cell types [112-117].  It has been shown that 
BMPCs can differentiate into SMC using biochemical stimulation. Arakawa et al., [117] 
observed that a clonal cell line isolated from bone marrow could differentiate into smooth muscle 
when grown in the presence of 2-mercaptoethanol and ascorbic acid.  The cells were positive for 
SMC-specific genes, including h1-calponin, h-caldesmon and myosin heavy chain.  They further 
observed that ascorbic acid was a potent factor inducing the expression of h1-calponin, a marker 
for contractile SMC phenotype.  Another study has shown the ability of embryonic derived stem 
cells to differentiate into smooth muscle when cultured in high concentrations of retinoic acid 
and dibutyryl cAMP [118].  These embryonic cells were positive for myosin heavy chain, 
contained typical ion channels (Ca2+-activated maxi K+, delayed-rectifier K+, and 
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dihydropuridine-sensitive (L-type) Ca2+ channels) and responded to specific agonists with an 
increased Ca2+ influx.  Furthermore, the growth factors PDGF [119-122], TGF-β [122-126], and 
VEGF [127, 128] are known to play pivotal roles in smooth muscle differentiation and 
migration.  In particular, VEGF is an important molecule during development of the vascular 
system, and it is also known that bone marrow derived progenitor cells express the functional 
VEGF receptor, VEGFR1 (FLK-1/KDR) [129, 130], possibly suggesting that they, too, can 
respond to VEGF stimulation. 
TGF-β is a cytokine thought to play a vital role in vascular development and SMC 
differentiation [123].  The role of TGF-β in differentiation of various cell types to contractile 
smooth muscle cells has been studied.  It has been reported that neural crest cells cultured in 
TGF-β show expression of both α-SMA and calponin [124, 131], but no functional studies were 
performed.  Another study showed that adipose derived stem cells significantly up-regulated 
expression of both α-SMA and h1-calponin when cultured in media supplemented with TGF-β.  
It has previously been shown that culture of human mesenchymal stem cells in the presence of 
TGF-β causes in an up-regulation of α-SMA and calponin after 14 days in culture and decreased 
proliferation [132].  The regulatory roles that TGF-β plays in cell proliferation, differentiation, 
migration and production of ECM [133], make it an exceptional candidate for use in the 
differentiation of BMPCs to SMCs. 
Utilization of a bioreactor system which exposes constructs containing cells to 
mechanical and/or chemical stimuli can enhance the differentiation of stem cells to various 
phenotypes, including that of a contractile smooth muscle cell.  Due to the decrease in urethral 
resistance that accompanies SUI (see Section 1.2), a cell-based therapy which took advantage of 
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differentiation capabilities of a bioreactor could provide a functional therapy capable of 
providing immediate relief from SUI. 
1.6 BIOMECHANICS OF THE URETHRA 
The urethra is a complex structure composed of various cell types as well as extracellular matrix, 
and both neuronal and vascular innervation (see Section 1.1.2).  To better understand the 
pathological progression of urethral dysfunctions, such as SUI, it is important to understand how 
each of these components contributes to healthy urethral function and how they are altered in the 
diseased state.  Understanding the mechanical contribution of each of these components will aid 
in the development of new treatment methods, which can better target the damaged component. 
The urethra is a soft tissue composed of both active (contractile muscle) and passive 
(ECM, urothelium, etc.) components.  These components are mainly circumferentially-oriented 
to provide a strong force in response to increased intraluminal pressures and prevent urine 
leakage.  The urethra, like all soft tissues, is viscoelastic and its elasticity depends on the rate of 
load, where the muscular components provide long-term stability [16].  Although there is limited 
information regarding the mechanical characterization of the urethra, some studies have 
attempted to explore the mechanical contributions of the urethral components. 
1.6.1 In-Vivo Studies 
An early study of healthy urethral biomechanics assessed changes in diameter with increases in 
intravesicle pressure.  Anesthetized, female, mongrel dogs were assessed for urethral 
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displacement at the proximal, middle and distal portions of the urethra as the bladder was filled.  
The proximal and middle portions had greater compliance and resistance to flow than the distal 
portion [134].  Other studies have used a probe, composed of a balloon attached to a catheter, 
which is inserted into the urethra to conduct inflation studies.  Measurements of intraurethral 
pressure and cross-sectional area are used to measure the rigidity of the urethra.  These studies 
showed increased rigidity in the middle and distal portions compared to the proximal portion of 
the urethra in young healthy women [135, 136].  In a comparison of healthy and SUI women, 
investigators found that the proximal and middle portions of the urethra had decreased response 
to incidents of stress, indicating their importance to maintaining continence [137]. 
Although in-vivo studies are ideal as the tissue is behaving in its native environment, they 
are limited by the investigative techniques with which they are conducted.  Insertion of a catheter 
or probe into the urethra changes the shape of the lumen and therefore the pressure distribution to 
maintain continence, yielding inaccurate readings.  It has also been reported that these 
measurements are dependent on the size of the catheter/probe used as well as the position of the 
transducer along the length and circumference of the urethra [138, 139]. 
1.6.2 Ex-Vivo Studies 
Until recently, there had only been one ex-vivo study of the mechanical properties of the urethra.  
The first study assessed an intact urethral specimen for anisotropy.  The urethra from a female 
mongrel dog was isolated and mounted into a system where it was placed under static pressure 
and length was measured.  The study reported that the circumferential components were stronger 
than the longitudinal ones, making the urethra anisotropic [140].  This study, however, failed to 
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maintain in-vivo length and reported that samples retracted an average of 4.7% following 
isolation, which could contribute to the tissues response to increases in pressure. 
More recently, several studies from our laboratory have assessed the ex-vivo 
biomechanical characteristics of the urethra in both a healthy and various diseased states [53, 54, 
101, 141, 142].  These studies all used a modified ex-vivo system to assess pressure-diameter 
relationships at various locations along the length of a rat urethra [53, 101, 142, 143].  A study 
on healthy urethras reported that the proximal portion of the tissue was the most compliant at low 
pressures, followed by middle and distal portions, respectively.  This study also reported on the 
presence of smooth muscle tone, both smooth and striated muscle contraction and relaxation in 
response to various chemical agents [142].  Further studies explored the biomechanical 
contributions of each muscle component to urethral function at the middle portion of the urethra.  
It was reported that the striated muscle only contributed one third of that of the smooth muscle to 
force generation and acted for a shorter period of time [143].  Another study assessing the affects 
of VD on urethral biomechanics reported that VD increased compliance of the proximal urethra, 
stiffness of the distal portion and altered basal tone [54].  Diabetes, induced by streptozotocin, 
increased stiffness and altered urethral response to contractile or relaxation agents [101]. 
It has been well established that an ineffective continence mechanism is accompanied by 
damage to both the muscular and ECM components of the urethra in Sections 1.2 and 1.6.  This 
damage alters the mechanical properties of the urethra, decreasing its ability to contract and 
resist increases in pressure.  Therefore, the most effective treatment would be one that targeted 
both the functional and structural damages by providing both support and contraction to the 
urethra.  The use of autologously derived fibrinogen, thrombin and stem cells to create a 3-D 
support for the urethra would allow the entrapped cells to produce their own ECM and to become 
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integrated with the native urethra and provide structural support.  Utilization of mechanical 
and/or biochemical stimulation within a bioreactor could enhance the orientation or cells as well 
as collagen production and even differentiation to a contractile smooth muscle phenotype to 
provide functional support to the urethra as well. 
1.7 HYPOTHESES AND SPECIFIC AIMS 
While efforts have been made to find a treatment for SUI, the current treatments are only 
satisfactory for short times, or can dissipate due to re-absorption into the body over time.  To 
address this we developed a tissue engineered urethral wrap (TEUW) from fibrin and bone 
marrow progenitor cells, to provide mechanical and functional support to the diseased urethra.  
This study utilizes both a custom-designed bioreactor culture system, to provide chemical and/or 
mechanical stimulation to 3-D TEUWs, as well as an ex-vivo testing system, to determine the 
mechanical properties of TEUWs following bioreactor culture and/or urethral samples following 
implantation of a TEUW.  Biomechanical data were compared to micro-structural and 
immunohistochemical analyses.  The hypotheses and specific aims corresponding are as follows: 
Hypothesis 1: A living, functional, smooth muscle-populated tubular construct can be 
fabricated in-vitro by mechanically and/or biochemically stimulating bone marrow derived 
progenitor cells (BMPCs) within a natural biological matrix. 
Specific A im 1  (addresses Hypothesis 1 ): To fabricate a living, functional smooth 
muscle populated tubular construct from BMPCs and a natural biological matrix that is suitable 
for implantation as a TEUW.  This will be achieved by determining the in-vitro stimulation 
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regimen - chosen from carefully-chosen combinations of mechanical strain and biochemicals - 
that yield optimal histological, functional and biomechanical properties. 
Hypothesis 2 : A TEUW can be successfully implanted and will reverse the short-term 
changes in mechanical and functional properties of the urethra found in a rat model of SUI. 
Specific Aim 2  (addresses Hypothesis 2): To assess a TEUW composed of the BMPC-
derived SMC-populated constructs from Specific Aim 1.  Assessments will include both in-vitro 
and in-vivo analyses, using histological, functional, biomechanical and immunological 
endpoints.  Results will be compared with normal and diseased native urethra, as well as a 
TEUW constructed using isolated urethral SMCs. 
 
In order to appropriately develop our TEUW, changes to urethral properties due to 
common risk factors were first assessed (Chapter 2.0 ).  To differentiate the stem cells within 
our TEUWs, an appropriate seeding density and compaction culture duration were determined 
(Chapter 4.0 ) prior to development of a bioreactor capable of providing the desired mechanical 
and/or chemical stimuli (Chapter 5.0 ) for differentiation of BMPCs to contractile SMCs in 3-D.  
In order to verify that the TEUW is capable of acting as a urethral support both structurally and 
functionally, an analysis of its mechanical and phenotypic properties was necessary (Chapter 
6.0 ).  Next, verification of our in-bred animal model was necessary and performed against a 
commonly used out-bred rat strain (Chapter 3.0 ).  To understand the structural and functional 
effect of the TEUW on the native urethra, in-vivo studies were performed and specimens 
analyzed mechanically to provide insight into the contribution of the TEUW to the native tissue 
as well as how the diseased tissue differs from that of controls (Chapter 7.0 ).  Distinguishing 
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which components are most influenced may help to provide insights to using a TEUW as a 
treatment for SUI. 
 
  
 37 
2.0  EFFECTS OF OVARIECTOMY ON THE MECHANICAL CHARACTERISTICS 
OF THE FEMALE RAT URETHRA 
2.1 SIGNIFICANCE OF OVARIECTOMY ON URETHRAL FUNCTION 
There are many contributing factors to the onset of SUI.  Seventy percent of women report 
symptoms of SUI following menopause [144].  Menopause causes many changes to a woman’s 
body, including decreased levels of estrogen and progesterone.  Estrogen provides increased 
periurethral resistance and α-adrenoreceptor activity in the urethral smooth muscle through the 
large number of receptors in the proximal urethra [145].  Following estrogen deficiency from 
menopause, it is common for women to develop urinary disorders such as frequency, urgency 
and incontinence [36, 144].  Although estrogen plays an important role in the maintenance of 
continence, the use of hormone therapy as a treatment for SUI has shown mixed results [36]. 
In order to better assess the role of estrogen in urinary continence, an ovariectomized 
animal model is used.  The ovariectomy model causes estrogen deficiency by the bilateral 
removal of the ovaries.  While numerous studies have assessed the effects of estrogen deficiency 
or therapy on the LPP, voiding pattern and innervations of the ovariectomized urethra with and 
without VD [36, 49, 50], none have assessed the effects on the mechanical properties of the 
urethra. 
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 Assessment of the urethral closure mechanisms in-vivo as well as the biomechanical 
characteristics following ovariectomy can provide insight on the role of estrogen in maintaining 
continence and aid in the development and initiation of new and better treatments for urinary 
dysfunction following menopause. 
2.2 METHODS 
2.2.1 Animals 
Adult, female, virgin Sprague-Dawley rats (200-250 g) (Hilltop Lab Animals, Inc., Scottdale, 
PA) were used in this study.  Animals were housed at the University of Pittsburgh under the 
supervision of the Department of Laboratory Animal Resources.  The policies and procedures for 
the animal studies are in accordance with those detailed in the Guide for the Care and Use of 
Laboratory Animals, published by the US Department of Health and Human Services.  
Procedural protocols were approved by the University of Pittsburgh’s Institutional Animal Care 
and Use Committee. 
2.2.2 General Surgical Procedures 
Animals were divided into three groups (Figure 2.1): ovariectomy (Ov), sham and control.  At 
day 0, under 4% isoflurane anaesthetic, Ov animals received a midline incision and two 
longitudinal muscle incisions through which the fallopian tubes and ovarian branch of the uterine 
artery were exposed and ligated, followed by removal of both ovaries [50].  Sham animals 
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received the incisions and manipulation of the internal space without ovary removal and controls 
received no procedures at all. 
Six weeks later (Figure 2.1), animals were assessed for urethral response to sneeze (see 
Section 2.2.3), maximum intravesical pressure during sneeze (MIPS; see Section 2.2.4), and 
urethral ex-vivo mechanical properties (see Section 2.2.5).  Rats were anesthetized by 4% 
isoflurane inhalation, and the bladder was exposed via a midline incision.  Ligation of both 
ureters was performed to prevent migration of urine into the bladder, which could alter 
intravesical pressure readings. The colon was cleared of feces through a small incision.  
Following all surgical procedures, isoflurane anesthetic was discontinued and replaced with 
urethane anesthetic (1.2 g/kg, subcutaneous, Sigma, St. Louis, Mo.).  Additional doses of 
anesthetic were administered intravenously, as required, during experimentation. 
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Figure 2.1 Schematic of the experimental design. 
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2.2.3 Urethral Response During Sneeze 
All groups were subjected to sneeze testing as previously reported [146, 147].  Briefly, bladders 
were manually emptied by compression and a catheter, with a side-mounted microtransducer, 
(SPR-524, Millar Instruments, Houston, TX) was inserted into the urethra via the external 
orifice.  The sensor was positioned at the middle urethra on the inner urethral surface, based on 
previous studies.  To evaluate the intensity of the induced sneeze, which varied with each sneeze 
event, pressure increases in abdominal pressure (Pabd) during sneezing were also measured via an 
intra-abdominal balloon catheter.  The sneeze reflex was induced by inserting a cut whisker into 
the animal’s nostril.  Prior to and following initiation of the sneeze, urethral baseline pressure 
(UBP) and Pabd were measured in cmH2O. During sneeze, amplitude of the urethral pressure 
response (A-URS) and Pabd were measured in cmH2O.  The average of at least 10 measurements 
was taken as the value of each metric for individual rats. 
2.2.4 MIPS 
All groups were subjected to MIPS testing as previously reported [148].  Briefly, a catheter (PE-
90) connected to a pressure transducer (Transbridge 4M, World Precision Instruments, Sarasota, 
FL) was inserted into the bladder to measure intravesicle pressure.  While in the supine position, 
bladders were emptied by manual pressure and filled with 0.4 mL of saline solution containing 
Evans blue (100 µg/mL; Sigma, St. Louis, MO).  Intravesical and abdominal pressures were 
recorded at 400 Hz with data acquisition software (Chart, AD Instruments) on a computer 
equipped with an analog-to-digital converter (Power Lab, AD Instruments).  Sneezing was 
induced by inserting a cut whisker into the nostril of the animal at least 50 times to achieve 
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intravesical pressures large enough to cause leakage.  The maximum intravesical pressure during 
sneeze was recorded.  If leakage occured, the lowest pressure to cause leakage was recorded. 
2.2.5 Biomechanical Testing 
Following MIPS measurements, the urethra was excised and tested as previously described by 
our group [54, 142, 143].  Briefly, PE-50 tubing (Becton-Dickson, Franklin Lakes, NJ), was 
inserted through the urethra into the dome of the bladder.  The bladder dome, as well as the 
external urethral meatus, was ligated to the catheter with 4-0 silk suture (Syneture, Mansfield, 
MA).  The ureters were ligated and served as anatomical landmarks for the maintenance of in in-
vivo length during mechanical testing.  The urethra was then separated from the surrounding 
tissues and placed in cold, oxygenated Media 199 (Sigma-Aldrich, St. Louis, MO), containing 
antibiotic/antimycotic and L-glutamine (Invitrogen, Carlsbad, CA) to prevent hypoxia of the 
tissue. 
The urethra was mounted onto stainless steel cannulae within a bathing chamber filled 
with Media 199 and kept at physiologic conditions via a circulation loop and gaseous mixture of 
95% O2 and 5% CO2.  A calibrated hydrostatic reservoir was used to increase intraluminal 
pressure from 0-20 mmHg in 2 mmHg increments.  Outer diameter and pressure were 
continuously measured during over the duration of the experiments.  Due to the heterogeneity of 
the urethra, measurements were taken at proximal, middle, and distal segments along its length 
[54, 142].  Samples were assessed in both baseline (without pharmacological agents) and passive 
(3 mM EDTA) conditions.   
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2.2.6 Histology 
Following each experiment, urethras were placed into 4% paraformaldehyde (Fisher, Pittsburgh, 
PA) followed by 30% sucrose.  Urethras were divided into proximal, middle, and distal portions, 
each portion was cut in half, and each half processed into 10 μm paraffin or frozen sections.  
Paraffin sections were dewaxed, rehydrated with an ethanol series, and stained with Lillie’s-
modified Masson’s trichrome, hematoxylin and eosin (H&E), and picrosirius red (PSR).   
2.2.7 Mechanical Characteristics 
Inner diameters of tested urethras were estimated for proper calculation of various mechanical 
parameters [54].  Paraffin sections stained for Lillie’s-modified Masson’s trichrome were imaged 
as described above and used for thickness assessment. 
Images were imported to Scion Imaging software (version 4.0.3.2, Scion, Frederick, MD) 
for quantification of the specimen radial thickness (50 to 60 measurements per cross-section).  
The average of thickness measurements from 3 to 4 cross-sections per specimen was used as the 
thickness for that specimen.  Assuming incompressibility and constant length during testing, the 
inner diameter at zero pressure was calculated by subtracting twice the average thickness from 
the measured outer diameter.  The inner radius at all other pressures was calculated as [53]: 
2
0,
2
0,
2
,, PiPoPoPi RRRR +−=      (1) 
Here, Ri,P and Ro,P are the inner and outer radii at any applied pressure, P, and Ri,P0 and Ro,P0 are 
the inner and outer radii at zero pressure.  Compliance (C), a measure of the distensibility of a 
tube, was calculated from measurements within 0 to 20 mmHg as [53]: 
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where IDmax is the inner diameter at maximum pressure (Pmax), and IDmin is the inner diameter at 
minimum pressure (Pmin) [53].  As compliance is a linear measure and our pressure diameter 
curves are non-linear, it was calculated over each applied pressure increment.  To assess the 
mechanical properties over the full range of intraluminal pressures, beta stiffness (β) was 
calculated as: 
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where P10=10 mmHg (the midpoint) and ID10 is the corresponding inner diameter diameter [53]. 
2.2.8 Statistics 
Data is represented as the average ± standard error of the mean.  Excessively large sneezes, 
which induced increases in Pabd greater than two standard deviations above the average, or very 
small sneezes, which induced increases in Pabd less than 3 cmH2O, were excluded from data 
analyses.  The values of the A-URS and UBP as well as increases in Pabd during sneezing were 
averaged in each rat.  The average of each group of animals was then calculated from the 
averaged value in each rat.  Statistical comparisons were performed using a Student's t-test.  
Significance was detected at p-values less than 0.05. 
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2.3 RESULTS 
2.3.1 Urethral Response During Sneeze 
Ov rats had a significantly lower A-URS and UBP than both control and sham groups, which had 
similar A-URS and UBP values (Figure 2.2).  The ΔPabd was similar for all groups [149]. 
 
 
 
Figure 2.2 Active urethral response to sneeze (A-URS) and urethral baseline pressure (UBP) for control (n=7), 
sham (n=12) and Ov (n=12) groups.  Values are shown as average ± SEM.  *p<0.05. 
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2.3.2 Maximum Intravesical Pressure During Sneeze 
Animals receiving ovariectomy had a significantly lower MIPS than controls (Figure 2.3) [149].  
Although the Ov animals had a lower MIPS than shams (Figure 2.3), they did not quite reach 
significance (p = 0.07) [149].  During sneeze, no animals from either the control or sham groups 
had visible leakage from the urethral orifice, however, five out of the eight (62.5%) Ov animals 
did leak during sneeze.  The Ov animals that leaked had an average MIPS of 71.5 ± 8.18 cmH2O, 
while those that did not had an average of 65.7 ± 3.25 cmH2O (Figure 2.4, p=0.62) [149]. 
 
 
 
 
Figure 2.3 MIPS results for control (n=6), sham (n=6) and ovariectomy (n=8) groups.  Values are shown as average 
± SEM.  *p<0.05. 
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Figure 2.4 MIPS results for ovariectomy (n=8) animals that did (n=5) and did not (n=3) leak.  Values are shown as 
average ± SEM. 
2.3.3 Ex-Vivo Mechanical Analysis 
Pressure-diameter curves show a trend towards an increasing compliance in the proximal and 
middle urethral portions with a gradient from controls to Ov animals in both the baseline and 
passive states (Figure 2.5A-B, Figure 2.6A-B).  Control and Ov distal portions had similar 
pressure-diameter curves, shifted to the right of the sham group (Figure 2.5C, Figure 2.6C), 
indicating that they are more compliant than the sham group.  An increasing gradient in baseline 
compliance from control to Ov rats in the proximal (low and overall pressure ranges) and middle 
(low, middle and overall pressure ranges) portions of the urethra is shown in Table 2.1.  There is 
also an increasing gradient in passive compliance from control to Ov rats in the proximal (low, 
middle and overall pressure ranges) and middle (low and overall pressure ranges) portions of the 
urethra, with a decreasing gradient in both the proximal and middle portions at high pressure 
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ranges (Table 2.2).  The sham distal urethra had compliance values significantly lower than the 
control urethra at both low (0-6 mmHg) and overall (0-20 mmHg) pressure ranges in the passive 
state (Table 2.2).  Beta stiffness for the proximal portion of the Ov urethra in the baseline state 
was significantly lower than the corresponding control portion (Table 2.1).  There were no 
significant differences between the sham and Ov groups, although there is a clear trend towards 
the Ov group having a larger compliance value than the control and sham groups. 
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Figure 2.5 Baseline pressure-diameter curves for (A) proximal, (B) middle and (C) distal portions of control (n=6), 
sham (n=5) and Ov (n=10) urethras.  Values shown as average ± SEM. 
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Figure 2.6 Passive pressure-diameter curves for (A) proximal, (B) middle and (C) distal portions of control (n=6), 
sham (n=5) and Ov (n=10) urethras. Values shown as average ± SEM. 
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Table 2.1 Compliance and beta stiffness values for control (n=6), sham (n=5) and Ov (n=10) urethras in baseline 
conditions.  Values are shown as average ± SEM.  *p<0.05 compared to corresponding control condition.  Red = 
increasing trends in the proximal portion from control to Ov groups, Green = increasing trends in the middle portion 
from control to Ov groups and bold = significant differences compared with the corresponding control portion. 
 
 
 
 
 
Baseline 
Low 
Pressure    
(0-6 mmHg) 
Middle 
Pressure    
(6-12 mmHg) 
High   
Pressure       
(12-20 mmHg) 
Overall 
Pressure   
(0-20 mmHg) 
Beta 
Stiffness 
Compliance   
x 100 
(mmHg-1) 
C
on
tr
ol
 
Proximal 11.80 ± 4.22 1.95 ± 0.53 1.20 ± 0.23 5.46 ± 1.53 8.04 ± 2.17 
Middle 6.97 ± 1.93 1.80 ± 0.28 0.51 ± 0.80 3.15 ± 0.79 5.81 ± 1.13 
Distal 3.79 ± 1.06 3.10 ± 1.01 1.67 ± 0.29 3.15 ± 0.19 6.11 ± 1.12 
Sh
am
  
Proximal 20.36 ± 15.45 4.04 ± 1.77 2.78 ± 1.46 10.75 ± 5.24* 5.76 ± 1.14 
Middle 20.36 ± 15.45 4.04 ± 1.77 2.78 ± 1.46 10.75 ± 5.24 4.54 ± 1.00 
Distal 0.94 ± 0.97 1.49 ± 0.57 0.94 ± 0.26 1.25 ± 0.62 10.30 ± 2.47 
O
v 
Proximal 86.24 ± 65.63 3.26 ± 0.48 1.49 ± 0.30 35.60 ± 25.83 3.66 ± 0.70* 
Middle 23.29 ± 13.47 4.48 ± 1.01 1.89 ± 0.34 12.79 ± 6.12 4.43 ± 0.82 
Distal 3.06 ± 1.64 3.40 ± 1.20 1.13 ± 0.26 2.98 ± 1.12 7.30 ± 1.54 
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Table 2.2 Compliance and beta stiffness values for control (n=6), sham (n=5) and Ov (n=10) urethras in passive 
conditions.  Values are shown as average ± SEM.  *p<0.05 compared to corresponding control condition.  Red = 
increasing trends in the proximal portion from control to Ov groups, Green = increasing trends in the middle portion 
from control to Ov groups and bold = significant differences compared to the corresponding control portion. 
 
Passive 
Low 
Pressure    
(0-6 mmHg) 
Middle 
Pressure    
(6-12 mmHg) 
High Pressure     
(12-20 mmHg) 
Overall               
(0-20 mmHg) 
Beta 
Stiffness 
Compliance 
x 100 
(mmHg-1) 
C
on
tr
ol
 
Proximal 15.41 ± 6.80 1.38 ± 0.31 1.17 ± 0.28 6.20 ± 2.12 9.22 ± 2.73 
Middle 11.68 ± 4.37 1.45 ± 0.26 1.24 ± 0.35 5.06 ± 1.38 8.52 ± 1.33 
Distal 6.90 ± 1.76 1.39 ± 0.28 1.31 ± 0.23 3.39 ± 3.39 8.72 ± 1.57 
Sh
am
  
Proximal 24.79 ± 11.28 1.59 ± 0.44 1.13 ± 0.43 9.27 ± 3.53 6.40 ± 1.54 
Middle 13.62 ± 5.64 2.20 ± 0.85 1.21 ± 0.35 6.06 ± 1.71 7.39 ± 1.70 
Distal 2.40 ± 1.30* 1.07 ± 0.58 0.86 ± 0.20 1.56 ± 0.64* 4.07 ± 5.48 
O
v 
Proximal 47.46 ± 28.24 1.95 ± 0.00 0.98± 0.31 17.00± 9.25 6.42 ± 0.91 
Middle 23.74 ± 12.24 1.50 ± 0.29 1.11 ± 0.29 9.82 ± 4.80 8.19 ± 1.91 
Distal 6.95 ± 2.48 1.37 ± 0.34 0.99 ± 0.19 3.48 ± 1.21 9.32 ± 2.02 
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2.4 DISCUSSION 
Mid-urethral response to sneeze was significantly affected by ovariectomy.  Ov rat UBP and A-
URS were significantly lower than both control and sham groups (Figure 2.2), indicating 
changes to either the neural or muscular components [148].  Ov MIPS values were also 
significantly lower than controls (Figure 2.3), with over 60% of Ov rats leaking during sneeze, 
while neither control nor sham animals leaked.  Both proximal and middle portions of the Ov 
urethra showed trends towards an increased compliance over both control and sham groups in 
both the baseline and passive states (Figure 2.5 and Figure 2.6), although not significantly. 
Previous studies showed no effects of ovariectomy on urethral function up to four weeks 
following creation of the model [37, 49, 50].  However, we have assessed both short (3 weeks) 
and longer (6 weeks) time points and found that although the urethral response to sneeze may be 
impaired early on, SUI is not induced until later [149].  Sievert et al., assessed urethral leakage 
during stress and reported that delivery alone or delivery followed by Ov (4 weeks postpartum) 
produced the same number of incontinent animals (16.7%) 8 weeks postpartum [49].  Our 
laboratory has reported that although there was a decreased urethral reponse in virgin rats 3 
weeks following ovariectomy, there was 0% incontinence [149], indicating that the trauma of 
vaginal delivery and/or distension is the main short-term contributor to SUI.  While Sievert et al., 
reported an increased percentage of incontinence with the addition of vaginal distension 
immediately following delivery (58.3%) or vaginal distension plus Ov (4 weeks postpartum; 
72.7%) [49], our laboratory has shown incontinence in over 60% of virgin rats 6 weeks 
following ovariectomy [149], showing the isolated effects of estrogen deficiency on urethral 
function and maintenance of continence. 
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To our knowledge, there have been no other reports on the ex-vivo biomechanical effects 
of ovariectomy on the urethra.  However, there have been several reports on how SUI [53, 54] 
and diabetes [101] alter urethral biomechanics.  Knowledge of how various conditions alter the 
mechanical properties of the urethra can provide valuable information for the development of 
new and effective treatments.  Although we expected to see no difference between sham and 
control groups, the trend towards an increased compliance in proximal and middle urethral 
portions of shams (Table 2.1 and Table 2.2) could be due to damage of the pudendal nerve 
during internal manipulation to create the sham ovariectomy model, which has previously been 
reported [150].  As pudendal nerve transaction/crush is a commonly used model of SUI [56, 61, 
147], it is possible that damage during sham surgeries contributed to increased urethral 
compliance. 
The gradient of increasing compliance from controls to Ov animals in the baseline state 
(Table 2.1) indicates that the muscular components of the urethra have been compromised.  
Since it has previously been reported that estrogen levels do not influence the size of urethral 
muscle fibers [151], the increase in compliance following ovariectomy may be a result of altered 
contractile machinery.  Sievert et al., reported decreased urethral levels of caveolin-1 (in smooth 
muscle) and -3 (in striated muscle) following delivery and ovariectomy compared to virgins [49].  
Caveolins are membrane proteins thought to be restricted to muscle tissues and to contribute to 
calcium homeostasis [152].  Caveolins are involved in several signalling pathways and a defect 
in the caveolin gene can result in muscular dystrophy [152].  While, Sievert et al., observed a 
similar decrease of caveolin-1 in animals receiving vaginal dilation or vaginal dilation and 
ovariectomy following delivery, the level of caveolin-3 was lowest in animals which received 
only ovariectomy following delivery [49], indicating that the trauma of vaginal distension may 
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damage the contractile ability of urethral smooth muscle, while estrogen deficiency damages the 
striated sphincter, which provides the main mechanism for maintaining continence.  It is also 
possible that the trauma of childbirth activates a repair mechanism that altered hormone levels 
alone do not. 
The gradient increase in low pressure compliance from shams to Ov animals in the 
passive state in this study is similar to trends seen in the comparison of control and vaginally 
distended rats [53].  The study of vaginal distension also reported significantly more collagen in 
the middle portion of the diseased urethra per cross-sectional area via trichrome staining, but 
significantly less from a biochemical assay.  The study also reports significantly more elastin in 
the vaginally distended urethra than in controls [53], all of which could contribute to the changes 
in mechanical properties.  Previous studies have reported decreases in the number of blood 
vessels within the submucosal layer of the urethra and collagen-I, which provides structural 
support and rigidity to the urethral wall, following ovariectomy [145, 153].  Increased collagen-
III, which provides elasticity to the urethra, has also been reported following ovariectomy [153].  
These changes in extracellular proteins are further supported by the increased passive 
compliance in Ov animals seen in Table 2.2.  The large amount of variability in ovariectomy 
mechanical data could be a result of the variable leakage response to sneeze.  SUI has previously 
been shown to increase urethral compliance [53] making it plausible that the high variability of 
SUI in Ov rats also causes a large variability in the mechanical properties of those urethras.  
Although this study provided evidence that estrogen deficiency alone has a large role in 
proper urethral function and the maintenance of continence, further analyses should be 
performed.  This study was designed to focus solely on the effect of estrogen on urethral 
response, and we acknowledge that utilizing virgin rats limits our correlation to human clinical 
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relevance.  Increasing the n value for sham animals could decrease data variability and help to 
more clearly identify differences in mechanical behaviour.  Further studies, assessing the same 
urethral responses, in retired breeders, are currently underway.  An assessment of pudendal nerve 
damage, such as staining for a neuronal marker such as PGP 9.5 in the middle urethra, in sham 
rats could also be performed to explain the large amount of variability in our mechanical data.  
Quantification of the urethral ECM and muscular components at both 3 and 6 weeks following 
ovariectomy would also provide further support of the differences in mechanical properties seen 
in this study.  Another limitation of this work could be a lack of uniformity in the thickness 
measurements around the circumference of the urethra, which were used to calculate all 
mechanical parameters.  We did see a minimal variation in thickness measurements within each 
section and portion.  For example, thickness measurements from a Sham urethra were as follows: 
one proximal tissue section had an average thickness of 0.2523 ± 0.0333 mm, while an average 
of the proximal portion (from four tissue sections) was 0.2401 ± 0.0043 mm.  The average for 
the middle portion was 0.3590 ± 0.0016 mm and 0.3623 ± 0.0070 mm for the distal portion  
Although many factors such as childbirth and nerve injury contribute to the development 
of SUI, symptoms may not appear until years following the injury.  The prevalence of SUI 
increases with age and onset commonly occurs following menopause, indicating a potential 
hormonal role in the continence maintaining mechanism.  Estrogen has been shown to 
significantly contribute to the stability and regrowth of neuronal fibers [150], and loss of 
estrogen is associated with a higher incidence of SUI [36, 37, 49].  Therefore, it is possible that 
estrogen aids the body in compensating for a damaged continence mechanism.  Since differences 
in urethral function following ovariectomy are observed without urethral trauma, the role of 
estrogen in urinary continence warrants further analysis. 
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This work provides evidence that estrogen deficiency alone affects both the smooth and 
striated muscle response under stress conditions.  We have also shown that muscular and 
extracellular matrix components are less resistant to increases in pressure in both the proximal 
and middle portions of the ovariectomy urethra, indicating that estrogen plays an important role 
in the continence mechanism.  Knowing how the mechanical properties of the urethra change 
following menopause may aid in the development of preventative treatments for SUI in pre-
menopausal women. 
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3.0  STRAIN DEPENDENCY OF URETHRAL FUNCTIONAL AND MECHANICAL 
PROPERTIES IN THE RAT 
Over the past decade therapies and various treatments for stress urinary incontinence [154] have 
emerged, including injection of bulking agents [29], placement of synthetic slings [154], 
electrical stimulation [155] and the injection of stem cells [64, 156-158].  As technology 
advances and more cell-based therapies are developed, it is imperative that these treatments are 
tested in an appropriate animal model. 
To date, the majority of lower urinary tract studies have been performed in the Sprague-
Dawley (SD) rat [35, 54, 64, 141, 148], since the structure of the rat urethra is very similar to that 
of humans [159].  This out-bred, all-purpose strain is used in many areas of research [160].  
However, as cellular treatments progress, a new model may be more appropriate for the initial 
validation of the treatment.  Utilization of in an in-bred animal would allow for fine tuning of the 
therapy in a more controlled in-vivo study, without increased variability from genetic variation, 
or immune responses by the test animal.  The Lewis rat, an in-bred strain, is generally used in 
immunological and stem cell research studies and could serve as a better model for investigating 
possible stem cell therapies to be used in the lower urinary tract [160].  To this end, the lower 
urinary tract properties and response to urethral dysfunction would need to be verified in the 
Lewis rat. 
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The purpose of this portion of the dissertation work was to verify the Lewis rat as a 
model of SUI by pudendal nerve transection for cellular based thereapies, by comparing it to the 
commonly used SD rat. 
3.1 MATERIALS AND METHODS 
3.1.1 Animals 
Adult, female, SD and Lewis rats (200-250 g) (Hilltop Lab Animals, Inc., Scottdale, PA) were 
used in this study.  Animals were housed at the University of Pittsburgh under the supervision of 
the Department of Laboratory Animal Resources.  The policies and procedures for the animal 
studies are in accordance with those detailed in the Guide for the Care and Use of Laboratory 
Animals, published by the US Department of Health and Human Services.  Procedural protocols 
were approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee. 
3.1.2 Overview of Experiments 
Five types of experiments were performed.  Experiment 1 evaluated, in SD and Lewis rats, the 
effects of SUI induced by bilateral pudendal nerve transection on the leak point pressure (LPP), a 
common in-vivo measure of urethral function [146, 157].  Experiment 2 compared the 
contribution of the striated sphincter to the continence mechanism in SD and Lewis rats using a 
specific inhibitor of skeletal muscle activity.  Experiment 3 assessed common functional indices 
of the urethra during sneezing in continent SD and Lewis rats.  Experiment 4 utilized our ex-vivo 
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urethral testing system [54, 141, 142] to assess the mechanical properties of SD and Lewis 
urethras.  Experiment 5 evaluated the ex-vivo functional response of both SD and Lewis urethras 
to smooth and striated muscle agonists.  Each experiment, as well as methodology common to 
them, are detailed below. 
3.1.3 Surgical Procedures 
The SUI group for each strain in Experiment 1 was created by anesthetizing the animal with 4% 
isoflurane, and then transecting the pudendal nerves bilaterally using aseptic, surgical techniques 
[147].  Since this common model for SUI [161, 162] utilizes complete transection of the nerve, it 
provides an immediate effect.  However, animals were assessed one week following nerve 
transection. 
For all experiments, rats were anesthetized by isoflurane inhalation, and the bladder was 
exposed via a midline incision.  Ligation of both ureters was performed to prevent flow of urine 
into the bladder, which could alter intravesical pressure readings. The colon was cleared of feces 
through a small incision.  Following all surgical procedures, isoflurane anesthetic was 
discontinued and replaced with urethane anesthetic (1.2 g/kg, subcutaneous, Sigma, St. Louis, 
Mo.).  Additional doses of anesthetic were administered intravenously, as required, during 
experimentation. 
For Experiments 1 and 2, a catheter (PE-90) was inserted into the bladder dome for 
recording of intravesical pressure and then the spinal cord was transected at the T9-T10 level 
after laminectomy.  A sterile sponge (Gelfoam, Upjohn, Kalamazoo, Mich.) was placed between 
the cut ends of the spinal cord and the overlying muscle and skin were sutured closed.  Spinal 
transection eliminates the voiding reflex mediated by spinobulbospinal pathways, but still allows 
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spinal urethral contractile reflexes via sympathetic and somatic nerves to remain active during 
bladder filling.  In addition, for Experiment 2, catheters were placed in the carotid artery (PE-50) 
to measure blood pressure, in the jugular vein (PE-10) for administration of intravenous drugs, 
and in the trachea (PE-160) for artificial respiration. A small balloon-catheter was inserted into 
the abdominal cavity via the rectum and connected to a pressure transducer to record abdominal 
pressures (Pabd) during Experiment 3. 
3.1.4 Experiment 1: Effects of SUI on Sprague-Dawley and Lewis Rat Leak Point 
Pressure (LPP). 
Continent and SUI rats from each strain were compared.  One week following creation of the 
SUI model, the LPP was assessed in each animal using the vertical tilt table method (V-LPP) 
[64].  Briefly, rats were mounted onto the tilt table, and the bladder catheter was attached to a 
pressure reservoir and a pressure transducer (BLPR, World Precision Instruments, Sarasota, Fla.) 
via a 3-way stopcock.  Intravesical pressure was increased in 2 cmH2O increments until leakage 
was visible, while data was recorded with ChartTM software (AD Instruments, Castle Hill, NSW, 
Australia) on a computer with a PowerLab® analog-to-digital converter.  The measure was 
repeated a minimum of 2 times.  The average of the measurements was taken as the V-LPP for 
that animal. 
3.1.5 Experiment 2: Contribution of the Striated Sphincter to the Continence Mechanism 
Continent SD and Lewis rats were prepared and tested for LPP as described above, but in the 
supine position (Su-LPP) as vertical positioning caused a significant decrease in blood pressure 
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following intravenous injections of alpha-bungarotoxin, a neuromuscular blocking agent.  
Following initial Su-LPP testing, animals were injected with divided doses of 333 μg/kg alpha-
bungarotoxin dissolved in sterile saline at 10 minute intervals, and tested for Su-LPP again.  
Animal respiration was maintained by a ventilator (3.5 mL/stroke, 80 strokes/min) following 
injection of alpha-bungarotoxin [163]. 
3.1.6 Experiment 3: Assessment of Urethral Response During Sneeze 
Continent SD and Lewis rats were subjected to sneeze testing as previously reported [148] and as 
described in Section 2.2.3.  Briefly, bladders were emptied and a catheter with a side-mounted 
microtransducer, (SPR-524, Millar Instruments, Houston, TX) was inserted into the urethra via 
the external orifice.  The sensor was positioned at the middle urethra on the inner urethral 
surface, based on previous studies [146].  The sneeze reflex was induced by inserting a cut 
whisker into the animal’s nostril [148].  Prior to and following initiation of the sneeze, urethral 
baseline pressure (UBP) and abdominal pressure (Pabd) were measured in cmH2O [148]. During 
sneeze, amplitude of the urethral pressure response (A-URS) and Pabd were measured in cmH2O 
[148].  The average of at least 10 measurements of each metric was taken as the value for 
individual rats [146, 148]. 
3.1.7 Experiment 4: Ex-Vivo Biomechanical Analysis 
Following LPP measurements, the urethra was excised and tested as previously described by our 
group [54, 141, 142] (see Section 2.2.5).  Briefly, PE-50 tubing (Becton-Dickson, Franklin 
Lakes, NJ), was inserted through the urethra into the dome of the bladder.  The bladder dome, as 
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well as the external urethral meatus, was ligated around the catheter with 4-0 silk suture 
(Syneture, Mansfield, MA).  The ureters were ligated and served as anatomical landmarks for the 
maintenance of in-vivo length during mechanical testing.  The urethra was then separated from 
the surrounding tissues and placed in cold, oxygenated media 199 (Sigma-Aldrich, St. Louis, 
MO), containing antibiotic/antimycotic and L-glutamine (Invitrogen, Carlsbad, CA) to prevent 
hypoxia of the tissue.  Tissue was transported to our testing facility on ice. 
The urethra was mounted onto stainless steel cannulae within a bathing chamber filled 
with media 199 and kept at physiologic conditions via a circulation loop and gaseous mixture of 
95% O2 and 5% CO2.  A hydrostatic reservoir was used to increase intraluminal pressure from 0-
20 mmHg in 2 mmHg increments.  Outer diameter and pressure were continuously measured 
over the duration of the experiments.  Due to the heterogeneity of the urethra, measurements 
were taken at proximal, middle, and distal segments along its length [54, 142].  Samples were 
assessed in both baseline (without pharmacological agents) and passive (in the presence of 3 mM 
EDTA) conditions. 
3.1.8 Experiment 5: Ex-Vivo Functional Analysis 
Urethras isolated from continent animals (see Section 2.2.5) from each strain were mounted in 
our ex-vivo testing system as described in Section 2.2.5, and subjected sequentially to: 0 mmHg 
and 8 mmHg intralumenal pressures, Nω-nitro-L-arginine (100 μM; to remove endogenous nitric 
oxide synthase activity), phenylephrine (40 μM; to assess smooth muscle contraction), 
acetylcholine (5 mM; to assess striated muscle contraction) and EDTA (3 mM; to inhibit 
muscular response) as previously described [141].  Each stimulus was followed by a 30 minute 
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equilibration period, and the outer diameter of the middle portion of the urethra was continuously 
recorded at 1 Hz. 
3.1.9 Histology 
Following each experiment, urethras were placed into 4% paraformaldehyde (Fisher, Pittsburgh, 
PA) followed by 30% sucrose.  Urethras were divided into proximal, middle, and distal portions, 
each portion was cut in half, and each half processed into 10 μm paraffin or frozen sections. 
Paraffin sections were dewaxed, rehydrated with an ethanol series, and stained with 
Lillie’s-modified Masson’s trichrome, hematoxylin and eosin (H&E), and picrosirius red (PSR).  
Frozen sections were stained for alpha-smooth muscle actin [164] and fast-twitch striated muscle 
(SKEL; Sigma-Aldrich, St. Louis, MO).  Sections were permeabilized with 0.1% (v/v) Triton-X-
100 in phosphate buffered saline (PBS) for 15 minutes and then blocked in PBS containing 
0.02% (w/v) bovine serum albumin (Fraction V; Sigma-Aldrich, St. Louis, MO) and 0.015% 
(w/v) glycine (Sigma-Aldrich, St. Louis, MO) for 45 minutes.  Sections were incubated with a 
primary antibody against either SMA (clone 1A4; Sigma-Aldrich, St. Louis, MO; 1:500 in 
blocking solution) or SKEL (clone NOQ7.5.4D; Sigma-Aldrich, St. Louis, MO; 1:250 in 
blocking solution) for 1 hour in a humidification chamber at room temperature.  Unbound 
primary antibody was removed from sections by multiple washes with PBS.  Next, sections were 
incubated with an Alexa 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA; 1:500 in 
blocking solution) for 1 hour at room temperature in a humidification chamber.  All sections 
were counterstained with DAPI for nuclear visualization and mounted with gelvatol.  Sections 
were imaged with a color, digital camera (QImaging, Surrey, BC, Canada) on an E800 Nikon 
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Eclipse microscope (Nikon, Melville, NY) using NIS Elements BR 3.0 software (Nikon, 
Melville, NY). 
3.1.10 Quantification of Muscle Components 
Frozen sections stained for SMA and SKEL were used to quantify the cross-sectional area of 
smooth and striated muscle in each portion of the urethra.  Total cross-sectional area was 
determined for each section using the NIS-Elements BR 3.0 software (Nikon, Melville, NY) area 
tool.  The luminal and external circumference were manually outlined, and the difference 
between those areas was taken as the total cross sectional area.  The total area stained positive for 
either SMA or SKEL was calculated using the NIS-Elements BR 3.0 software (Nikon, Melville, 
NY) thresholding tool, which calculates the total area of fluorescence within a set intensity 
range.  The intensity range was manually adjusted for each section such that only the visible 
fluorescence was incorporated into the measurement.  The sum of the area associated with each 
fluorescent element was taken as the total positive area.  The average percent of total area 
positively stained for each antibody is reported. 
3.1.11 Geometric Estimation and Mechanical Characteristics 
Inner diameters of tested urethras were estimated for proper calculation of various mechanical 
parameters [54] (see Section 2.2.7).  Paraffin sections stained with Lillie’s-modified Masson’s 
trichrome were imaged as described above and used for thickness assessment as previously 
described [54] (see Section 2.2.7). 
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Compliance, a linear measure of the distensibility of a tube, was calculated for each 
applied pressure increment as previously described [54] (see Section 2.2.7). 
3.1.12 Statistics 
Data are represented as the average ± standard error of the mean.  Statistical comparisons were 
performed using a Student's t-test.  For the alpha-bungarotoxin studies, a paired Student's t-test 
was used.  Significance was detected at p-values less than 0.05. 
3.2 RESULTS 
3.2.1 In-Vivo Leak Point Pressure in Continent and SUI Animals 
SUI SD animals had a significantly lower V-LPP than continent SD controls, but this difference 
was not detected in the Lewis rat (Figure 3.1).  The continent and SUI Lewis rat also had a 
significantly lower V-LPP than the continent SD rat (Figure 3.1).  In the supine position, which 
was necessary to test the effect of alpha-bungarotoxin, the continent SD rat maintained a 
significantly higher LPP than that of the Lewis rat (Figure 3.2). The injection of alpha-
bungarotoxin (333 μg/kg, i.v.) significantly decreased Su-LPP in the SD rat, but did not alter Su-
LPP in the Lewis rat (Figure 3.2).  
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Figure 3.1 Vertical leak point pressure (V-LPP) for both Lewis (n=3) and Sprague-Dawley (n=2) rats in both 
Continent and SUI states.  Data shown as average ± SEM, *p<0.05. 
 
 
 
Figure 3.2 Supine leak point pressure (Su-LPP) for both Lewis (n=7) and Sprague-Dawley (n=4) rats before and 
after injection with alpha-bungarotoxin (333 μg/kg, i.v.).  Data shown as average ± SEM, *p<0.05. 
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3.2.2 Urethral Pressure During Sneeze 
In the supine position the Lewis rats had a significantly lower urethral baseline pressure than the 
SD rats prior to and during sneeze (Figure 3.3).  However, there was no difference between the 
two strains of rats in the peak urethral pressure response or the peak abdominal pressure response 
during sneeze. 
 
 
 
Figure 3.3 Urethral pressure response (A-URS) during sneeze, urethral baseline pressure (UBP) and change in 
abdominal pressure (ΔPabd) for both Lewis (n=8) and Sprague-Dawley (n=10) rats.  Data shown as average ± SEM, 
*p<0.05. 
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3.2.3 Ex-Vivo Mechanical Characteristics 
Pressure-diameter (P-D) curves obtained from ex-vivo mechanical testing of the urethras in their 
baseline conditions are shown in Figure 3.4.  In the proximal urethra the P-D curve for SD rats 
was shifted to the right of the curve for Lewis rats; representing a slightly larger compliance with 
increasing pressure in SD rats (Figure 3.4A).  The Lewis middle urethra showed a larger 
distension at low pressures, indicating an increased compliance compared to the SD mid-urethra 
(Figure 3.4B).  There were no detectable differences between strains in the distal portion 
(Figure 3.4C). 
In the passive state, the P-D curves for both the proximal and middle portions of the 
Lewis urethra were shifted to the right of the curves for SD rats, while the curves for the distal 
portion were shifted to the left (Figure 3.5A-C).  Calculated compliance values were greater in 
the Lewis urethra at low pressures in the middle portion in the baseline state as well as in the 
proximal and middle portions in the passive state (Figure 3.6).  The passive, distal, SD urethra 
was more compliant than the corresponding Lewis urethra, although not significantly (data not 
shown). 
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Figure 3.4 Baseline pressure-diameter curves from the (A) proximal, (B) middle and (C) distal urethral portions of 
continent Lewis (n=4) and Sprague-Dawley (n=6) rats.  Data shown as average ± SEM, *p<0.05.  NID = normalized 
inner diameter. 
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Figure 3.5 Passive pressure-diameter curves from the (A) proximal, (B) middle and (C) distal urethral portions of 
continent Lewis (n=4) and Sprague-Dawley (n=6) rats.  Data shown as average ± SEM, *p<0.05.  NID = normalized 
inner diameter. 
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Figure 3.6 Baseline and passive compliance values for the proximal and middle urethral portions of continent Lewis 
(n=4) and Sprague-Dawley (n=6) rats.  Data shown as average ± SEM, *p<0.05. 
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3.2.4 Ex-Vivo Functional Characteristics of the Middle Urethra of Continent Animals 
Diameter profiles for SD urethras showed a distinct response to each drug, while Lewis urethras 
tended to drift without a clear response (Figure 3.7).  In SD urethras (n=3) Nω-nitro-L-arginine 
(100 μM, a NOSi), did not elicit a consistent change in outer diameter; whereas phenylephrine 
(PE, 40 μM) and acetylcholine (5 mM) both produced a contraction.  Subsequent addition of 
EDTA completely reversed the contractile response (Figure 3.7).  Lewis urethras, which 
exhibited a large increase in outer diameter in response to an 8 mmHg pressure, appeared to be 
unresponsive to any drugs tested (Figure 3.7).  Peak response was calculated with respect to the 
initial pressure increase (Figure 3.8A) as well as with respect to the equilibrated diameter from 
the previous condition (Figure 3.8B).  With respect to 8 mmHg and the previous condition, the 
SD urethra had a greater response to both PE and Ach, although not significantly.  The Lewis 
urethra had a much larger change in outer diameter than the SD urethra to 8 mmHg (Figure 
3.8B), confirming our mechanical data (Section 3.2.3), which showed a trend towards an 
increased compliance in the middle urethra of the Lewis rat. 
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Figure 3.7 Middle urethral response of all three continent Lewis and Sprague-Dawley rats tested to various agonists 
and antagonists (100 μM Nω-nitro-L-arginine, 40 μM phenylephrine, 5 mM acetylcholine and 3 mM EDTA).  Data 
was measured at 1 Hz with 30 minute equilibrations at each condition.  “Time” represents the seconds into the 
initiation of the measurements when data was obtained.  Outer diameter measurements were normalized to the initial 
outer diameter at 0 mmHg. 
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Figure 3.8 Percent outer diameter change of the middle urethra of continent Lewis (n=3) and Sprague-Dawley (n=3) 
rats to various agonists and antagonists (100 μM Nω-nitro-L-arginine, 40 μM phenylephrine, 5 mMacetylcholine 
and 3 mM EDTA) with respect to 8 mmHg (A) and the equilibrated previous condition (A).  Data was measured at 1 
Hz with 30 minute equilibrations at each condition.  Outer diameter measurements were normalized to the initial 
outer diameter at 0 mmHg. 
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3.2.5 Histology 
Qualitatively, it appeared that the SD urethra had greater overall muscularity than the Lewis 
urethra, which appeared to have a greater amount of extracellular matrix via Masson’s trichrome 
staining (Figure 3.9).  Semi-quantification revealed that all portions of the Lewis urethra have a 
higher percentage of smooth muscle than the SD urethra (Figure 3.10A), while all portions of 
the SD urethra contain a higher percentage of fast-twitch striated muscle than the Lewis urethra, 
with proximal and distal portions being significantly different (Figure 3.10B).  It was also 
observed that the SD rats had a larger total cross-sectional area in all three portions of the 
urethra, than the Lewis rat (Figure 3.10C). 
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Figure 3.9 Masson’s trichrome staining of proximal, middle and distal portions of continent Lewis and SD urethras.  
Images are representative and taken at 4x.  Red = muscle, blue/green = collagen, black = nuclei. 
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Figure 3.10 Percent of the total cross-sectional area staining positive for (A) smooth muscle actin or (B) fast twitch 
skeletal muscle and (C) total cross-sectional area of both the Lewis (n=7) and Sprague-Dawley (n=4-7) urethra.  
Data shown as average ± SEM, *p<0.05. 
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3.3 DISCUSSION 
In-vivo and ex-vivo experiments revealed that the normal properties of the urethra and the 
response of the urethra to bilateral pudendal nerve transection are markedly different in the 
Lewis and SD rats.  Lewis rats exhibited a significantly lower LPP and intraurethral baseline 
pressure in-vivo (Figure 3.3) and higher compliance (Figure 3.4) at the middle urethra in-vitro 
compared to the measurements in SD rats. In addition Lewis rat LPP was unaffected by pudendal 
nerve transection, whereas LPP was significantly reduced by nerve transection in SD rats 
(Figure 3.1).  Injection of alpha-bungarotoxin also had no effect on LPP in Lewis rats, while 
significantly decreasing the LPP in SD rats (Figure 3.2), indicating a greater contribution of 
striated muscle to the maintenance of continence in the SD rat, compared to the Lewis rat.  The 
SD rat urethra in comparison to the Lewis rat urethra had a larger cross sectional area at all three 
segmental levels and had a muscular layer that exhibited a significantly greater proportion of 
striated versus smooth muscle (Figure 3.10).  These functional, morphological and mechanical 
differences suggest that the Lewis rat has a lower level of intrinsic and neurally mediated 
contractile activity of the urethral muscle; and therefore is not a useful model for SUI induced by 
neural injury or neurogenic disorders. 
To our knowledge, only one other publication [160] has described the properties of the 
urethra in the Lewis rat.  In this study, LPP was measured in normal animals and in the vaginal 
distension model of SUI.  It was reported that vaginal distension, an acute model of SUI, did 
result in a significant decrease in LPP, but almost the same decrease in LPP occurred in the sham 
group.  In addition the Lewis rats had a noticeably lower LPP compared to SD rats [160]. 
In our current study, we chose a chronic model of SUI: bilateral pudendal nerve 
transection [146, 162].  The pudendal nerve innervates the external urethral striated sphincter and 
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plays a major role in maintaining continence [165].  Following nerve transection, there is a 
significant decrease in the pressure required to induce urine leakage that persists for 6weeks 
[162] in contrast to the rapid recovery that occurs in the vaginal distension model [146, 162, 
166].  Lewis rats were unaffected by pudendal nerve transection and had significantly lower LPP 
values than those in SD rats (Figure 3.1), which are in agreement with LPP values previously 
published in SD rats [46, 64, 146].  However, these results vary from reports that SUI, due to 
vaginal distension, significantly lowers LPP in both strains [51, 160]. 
The unaltered LPP following alpha-bungarotoxin in the Lewis rats (Figure 3.2) indicates 
that the striated sphincter does not contribute to urethral outlet resistance or the maintainence of 
continence under the conditions of our experiments.  This contrasts with the prominent lowering 
of LPP by alpha-bungarotoxin in the SD rat in the same experimental model (see also a previous 
report [167]).  The more abundant striated muscle in the SD rat (Figure 3.10) is consistent with 
the greater contribution of the striated sphincter to LPP in this strain.  In addition it is probable 
that the reflex activation of the striated sphincter muscle is lower in Lewis rats than in SD rats 
because transection of the pudendal nerve, which innervates and activates the striated sphincter, 
did not affect LPP in the Lewis rat but significantly reduced it in the SD rat. 
Although LPP was lower in the continent Lewis rat due to insignificant contribution of 
striated muscle to the urethral continence reflex induced by passive intravesical pressure 
increases, as compared to the continent SD rat, midurethral pressure responses to sneeze 
measured by microtranducer-tipped catheters were not different in Lewis and SD rats while UBP 
in Lewis rats was significantly lower than SD rats (Figure 3.3).  As reported previously, sneeze-
induced urethral closure mechanisms are mediated by somatic nerve-induced reflex contractions 
of external urethral sphincter and pelvic floor striated muscles, and directly induced by sneeze 
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without intravesical pressure increases [15, 19].   Thus the striated muscle-mediated urethral 
continence reflex induced by strong, phasic stimuli such as sneeze seems to be still maintained in 
the Lewis rat. 
Because smooth muscle represents a greater proportion of the muscle mass in the Lewis 
rat urethra, it might be expect that smooth muscle activity would make a greater contribution to 
the continence mechanism.  However, the lower UBP indicates a decreased activity of the 
urethral smooth muscle in the Lewis rat compared to SD (Figure 3.3), and may explain the 
increased compliance of the Lewis urethra compared to the SD urethra (Figure 3.4).  This 
decreased smooth and striated muscle activity was confirmed in ex-vivo studies showing a clear 
response of the SD urethra to various agents, while it appeared that the Lewis urethra did not 
respond (Figure 3.7).  Quantification of the tissue response, showed an increased contraction of 
the SD urethra in response to PE and Ach, although not significantly greater than the Lewis 
urethra (Figure 3.8).  Although the inconsistent drift of the Lewis urethra during testing, could 
be introducing a response independent of the agents. 
There are many possible reasons for the differences found in urethral function between 
these animals.  First, receptor expression in the smooth and/or striated muscle cells could be 
lower, thereby diminishing the response to contractile agents.  Second the Lewis rats may have 
an increased sensitivity to the anesthetic used in the in-vivo experiments which would reduce 
reflex activity of the sphincter.  However no obvious differences in the depth of anesthesia were 
observed in the two strains.  Furthermore the same dose of anesthetic was used in experiments in 
another laboratory when SUI induced by vaginal distension reduced LPP in the Lewis rat [160].  
The vaginal distension model used in the latter studies may produce a more extensive injury to 
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smooth muscle and blood vessels as well as nerves in the urethra and therefore produce a larger 
change in LPP. 
Although this study systematically attempted to determine the cause of differences in 
urethral function between these strains, further studies are needed to address this issue.  
Increasing the number of studies for the pharmacological endpoints may reveal a more concrete 
difference in the urethras response to various agents.  A better understanding of the neural 
control of the urethra could be obtained by quantifying the density and type of innervation of the 
urethra in the two strains by using immunohistochemistry to identify cholinergic and adrenergic 
nerves. In addition assessing the expression of various transmitter receptors using molecular 
techniques and the effects of electrical stimulation of nerves could be useful.  All of our work 
was performed in anesthetized animals, therefore assessing micturition frequency and volume in 
a metabolic cage [168] or performing awake cystometry [169] might eliminate any functional 
differences as a result of anesthesia although the LPP measurements are technically difficult to 
perform in awake condtions. 
Studies in Sprague-Dawley rats have provided considerable insight into the function of 
the lower urinary tract.  This out-bred, all-purpose animal has yielded an abundance of 
information on factors which contribute to and therapies that provide relief from many urethral 
disorders.  However, as stem-cell therapies continue to develop for urethral dysfunctions, an in-
bred strain with less genetic variation may be more suitable for initial validation of these 
therapies to avoid rejection issues.  Due to differences between SD and Lewis rats in regard to 
inflammatory responses [170], adaptive behavior [171], and response to pharmacological agents 
[172], the mechanisms contributing to the differences in urethral properties in these two strains 
warrant further investigation. 
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In summary, this work has provided strong evidence that functional and mechanical 
characteristics of the urethra are markedly different in Lewis and SD rats.  We have also shown 
that pudendal nerve transection is not an appropriate model of chronic SUI in the Lewis rat. 
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4.0  MECHANICAL AND HISTOLOGICAL CHARACTERIZATION OF A TISSUE 
ENGINEERED URETHRAL WRAP 
4.1 NEED FOR A TISSUE ENGINEERED URETHRAL WRAP 
Urethral dysfunction commonly accompanies many conditions and diseases including spinal 
cord injury and diabetes.  One consequence of urethral dysfunction is urinary incontinence.  
Urinary incontinence is a condition in which urine leakage occurs due to an inability of the lower 
urinary tract to maintain continence [25].  One of the most predominant forms of urinary 
incontinence is SUI [25], which is an involuntary loss of urine that occurs in the absence of a 
bladder contraction but in the presence of an increase in abdominal pressure, generally caused by 
laughing, coughing, or sneezing.  SUI is associated with a weak urethral sphincter, which is 
incapable of preventing urine flow [173]. 
Currently there are several treatments for SUI including muscle therapy, injection of 
bulking agents, and surgical treatments.  However, each of these treatments is accompanied by 
additional complications or may dissipate by re-absorption into the body over time, requiring 
additional or multiple treatments [25, 29, 42].  The inability of current treatments to provide 
long-lasting and worry-free relief from SUI requires a new approach for treatment. 
The trauma to the urethra and its surrounding organs and supportive structures during 
vaginal childbirth, resulting in SUI, can be detrimental to both organ function and support.  It has 
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previously been shown in a rat model, that in the presence of SUI, the urethra and surrounding 
structures experience varying degrees of hypoxia, atrophy, and denervation [35, 52, 174].  This 
breakdown of urethral composition is what most likely leads to the significant decreases in 
intravesicle pressure required to cause urine leakage in SUI [46, 165].  Previous studies from our 
group have shown altered mechanical properties of the urethra in a rodent model of SUI, 
particularly in the proximal portion [54].  These studies showed that SUI results in increased 
compliance in the proximal portion of the urethra at low pressures compared to healthy controls.  
Beta stiffness values for SUI specimens decreased in the proximal portion, but increased in the 
middle portion of the urethra compared to controls.  A decrease in muscular tone as well as a 
disruption of urethral extracellular matrix in this model of SUI may contribute to an inability of 
the urethra to resist deformation due to increases in intraluminal pressures [54]. 
Regenerative medicine poses many possible, cellular-based approaches to treat the 
structural and functional complications of SUI.  Some investigators have been exploring the 
injection of muscle-derived stem cells directly into the urethra [64, 157, 158, 175]. We believe 
that the mechanical and structural damages that accompany SUI render tissue engineering a 
possible solution for the urethra.  Cell injection alone may require significant time for the cells to 
become acclimated to their new environment and begin to work towards returning function.  The 
use of a biomaterial can provide a temporary matrix for the cells and acutely enhance any 
biological and mechanical benefits of the therapy [176]. 
The new therapy we propose for urethral dysfunction is to fabricate a tissue engineered 
urethral wrap (TEUW) utilizing fibrin and bone marrow progenitor cells (BMPCs), allowing for 
both an autologous matrix and cell source.  The TEUW can be placed around the native, diseased 
urethra in a cuff-like fashion and will acutely act as a bulking agent, to prevent overexpansion of 
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the urethra, and chronically provide improved functionality to the diseased tissue.  The goals of 
this work were to develop a TEUW with mechanical properties similar to that of the native 
urethra, and to show proof of concept that the TEUW is able to provide resistance to increased 
dilation of the urethra, under increased intraluminal pressures. 
4.2 MATERIALS AND METHODS 
4.2.1 Cell Source and Culture.  
Male, Lewis rat bone marrow progenitor cells (BMSCs), obtained from the Tulane Center for 
Gene Therapy [177], were cultured in complete media (α-modified Eagle’s medium (α-MEM; 
12561-072; Invitrogen, Carlsbad, CA) supplemented with 20% fetal bovine serum (FBS; lot 
selected; Atlanta Biologicals, Atlanta, GA), 1% antibiotic/antimycotic (Invitrogen, Carlsbad, 
CA), and 2 mM L-glutamine (Invitrogen, Carlsbad, CA)) at 37°C and with humidified air 
containing 5% CO2.  Media was changed every 48 hours, and cells were grown to ~80% 
confluence. 
4.2.2 Fabrication and Culture of Tubular Constructs 
Tubular constructs were fabricated (Figure 4.1) by first positioning a Teflon® mandrel 
concentrically within a glass sheath (Figure 4.1A).  A mixture containing 3 mg/mL bovine 
fibrinogen (Sigma-Aldrich, St. Louis, MO) with 0.5 units/mg bovine thrombin (Sigma-Aldrich, 
St. Louis, MO) and 0.75 x 106, 1.00 x 106, or 1.25 x 106 cells/mL in serum-free α-MEM was 
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poured around the mandrel and incubated at 37˚C  and 5% CO2 for 45 minutes (Figure 4.1B).  
Following incubation, tubular constructs were removed from the mold (Figure 4.1C-E) and 
placed into a dynamic spinner flask culture, containing complete media, supplemented with 0.3 
mM ascorbic acid and 0.1 g/mL (puriss grade) aminohexanoic acid (Sigma-Aldrich, St. Louis, 
MO).  Constructs were maintained in spinner flask culture for either 3 or 5 days.  Constructs 
were then assessed for geometric dimensional changes (compaction) and viability, mechanically 
tested, and histologically assessed. 
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Figure 4.1 Fabrication of TEUWs. (A) Mold comprised of a rubber stopper, glass sheath and Teflon® mandrel used 
to create the tubular construct. (B) Fibrin-cell mixture following gelation in the mold. (C) Tubular construct on 
mandrel following removal of the glass sheath. (D) Tubular construct after being completely removed from the 
mold. (E) End view of a section of the tubular construct. Constructs fabricated with 1.00 x 106 cells/mL following 
gelation (D), and spinner flask culture for either 3 (F) or 5 (G) days.  Scale is in cm. 
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4.2.3 Compaction and Viability 
Initial construct length was determined from the dimensions of the mold.  Following culture, 
construct length was measured with calipers, unloaded outer diameter via a He-Ne laser 
micrometer and inner diamter via histology.  Compaction was determined as a percentage of the 
original volume of the construct. 
 Viability of cells within the construct was assessed using the 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay [102].  First, construct length was measured 
and a small ring of the construct was removed and its length was measured.  The ring was cut 
into 4 equal sections, and each was placed in an individual well of a 96-well plate containing 200 
μL of media and 20 μL of MTT solution (Sigma-Aldrich, St. Louis, MO).  The plate was 
incubated for 4 hours at 37°C, 5% CO2.  Following incubation, the solution was removed from 
each well and was replaced with 200 μL of 4 nM HCl in isopropanol.  The plate was stored at 
4°C overnight.  The following day, 100 μL from each well was moved to a clean well and the 
plate was read on a spectrophotometer at 530 nm.  Absorbance values were converted to cell 
number based on a standard curve generated with cells from 2D culture.  Total cell number for 
each construct was determined by the calculated cell number from the MTT assay and the 
dimensions of the construct, assuming a homogeneous distribution. 
4.2.4 In-Vitro Mechanical Testing 
Mechanical testing was performed as previously described by our group [53, 54, 101, 142, 143] 
and described in Section 2.2.5.  Briefly, constructs were mounted on stainless steel tees in a 
bathing chamber and maintained in a physiologic environment via a circulation loop.  In order to 
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remove viscoelastic effects, constructs were preconditioned by changing intraluminal pressures 
from 0 to 8 mmHg every 10 s for 10 cycles with a fluid reservoir.  Preconditioning was followed 
by mechanical testing, which consisted of increasing the intraluminal pressure from 0 to 20 
mmHg in 2 mmHg steps, while simultaneously recording the outer diameter and intraluminal 
pressure of the construct [142].  Following this, burst pressure was determined by increasing the 
intraluminal pressure until failure of the construct [178].   
4.2.5 Histologic Assessment 
Following mechanical testing, specimens were fixed in 4% paraformaldehyde (Fisher, 
Pittsburgh, PA), cut in half and processed for both paraffin and frozen sections in 10 μm 
sections.  Paraffin sections were stained with Lillie’s-modified Masson’s trichrome, hematoxylin 
and eosin (H&E), and picrosirius red (PSR).  Frozen sections were stained for alpha-smooth 
muscle actin (α-SMA) and actin filaments (Sigma-Aldrich, St. Louis, MO).  Sections were 
permeabilized with 0.1% Triton-X-100 in phosphate buffered saline (PBS) for 15 minutes.  
Sections were then blocked in PBS containing 0.02% (w/v) bovine serum albumin (Fraction V, 
Sigma-Aldrich, St. Louis, MO) and 0.015% (w/v) glycine (Sigma-Aldrich, St. Louis, MO) for 45 
minutes.  Sections were incubated with a primary antibody against α-SMA (clone 1A4; Sigma-
Aldrich, St. Louis, MO) (1:500 in blocking solution) for 1 hour in a humidification chamber at 
room temperature.  Unbound primary antibody was removed from sections by multiple washes 
with PBS.  Next, sections were incubated with an Alexa 488-conjugated secondary antibody 
(Invitrogen, Carlsbad, CA) (1:500 in blocking solution) for 1 hour at room temperature in a 
humidification chamber.  Additional sections were incubated with Alexa 488-conjugated 
phalloidin (Sigma-Aldrich, St. Louis, MO) (1:250 in PBS) for visualization of f-actin filaments.  
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All sections were counter-stained with DAPI for nuclear visualization, and mounted with 
gelvatol.  Sections were imaged on a color digital camera (Olympus, Dulles, VA) on a BX45 
Olympus microscope (Olympus, Dulles, VA) using MagnaFire software (Olympus, Dulles, VA). 
4.2.6 Mechanical Characteristics 
The TEUWs were relatively thick, necessitating a determination of their inner diameter for 
proper calculation of various mechanical parameters.  Paraffin sections stained for Lillie’s-
modified Masson’s trichrome were imaged as described above and used for thickness assessment 
as described in Section 2.2.7. 
4.2.7 Ex-Vivo Studies 
To show that our TEUW is capable of providing bulking support to the native urethra upon 
implantation, preliminary ex-vivo studies were performed.  Adult, female, Sprague-Dawley rats 
(200-250 g) (Hilltop Lab Animals, Inc., Scottdale, PA) were used in the proof-of-concept 
assessment.  Animals were housed at the University of Pittsburgh under the supervision of the 
Department of Laboratory Animal Resources.  The policies and procedures for the animal studies 
are in accordance with those detailed in the Guide for the Care and Use of Laboratory Animals, 
published by the US Department of Health and Human Services.  Procedural protocols were 
approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee. 
 The SUI group was created by first anesthetizing the animal with 4% halothane, and then 
creating a bilateral pudendal nerve transection using aseptic, surgical techniques [147].  
Continent animals served as controls.  Two weeks after the initial procedures, animals were 
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anesthetized with urethane (1.2 g/kg), and the urethras were excised as previously described by 
our group [53, 54].  Briefly, PE-50 tubing (Becton-Dickson, Franklin Lakes, NJ), was inserted 
through the urethra into the dome of the bladder.  The dome of the bladder, as well as the 
external urethral meatus, was ligated to the catheter with 4-0 silk suture (Syneture, Mansfield, 
MA).  The ureters were ligated and served as anatomical landmarks for the maintenance of in-
vivo length during mechanical testing.  The urethra was then separated from the surrounding 
tissues and placed in oxygenated media 199 (Sigma-Aldrich, St. Louis, MO), containing 
antibiotic/antimycotic and L-glutamine (Invitrogen, Carlsbad, CA), to prevent hypoxia of the 
tissue.  Tissue was transported to our testing facility on ice. 
 Urethras were then fitted with a TEUW, which contained 1.00 x 106 cells/mL and had 
been cultured for 5 days in spinner flask.  The TEUW was cut along the longitudinal axis and 
placed around the native urethra, in a cuff-like fashion.  The construct was closed around the 
urethra by interrupted stitches with 10-0 nylon suture (AROSurgical, Newport Beach, CA).  
Urethra-TEUW specimens were mounted into the testing system and mechanically tested as 
described above.  Because the urethra is not homogeneous along its length, proximal, middle and 
distal segments were assessed individually [54, 141].  Following testing of the urethra in the 
presence of the TEUW, the TEUW was carefully removed, and the urethra was tested again.  
This testing order was necessary due to the ex-vivo placement of the TEUW requiring use of a 
dissection microscope and the desire to minimize handling of the tissue, which could cause 
differences in mechanical characteristics. 
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4.2.8 Statistics 
Data is represented as the average ± standard error of the mean.  Statistical comparisons were 
performed using the software package SPSS (version 16.0, SPSS, Inc., Chicago, IL).  For 
comparisons between groups, a one-way ANOVA was used with the factor being either time or 
seeding density.  Post-hoc testing was performed with a Bonferroni or Games-Howell test.  
Significance was detected at p-values less than 0.05. 
4.3 RESULTS 
4.3.1 TEUW Construct Appearance and Dimensions 
Following dynamic culture, constructs had an opaque, tissue-like appearance and maintained an 
open lumen (Figure 4.1F-H).  Constructs were easy to handle and capable of being mounted 
with 4-0 silk suture onto stainless steel cannulae.  Further tests showed that constructs were able 
to be sutured with 10-0 nylon suture without damage (data not shown). 
All constructs compacted to a great extent in all dimensions over their culture duration.  
The average compaction (Figure 4.2) for all constructs, regardless of density or culture duration, 
was 98.2%.  Constructs composed of 1.25 x 106 cells/mL compacted significantly more (p=0.02) 
at 5 days (1.27±0.13%) than 3 days (2.07±0.23%).  There were no other significant differences in 
compaction detected between time points or between seeding densities at 0.75 x 106 or 1.00 x 106 
cells/mL.  Values for all experiments can be found in Appendix D.  
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Figure 4.2 Average compaction, calculated at a percentage of the initial volume for constructs fabricated from 7.50 
x 105, 1.00 x 106, or 1.25 x 106 cells/mL for 3 (n=3) or 5 (n=4) days.  Overall is the overall average compaction from 
all seeding densities and culture durations.  Data shown as average ± SEM, *p<0.05. 
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4.3.2 Viability 
MTT results showed a trend towards a decrease in cell density with increased culture duration 
for all seeding densities (Figure 4.3).  There were no statistically significant differences in 
viability between seeding densities at either 3 or 5 days or between time points within a given 
seeding density. 
 
 
 
Figure 4.3 Average estimated total cells from the MTT assay for constructs fabricated from 7.50 x 105, 1.00 x 106, 
or 1.25 x 106 cells/mL for 3 (n=3) or 5 (n=4) days.  Data shown as average ± SEM.  No statistically significant 
differences were found between any groups. 
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4.3.3 Mechanical Characteristics 
Burst pressure results revealed a trend towards increased burst strength with increased culture 
duration for all seeding densities (Figure 4.4).  However, there was no obvious correlation to 
seeding density for either culture duration.  No significant differences were detected between any 
groups. 
 
 
 
 
 
Figure 4.4 Average burst pressure values for constructs fabricated from 7.50 x 105, 1.00 x 106, or 1.25 x 106 
cells/mL for 3 (n=3) or 5 (n=4) days.  Data shown as average ± SEM. 
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Pressure-diameter curves were non-linear, typical of native soft tissues, for all seeding 
densities at both culture durations (Figure 4.5).  The slopes of the pressure-diameter curves 
decreased with increased culture for 0.75 x 106 and 1.25 x 106 cells/mL, but increased for 1.00 x 
106 cells/mL.  All curves showed an initial resistance to pressure increases, which was 
maintained best by 0.75 x 106 at 3 days.  At 5 days, curves were similar for all constructs.  This 
trend can also be visualized in the stepwise compliance curves ( 
Figure 4.6), where it is obvious that as pressure increased, compliance values seemed to 
approach a threshold value at higher pressures.  Constructs composed of both 1.00 x 106 and 1.25 
x 106 cells/mL were more compliant at 3 days compared to 5 days at low pressures, while the 
inverse was true for 0.75 x 106 cells/mL constructs.  At 3 days 1.00 x 106 cells/mL and at 5 days 
0.75 x 106 cells/mL constructs were the most compliant at low pressures, while the remaining 
constructs were very similar to each other at 3 days, 1.25 x 106 was more compliant than 1.00 x 
106 cells/mL at 5 days.  Beta stiffness (Figure 4.7) values showed a consistent decreasing trend 
with increased culture duration for all seeding densities. 
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Figure 4.5 Average pressure-diameter curves for constructs fabricated from 7.50 x 105, 1.00 x 106, or 1.25 x 106 
cells/mL for 3 (n=3) or 5 (n=4) days, where NID is the diameter normalized to the diameter at 0 mmHg.  Data 
shown as average ± SEM. 
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Figure 4.6 Average stepwise compliance curves for constructs fabricated from 7.50 x 105, 1.00 x 106, or 1.25 x 106 
cells/mL for 3 (n=3) or 5 (n=4) days.  Data shown as average ± SEM. 
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Figure 4.7 Average beta stiffness values for constructs fabricated from 7.50 x 105, 1.00 x 106, or 1.25 x 106 
cells/mL  for 3 (n=3) or 5 (n=4) days.  Data shown as average ± SEM. 
 
4.3.4 Histology 
H&E staining showed a homogeneous distribution of cells through the thickness of all constructs 
(Figure 4.8A-F).  No differences in cell distribution or density were qualitatively detected 
between any groups.  Both trichrome and PSR staining were negative (data not shown), 
indicating that no collagen was produced for any seeding density during either 3 or 5 days of 
dynamic culture.  Staining for α-sma was also negative for all conditions, indicating that 
dynamic culture within a spinner flask is not enough to stimulate differentiation of these BMPCs 
to smooth muscle cells. 
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Figure 4.8 Representative H&E sections from constructs fabricated from 7.50 x 105 (A,D), 1.00 x 106 (B,E), or 1.25 
x 106 (C,F) cells/mL for 3 (A-C) or 5 (D-F) days.  Images taken at 10x, L indicates the lumen of each construct. 
 
 
4.3.5 Ex-Vivo Studies 
Placement of the TEUW around the diseased urethra (Figure 4.9) decreased compliance 
compared to the urethra alone (Figure 4.10).  The TEUW was able to provide some mechanical 
support to the diseased tissue, minimizing dilation of the proximal portion upon increases in 
intraluminal pressures. 
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Figure 4.9 Pictures of a healthy, unwrapped urethra (A), a wrapped urethra (B) and a wrapped urethra under 
pressure.  Arrows indicate sutures. 
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Figure 4.10 Average compliance values for dysfunctional urethras with and without a TEUW around the proximal 
portion of the urethra (n=2).  Data shown as average ± SEM. 
 
4.4 DISCUSSION 
We have demonstrated that a tissue engineered urethral wrap, composed of fibrin and bone 
marrow progenitor cells, may provide support to the diseased urethra.  Mechanical properties 
show burst pressures greater than typical peak intraurethral pressures (~40 mmHg in the rat 
[179]), while maintaining compliance values similar to those of a healthy urethra [142].  Ex-vivo 
testing provides proof-of-concept that when placed around a dysfunctional urethra, the TEUW 
lends structural support, decreasing the compliance of the tissue by not allowing it to distend as 
much as it would in its diseased state, allowing urine leakage. 
Current treatments for urethral dysfunction include the use of bulking agents, which 
dissipate over time; implantation of synthetic materials, which can cause erosion of the 
surrounding tissues [154], or use of urogenital tissue, which are limited in source and may cause 
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fistula or stricture formation [180].  Many tissue engineering approaches attempt to replace the 
damaged or diseased portion of the urethra, which may also lead to fistula or stenosis [181] and 
requires the replacement to withstand contact with urine as well as urethral pressures during 
micturition.  Our approach is based on augmenting the diseased tissue, while keeping it intact.  In 
using fibrin, the TEUW can degrade as the stem cells provide structural and biological support to 
the tissue. 
We observed a homogeneous cell distribution for all densities at both culture durations, 
which is typically seen in fibrin gels [96].  Our mechanical characteristics agree with those in the 
literature showing that mechanical properties increase with increasing compaction [97].  The 
inverse trend seen between cell viability and burst pressure disagrees with what has been 
reported previously for smooth muscle cells in fibrin [97].  This may be a result of the interaction 
between the BMPCs and fibrin during culture.  These BMPCs are highly proliferative and 
compaction of the constructs may be impeding this proliferation via contact inhibition.  The 
compaction seen in our constructs (1.81% of initial volume) is slightly greater than that 
published on fibrin gels containing smooth muscle cells (~3-4%) [94, 97, 182].  This difference 
could be a result of many factors including the concentrations of fibrin and/or thrombin [97] and 
the difference in the reaction of the cell type to the fibrin substrate. 
We believe that the lack of collagen production for constructs was due to our short 
culture durations.  Most in-vitro studies showing collagen production in fibrin involved culture 
for 2 or more weeks and used smooth muscle cells or fibroblasts, which tend to produce large 
amounts of collagen naturally [94, 100, 182].  We do believe that following implantation the 
body will act as a bioreactor and stimulate collagen production in-vivo, either by the BMPCs or 
by host cells that migrate into the TEUW. 
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Limitations of the current study include use of the MTT assay for cell viability.  Most 
metabolic viability assays, including the MTT assay, were developed for 2D cultures.  The three-
dimensional nature of our constructs presents many challenges in using this assay.  It may be 
more difficult for the reagents to diffuse through the matrix to reach the cells and the metabolic 
activity of cells in 3D may be very different than in 2D [183].  Other assays such as cell counting 
from histologic sections may have been more appropriate.  Additional mechanical testing, 
including tensile tests, would have been beneficial in determining the ultimate mechanical 
properties of these constructs.  Although we utilized ascorbic acid in the culture media to 
enhance collagen production other methods such as the addition of TGF-β or use of mechanical 
stimulation may have been more beneficial (Chapter 6.0 ) [94, 100, 102]. 
This study has laid a foundation for further development of the TEUW for urethral 
dysfunction.  We have developed a wrap with appropriate mechanical properties to provide 
support to the diseased urethra, and have shown that the TEUW is capable of decreasing the 
compliance of a diseased urethra.  The TEUW shows promise for an autologous therapy to 
provide support to the urethra.  We believe that our future studies will continue to show the short 
and long term benefits of the TEUW to urethral function. 
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5.0  DESIGN OF AN INDEPENDENT, MULTI-CHAMBER BIOREACTOR FOR 
TUBULAR CONSTRUCTS 
As tissue engineering and regenerative medicine continue to grow and expand so does bioreactor 
technology.  Bioreactors have been used for decades for the culture and rapid expansion of 
microbes or mammalian cells, but the expansion to culture of 3-D structures required the 
expansion of concepts and design [184].  Today, bioreactors are generally utilized to increase 
diffusion of nutrients from media to cells within a matrix as well as to provide stimuli to those 
cells to enhance maintenance of, or differentiation to, a desired phenotype.  A variety of 
bioreactors have been implemented [180, 184, 185] and some commercialized [186-188] to 
provide mechanical stimulation to constructs, with the majority of bioreactors designed for the 
culture of bone/cartilage replacements or vascular grafts [184, 189, 190] as reviewed below and 
summarized in Table 5.1. 
One bioreactor utilized compression loading of multiple samples simultaneously within a 
petri dish by paddles within static bathing media to enhance cell alignment for cartilage 
engineering [191].  Another cartilage bioreactor utilized biaxial strain, delivered by a 
piezoelectric stamp, to stimulate osteoblasts within a collagen gel [192].  This system utilized 
open loop circulation, where the constructs were continuously exposed to fresh media for the 1 to 
3 week culture period, and allowed for the stimulation of four independent constructs at a time 
[192].  A bioreactor for the development of bladder tissue utilized a pressure system where a 
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sheet of ECM seeded with cells was clamped between two chambers and exposed to pressure, 
which was controlled by a closed-loop feedback system, on one side [193].  Due to the short 
duration of these experiments (18 hours), no media circulation was utilized [193]. 
In contrast to cartilage tissue engineering, vascular or tubular tissue engineering tends to 
utilize one of two culture methods, perfusion or rotation.  One study assessed the difference 
between rotation and perfusion culture with two custom made systems, which can be run within 
a standard incubator and culture one construct at a time [194].  The rotating bioreactor consisted 
of a cylinder filled with media, in which the construct was immersed, which was placed on a 
variable speed rotator to provide mixing of the culture media for enhanced oxygen and nutrient 
uniformity [194].  The perfusion bioreactor utilized a continuous flow, closed-loop circulation, 
which provided pulsatile flow and shear stress to the lumen of the mounted construct [194].  
Other perfusion bioreactors for the delivery of pulsatile flow have also been developed [106, 
185, 195-197].  Some allow for only one construct [196, 197] to be cultured at a time with [197] 
or without [196] media changes over the culture duration, while others allow for the 
simultaneous culture of multiple constructs, which share bathing and/or luminal media [106, 185, 
195].  In addition, BOSE® and Tissue Growth Technologies (TGT) have developed several 
versatile, commercially available bioreactors including ones for compression, tension or 
perfusion with or without tension or compression, all of which are computer controlled and allow 
for culture of one or multiple constructs simultaneously and independently [186, 188]. 
However, these bioreactors have several shortcomings, including their large size [198, 
199], which requires them to be run on a bench top while maintaining appropriate gas and 
temperature conditions and also to utilize a large volume of media, increasing experimental cost.  
Another limitation of these bioreactors is the number of constructs they can culture at one time.  
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If they are built to accommodate multiple constructs, the constructs generally share media, 
generating replicates instead of independent experiments.  The independent culture of constructs 
is needed to limit cross-contamination of shared media between constructs by cells within one of 
the constructs.  Although the commercially available systems provide independent culture, they 
tend to be quite expensive. 
Development of a compact, multi-chamber bioreactor capable of accommodating up to 
four independently cultured constructs reduces experimental cost by decreasing required media 
volumes and eliminates additional means of temperature and gas regulation as it can be run 
within a standard cell culture incubator.  The separation of each unit allows various culture 
conditions to be run simultaneously and prevents cross-contamination between constructs.  The 
goal of this work was to design a space- and cost-efficient bioreactor for the perfusion of 
multiple tubular constructs, for augmentation of the urethra, under minimal pressure and flow. 
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Table 5.1 Summary of bioreactors and their main features. 
 Number of 
Constructs 
Media 
Volume 
Constructs 
Share Media 
Media Change/ 
Monitoring 
In 
Incubator 
Feedback 
Control 
Type(s) of 
Stimulus 
Punchard et 
al., 2007 [196] 
1 NA NA No/No Yes No Pulsatile Flow 
Xu et al., 2005 
[197] 
1 NA NA Yes/No Yes Yes Pulsatile Flow 
BOSE® [186] 1 and up NA No Yes/Yes Yes Yes 
Pulsatile, 
Compression 
and Tension 
TGT [188] 1-6 NA No Yes/Yes Yes Yes 
Pulsatile, 
Compression 
and Tension 
Huang et al., 
2005 [106] 
3 250 mL Yes No/No Yes No Pulsatile Flow 
Hahn et al., 
2007 [195] 
3 NA Yes No/No Yes No Pulsatile Flow 
Williams et al., 
2004 [185] 
1 and up 
1000 
mL 
Yes Yes/No Yes No Pulsatile Flow 
Au-yeng et al., 
2009 [191] 
4 7 mL Yes Yes/No Yes No Compression 
Meyer, et al., 
2005 [192] 
4 NA No Yes/No Yes No Biaxial Strain 
Arrigoni et al., 
2008 [194] 
1 100 mL NA No/No Yes No 
Pulsatile Flow 
or Rotation 
Wallis et al., 
2008 [193] 
1 NA NA No/No Yes Yes Pressure 
Altman et al., 
2002 [198] 
24 NA No Yes/Yes No Yes 
Rotational 
Strain 
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5.1 METHODS 
5.1.1 Bioreactor Design 
One design constraint for the bioreactor was limiting the size of the entire system to that of a 
standard incubator tray (18 x 18 in).  Another was minimizing the volume required for each 
circuit.  Easy access for sampling to measure environmental conditions (pH, pCO2, pO2 and 
pressure) for each circuit was desired.  Each circuit was designed to include a pump (Section 
5.1.1.1) to control flow, a culture chamber (Section 5.1.1.3) to house the constructs, a pulse-
dampener (Section 5.1.1.2) to remove pulsatility from the flow and a reservoir (Section 5.1.1.2) 
for media overflow.  All components were designed in SolidWorks® 2007 (CADVenture, 
Willoughby, OH) and fabricated at the University of Pittsburgh’s Department of Cell Biology 
and Physiology Machine Shop.  All ports and fittings were purchased from McMaster-Carr 
(McMaster-Carr, Robbinsville, NJ).  Bioreactor components were sterilized by autoclave or 
ethylene oxide (Anderson Products, Inc., Haw River, NC).  Each component of the chambers, 
pulse-dampener and reservoir was fabricated by milling them out of a solid block of Plexiglas.  
Helicoils were used for all components in each of the screw-holes to prevent stripping with 
repeated assembly and disassembly.   
5.1.1.1 Pump 
The pump for this system was a Masterflex® L/S pump (Model 77300-50, Cole-Parmer, 
Vernon Hills, IL) (Figure 5.1A).  The pump head chosen for this system was the L/S® 
Multichannel Pump Head for L/S pump tubing (Model EW-07535-04, Cole-Parmer, Vernon 
Hills, IL) (Figure 5.1B), with a flow range of 0.045 – 280 mL/min.  This pump head utilizes six 
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roller heads for low-pulsation flow and is stackable if additional circuits were required.  It is 
made of stainless steel and anodized aluminium and is able to run within an incubator 
environment.  Two-stop pharmed tubing is required for use in this head, L/S 16 pharmed tubing 
(Model 96114-16 Masterflex, Cole-Parmer, Vernon Hills, IL) was chosen based on our desired 
flow rates (Figure 5.1C).  A Masterflex controller/dispenser (Model 77300-70, Cole-Parmer, 
Vernon Hills, IL) (Figure 5.1D) was used to control the pump.  The controller was programmed 
for the pump head and tubing used in order to yield desired flow rates. 
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Figure 5.1 The Masterflex® L/S pump (A) with L/S® Multichannel Pump Head (B) and two-stop L/S 16 pharmed 
tubing (C) was controlled by the Masterflex controller/dispenser (D). 
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5.1.1.2 Pulse-dampener and reservoir 
The pulse-dampener was custom-designed as four independent chambers within one 
block unit (Figure 5.2 and Figure 5.3).  The unit is composed of a cap, rubber gasket and base.  
The pulse-dampener cap unit (Figure 5.2A and Figure 5.3A) consists of four hemispheres, each 
with a radius of 0.5 in.  The pulse-dampener base unit (Figure 5.2B and Figure 5.3B) consists of 
four cylinders, each with a radius of 0.5 in and a height of 0.75 in with both in- and out-flow 
ports on each pulse-dampener.  Each chamber can hold a total volume of 14 mL.  The three 
components are held together by compression with sixteen one-inch long thumb screws. 
The reservoir (Figure 5.4 and Figure 5.5) is a modified version of the pulse-dampener, 
where each hemisphere in the cap unit has a radius of 0.53 (Figure 5.4A and Figure 5.5A) and 
each cylinder in the base unit has a radius of 0.53 in and a height of 0.75 in (Figure 5.4B and 
Figure 5.5A).  Each chamber therefore holds a volume of 16 mL.  The reservoir unit is also 
equipped with female luers on the outer side, one at the center of each dome in the cap unit.  
These luers accommodate a double ended male luer with a 0.2 μm syringe filter (Corning, Inc, 
Corning, NY) to aid in gas exchange during culture.  However, most gas exchange occurs via 
silicone tubing (ID = 0.125 in, OD = 0.250 in, wall = 0.063 in; Masterflex, Cole Parmer 
Instrument Co., Vernon Hills, IL). 
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Figure 5.2 Solidworks® drawing of the (A) cap and (B) base of the pulse dampener.  Dimensions in inches. 
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Figure 5.3 Pictures of the bioreactor pulse-dampener as separate components from the top (A), with lid in place 
from the side (B) and with lid in place from the top (C).  Scale in inches. 
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Figure 5.4 Solidworks® drawing of the (A) cap and (B) base of the reservoir.  Dimensions in inches 
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Figure 5.5 Pictures of the bioreactor reservoir as separate components from the top (A), with lid in place from the 
side (B) and with lid in place from the top (C).  Scale in inches. 
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5.1.1.3 Construct-housing chambers 
Each culture chamber is comprised of a lid, base and rubber gasket (Figure 5.6 and 
Figure 5.7).  The lid (Figure 5.6A and Figure 5.7A) is a solid piece of Plexiglas® with a female 
luer port to accommodate an injection port for media sampling and addition of chemical agents 
to the culture.  Each construct-housing chamber (Figure 5.6B and Figure 5.7A) is outfitted with 
two ports for media inflow and outflow and two one-quarter inch swageloks® for the stainless 
steel tees described in Section 5.1.1.4.  The volume of the construct housing chamber is 149 mL.  
The three pieces are compression-fit with eight half-inch thumb screws.  The construct-housing 
chambers were designed for luminal flow to enter the constructs from the pulse-dampener and 
exit to the bathing chamber.  Media from the bathing chamber then flowed into the reservoir to 
be re-circulated through the system. 
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Figure 5.6 Solidworks® drawing of the top and side views of the chamber lid (A) and base (B).  Dimensions in 
inches. 
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Figure 5.7 Pictures of the bioreactor construct-housing chamber as separate components from the top (A), with lid 
in place from the top (B) and with lid in place from the side (C).  Scale in inches. 
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5.1.1.4 Tees and cannulae 
Each construct-housing chamber is equipped with two tees, which are comprised of 
several parts.  A three inch long piece of stainless steel tubing, with inner and outer diameters of 
0.12 and 0.25 inches, respectively, had the proximal end bored and threaded.  The end was then 
fitted with a male luer attached to a screw and a rubber gasket (Figure 5.8A-B).  The stainless 
steel tubing was also fitted with a female luer perpendicular to the long axis of the tubing and 
0.75 inches from its distal end (Figure 5.8A-B).  Tubular constructs are mounted onto cannulae 
(ID = 0.024 in, OD = 0.036 in, L = 1 in; Becton Dickson; Sandy, UT) cut to a length of 0.5 in 
(Figure 5.8C), which are then mounted onto the proximal stainless steel tees via luer fittings 
(Figure 5.8D). 
 
 
Figure 5.8 Side (A) and top (B) images of a stainless steel tees used in the bioreactor.  The cannulae on which the 
construct is mounted (C) is attached to the male luer of the stainless steel tees (D). 
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5.1.1.5 Filling of the bioreactor 
A system consisting of a 60 mL syringe (Becton-Dickinson, Franklin Lakes, NJ), a 
manifold (Medtronic, Minneapolis, MN), pigtails (Becton-Dickinson, Franklin Lakes, NJ), and 
male-to-male luers (Argon Medical Devices, Athens, TX) was utilized to fill the system by 
gravity.  The system (Figure 5.9A) was assembled by removing the plunger from the syringe, 
which was placed on a ring stand.  The syringe was attached to a five port manifold by a pigtail 
(Figure 5.9B).  The manifold ports were each attached to a pigtail which was connected to the 
female luer on the construct-housing chamber lid by a male-to-male luer (Figure 5.9C).  Media 
was poured into the syringe and flowed into the construct-housing chambers by gravity.  Each 
chamber was filled until the level of media reached its distal outflow port. 
5.1.1.6 Environmental conditions 
Since the bioreactor is run within a cell culture incubator, temperature and gas 
concentration are automatically regulated.  The main mechanism of gas exchange between the 
bioreactor and incubator was silicone tubing (ID = 0.125 in, OD = 0.063 in; Masterflex; Cole-
Parmer, Vernon Hills, IL).  As stated in Section 5.1.1.3, each chamber is equipped with an 
injection port.  This port was used to take media samples for measurement of pH, pCO2, and pO2 
via a blood gas analyzer (ABL5TM, Radiometer Medical A/S, Copenhagen, Denmark).  The 
female luers on the stainless steel tubing described in Section 5.1.1.4 served as the attachment 
site for pressure transducers (Edwards Life Sciences, Irvine, CA), which were used to monitor 
proximal and distal intraluminal pressures during culture.  Pressure transducers were zeroed to 
the atmosphere then opened to the system and allowed to stabilize prior to each measurement. 
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Figure 5.9 Photographs of the entire filling apparatus (A), the reservoir to the manifold (B) and the manifold to the 
chambers (C). 
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5.1.2 System Verification 
5.1.2.1 Flow rate 
Flow rate was determined by assembling the system on an incubator tray on the bench 
top.  The system was filled with deionized water, and the pump was turned on.  Once all air was 
removed from the circuit, the system was allowed to equilibrate for ten minutes.  Following 
equilibration, the tubing connected to the distal stainless steel cannula was separated from the 
chamber.  The fluid exiting the cannula was collected in a graduated cylinder for 20 seconds and 
the volume was recorded.  This process was performed for each circuit and repeated twice.  The 
average for each chamber was multiplied by three and taken as the flow rate (mL/min) for each 
chamber for the designated pump settings.  Values across chambers were compared to evaluate 
uniformity of flow. 
5.1.2.2 System sterility and stability 
Stability of the system was assessed by sterilizing the system and assembling in a cell 
culture laminar flow hood with sterile gloves.  The system was filled with complete media (as 
defined in Section 4.2.1) and run in the cell culture incubator for 5 days.  Environmental 
conditions were monitored for the duration of the experiment as described in Section 5.1.1.6.  A 
first assessment of system sterility was the opaqueness of the media.  ABL readings for pH, 
pCO2, pO2 and HCO3- were averaged both for each chamber over the entire culture duration and 
across all chambers each day.  Values were compared to control media contained in a vented 
conical tube within the same incubator as the bioreactor system. 
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5.1.2.3 Mounting of constructs 
Mounting of fibrin constructs (see fabrication in Section 4.2.2) was assessed on the 
bench top.  One cannula was placed onto the stylet for a spinal needle (Becton Dickson; Sandy, 
UT) (Figure 5.10A) and guided through the lumen of the construct.  Another cannula was placed 
on the stylet (Figure 5.10B).  The stylet was then mounted into a clamp assembly (Figure 
5.10C-D).  Cannulae were adjusted so that they were ~1 – 1.5 mm inside each end of the 
construct.  The construct was then tied to the cannulae with 4-0 silk suture (Syneture, Mansfield, 
MA).  The stylet was removed and a 3 mL syringe of blue dye was attached to one of the cannula 
and gently depressed until flow through the construct was visible.  The assembly was observed 
for leakage at the suture line. 
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Figure 5.10 Images depicting the process of mounting a construct onto the cannulae.  The guide is threaded through 
one cannula (A), the construct and then another cannula (B).  The guide is then placed into the clamp assembly (C-
D).  Scale in inches. 
5.1.3 Statistical Analyses 
Data is represented as the average ± standard error of the mean.  Flow rates were averaged for 
each chamber.  Environmental conditions were averaged for each chamber over the entire culture 
period as well as across chambers at each day of culture.  Bioreactor values were compared to 
those of media housed within a vented conical tube kept in the same incubator as the bioreactor.  
Statistical comparisons were performed using a Student's t-test.  Significance was detected at p-
values less than 0.05. 
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5.2 RESULTS 
5.2.1 Bioreactor Fabrication 
The entire system was able to fit on a standard cell culture incubator tray when assembled 
(Figure 5.11) and required only 500 mL of media for the culture of four independent constructs.  
As all of the components are sealed by compression, there is a pressure threshold, above which, 
leaking will occur.  However, all of our experiments were performed at low pressures, well 
below the threshold of leaking (~40 mmHg). 
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Figure 5.11 A picture of the entire bioreactor system assembled on a cell culture incubator tray.  Stars represent 
injection ports and pluses represent ports for pressure transducers. 
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5.2.2 Flow Rate 
A minimal average intraluminal flow rate of 3.6 mL was obtained for each of the four chambers 
(n=3) as seen in Table 5.2.  The average flow rate for each chamber was 3.6 mL (Figure 5.12).  
There were no significant differences between flow rates from any of the chambers. 
 
Table 5.2 Experimental values for flow determination for all chambers. 
 Run 1 
mL/min 
Run 2 
mL/min 
Run 3 
mL/min 
Average 
mL/min 
SEM 
mL/min 
Chamber 1 3.6 3.6 3.6 3.6 0 
Chamber 2 3.6 3.6 3.6 3.6 0 
Chamber 3 3.6 3.6 3.6 3.6 0 
Chamber 4 3.6 3.6 3.6 3.6 0 
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Figure 5.12 Average flow rates for each chamber (n=3) in the bioreactor circuit.  Values are shown as average ± 
SEM. 
5.2.3 Sterility and Stability 
The media in each chamber was clear and lacked cloudiness for the duration of the experiment, 
indicating no visible signs of contamination.  There were no significant differences between any 
chamber of the bioreactor and the conical tube for any environmental condition (Figure 5.13 and 
Figure 5.14).  Measurements are relatively uniform across chambers and timepoints (Table 5.3, 
Table 5.4, Table 5.5, and Table 5.6), with no significant differences detected.  Error bars for 
each condition are small, indicating minimal variation within each chamber over the culture 
duration. 
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Figure 5.13 Average environmental conditions for each chamber over the culture duration.  Values shown as 
average ± SEM. 
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Figure 5.14 Average environmental conditions across all chambers for each day of culture.  Values shown as 
average ± SEM.  Dotted lines indicate an acceptable range for each parameter as determined in Appendix E. 
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Table 5.3 pH values for each chamber at each day of culture. 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Chamber 1 7.30 7.29 7.28 7.30 7.28 
Chamber 2 7.33 7.29 7.26 7.31 7.28 
Chamber 3 7.30 7.31 7.28 7.31 7.30 
Chamber 4 7.28  7.30 7.32 7.30 
Conical Tube 7.36 7.31 7.30 7.30 7.30 
 
 
 
Table 5.4 pCO2 values (mmHg) for each chamber at each day of culture. 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Chamber 1 36 38 38 36 38 
Chamber 2 34 38 40 36 38 
Chamber 3 37 38 39 36 36 
Chamber 4 38  36 34 36 
Conical Tube 31 36 36 35 36 
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Table 5.5 pO2 values (mmHg) for each chamber at each day of culture. 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Chamber 1 158 144 145 145 139 
Chamber 2 157 143 137 141 140 
Chamber 3 152 148 141 140 140 
Chamber 4 155  139 134 146 
Conical Tube 151 136 138 138 137 
 
 
Table 5.6 HCO3- (mmol/L) values for each chamber at each day of culture. 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Chamber 1 17 17 17 17 17 
Chamber 2 17 17 17 17 17 
Chamber 3 17 18 18 17 18 
Chamber 4 17  17 17 17 
Conical Tube 17 18 17 17 17 
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5.2.4 Construct Mounting 
Constructs were easy to handle and mount.  In order to easily thread the guide through the lumen 
of the construct, it was necessary to open the lumen by gently guiding the construct onto the end 
of a pair of Dumont #2 Laminectomy Forceps (Fine Science Tools, Inc., Foster City, CA) 
(Figure 5.15A).  The stylet was then easily threaded through the lumen of the construct (Figure 
5.15B).  The construct was strong enough to be tied securely to the cannulae with suture without 
tearing (Figure 5.15D-E).  Following initialization of flow through the mounted construct, liquid 
was visible exiting the opposite cannula (Figure 5.15F).  There was no observed leakage at 
either suture site. 
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Figure 5.15 Mounting of a construct.  The lumen of the construct was located with forceps (A), the guide was 
passed through the lumen of the construct (B) and the other cannula was added (C).  The construct was then sutured 
to the cannula (D-E).  Flow through the construct, without leaking at the suture sites, was observed (F). 
5.3 DISCUSSION 
We have designed, fabricated and tested a novel, independent, multi-chamber bioreactor for the 
culture of tubular constructs.  Our system is compact and, when assembled, fits on a standard cell 
culture incubator tray.  The compact size and use of silicone tubing and filters for gas exchange 
allows the system to be run within a standard cell culture incubator, negating the need for 
exogenous temperature and gas regulation.  The system requires a minimal volume of media 
(500 mL for four constructs) and is able to accommodate constructs of various lengths and 
diameter.  The entire system remained stable (Figure 5.13 and Figure 5.14) over a 5 day culture 
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period and constructs were easily mounted onto cannulae (Figure 5.15) and into the system.  The 
independence of each chamber allows for simultaneous culture of various mechanical and/or 
chemical conditions. 
The development of bioreactors has enhanced the field of tissue engineering by providing 
tools to expose 3-D constructs to stimuli which enhance the formation of tissue-equivalents.  
Bioreactors are designed to control the culture environment, diffusion of nutrients and 
appropriate, tissue-dependent stimuli [184, 189].  Our bioreactor meets all of these criteria.  Our 
system is run within a cell culture incubator, which has well controlled temperature and gas 
parameters, allowing us to maintain tight control of environmental (pH, pCO2 and pO2) 
conditions over a 5 day culture period (Figure 5.13 and Figure 5.14).  The minimal variation 
seen over the culture period and lack of significant differences between the bioreactor and 
conical tubes, indicate that the bioreactor maintains a stable culture environment.  To address 
possible diffusion limitations, our bioreactor allows for intraluminal flow through the construct 
as well as flow of bathing media on the outer surface of the tubular constructs, allowing for 
nutrient diffusion from both directions.  Our system also allows us to assess the effects of 
varying intraluminal pressures or flow with or without the addition of chemical stimulation. 
Previously developed bioreactors have established the importance of mechanical and 
chemical factors in the mechanical integrity of the construct as well as cell proliferation, 
migration and differentiation [99, 180, 189, 200].  However, most bioreactors lack independence 
[185, 199, 201] or are of a large size [198, 199], necessitating a large volume of media and/or 
exogenous sources of temperature and gas regulation.  The independence of our system allows us 
to compare four constructs, each cultured under various conditions simultaneously.  This 
independent system also prevents cross-contamination and communication between constructs.  
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The compact size of our system minimizes the volume of media required as well as allows it to 
be run in an incubator, reducing experimental costs. 
While our bioreactor system is both cost- and space-efficient, it is limited in several 
ways.  Since the system was designed for low pressure experiments, the pulse-dampener, 
reservoir and chambers are sealed only by compression, limiting the internal pressures it can 
withstand without leaking.  Modifications to the components, such as inclusion of a sunken o-
ring in both the lid and base, or lids with a lip that protruded into the base and sealed with an o-
ring, could allow for higher pressurization.  Although the cannulae are adjustable to 
accommodate various length constructs, the size of the chambers restricts the maximum length of 
constructs which can be mounted in the system.  The pressure transducers used in this system are 
clinical grade with an error of ± 2 mmHg.  As this is designed as a low pressure bioreactor, an 
error of 2 mmHg is quite large.  More sensitive pressure transducers would allow tighter control 
of intraluminal pressures.  Pressures can be adjusted manually by a screw clamp, but the lack of 
an internal feedback system does not protect against pressure spikes or drops that may occur.   
This study has resulted in the development of a bioreactor for the culture of tubular 
constructs under minimal pressure and flow.  We have developed a compact and stable 
bioreactor for the mechanical and chemical stimulation of constructs to be used as a TEUW. 
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6.0  EFFECTS OF PRESSURE AND THE ADDITION OF TGF-ΒETA ON THE 
MECHANICAL AND PHENOTYPIC PROPERTIES OF A TEUW 
The importance of environmental (mechanical and chemical) cues on cell phenotype has been 
well documented [126, 202].  Studies indicate that progenitor cells can be differentiated toward a 
SMC-like phenotype via mechanical (refer to Section 1.5.1) and/or chemical (refer to Section 
1.5.2) stimulation.  Bioreactors can be utilized to expose cellular constructs to these 
environmental cues for regenerative medicine therapies.  The ability to pre-condition cells to the 
environment that they will be exposed to could enhance their function upon implantation and 
lead to a faster recovery. 
Regenerative medicine techniques, applied to the native urethra, may aid in improving 
urethral function and alleviate a number of conditions associated with lower urinary track 
dysfunction.  Implementation of a bioreactor for the differentiation of stem cells to SMCs via 
mechanical and or chemical stimulation, similar to that of the lower urinary tract, could provide 
both a structural and functional treatment for urethral dysfunctions such as SUI. 
The function and structure of the urethra expose it to intraluminal pressures, which in 
turn cause circumferential, radial and longitudinal deformations of the tissue.  These 
deformations can be best replicated, for tissue engineering purposes, in a perfusion bioreactor 
similar to those used for the development of tissue engineered vascular grafts [106, 185, 192, 
195-197] (recall Table 5.1).  These studies have shown how increases in intraluminal flow and 
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pressures can differentiate cells towards a SMC phenotype and develop a more suitable graft for 
tissue replacement than constructs cultured statically.  It has been reported that TGF-β plays a 
pivotal role in smooth muscle cell development and differentiation [123, 133].  Previous studies 
(recall Section 1.5.2) have shown the promise of TGF-β for the differentiation of stem cells 
towards a SMC phenotype with and without mechanical stimulation [124, 131, 203], making it 
an attractive option to aid in BMPC differentiation within a perfusion bioreactor. 
The goal of this work was to utilize a custom built bioreactor system (Chapter 4.0 ) for 
the differentiation of BMPCs to SMCs by mechanical and/or chemical stimulation for use as a 
treatment for SUI. 
6.1 METHODS 
6.1.1 Cell culture and Construct Fabrication 
Adult bone marrow derived progenitor cells were cultured according to Section 4.2.1.  Briefly, 
cells were plated on T-175 flasks at 200 cells/cm2 and cultured in complete media.  Media was 
changed every other day and cells were grown to ~80% confluence.  In order to fabricate 
independent constructs, we used a tiered method for culturing the cells.  One flask of cells (Flask 
1) was passed into four separate flasks (Flasks 1A-1D).  Each of the four flasks was passed into 
four flasks (i.e., A.1, A.2, A.3 and A.4) (Figure 6.1).  Each set these of flasks was trypsinized 
and combined into one conical tube, yielding four separate conical tubes of cells (A-D).  Each 
tube was then used to fabricate a construct (Figure 6.2) as described in Section 4.2.2.  Briefly, 
molds were assembled by inserting a mandrel into a stopper and placing the combination inside 
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of a glass sheath.  The cell-fibrin mixture (1x106 cells/mL) was placed in the annular space of the 
mold then into a cell culture incubator to gel. 
 
 
 
 
 
 
Figure 6.1 Passage of cells for construct fabrication for utilization in the bioreactor. 
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Figure 6.2 Schematic of cell culture to produce independent constructs. 
 
 
6.1.2 Dynamic Culture 
Following gelation, constructs were removed from the molds and each construct was placed into 
its own spinner flask containing complete media (as defined in Section 4.2.1) supplemented with 
aminohexanoic (0.1 g/mL) and ascorbic (0.3 mM) acids (Sigma-Aldrich, St. Louis, MO) to 
prevent fibrin degradation and enhance collagen production, respectively.  Constructs were 
cultured in spinner flasks for 5 days. 
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6.1.3 Bioreactor Priming 
The bioreactor was primed twenty-four hours prior to implantation of constructs to equilibrate 
the culture media.  The bioreactor components (see Section 5.1.1) were assembled in a sterile 
manner, filled with ~500 mL of complete media (as defined in Section 4.2.1) and placed into the 
cell culture incubator.  The system was run overnight to eliminate any air within the system lines 
and to stabilize in the culture environment.  Before mounting of the constructs into the 
bioreactor, a media sample was taken from each chamber of the bioreactor and analyzed on the 
ABL-5 (Radiometer Medical A/S, Copenhagen, Denmark) for pH, pCO2, pO2 and HCO3-. 
6.1.3.1 Construct mounting 
Following compaction, constructs were mounted onto cannulae as described in Section 5.1.1.4.  
Briefly, constructs were first measured for initial length and then one cannula was placed onto 
the stylet from a spinal needle.  The stylet was gently passed through the lumen of the construct 
and another cannula was placed onto the guide (Figure 5.15).  The construct was mounted onto 
the cannulae with 4-0 silk suture (Syneture, Mansfield, MA).  The stylet prevented the mounting 
from closing off the lumen of the cannulae.  Once secure, the suture-to-suture length was 
measured.  The stylet was removed, and the construct was bathed in media.  After all constructs 
were mounted, the bioreactors were removed from the incubator and placed into the laminar flow 
hood.  The mounted constructs were then inserted onto the stainless steel tees in each bioreactor 
chamber via luer fittings.  If needed, additional complete media was added to the chamber to 
completely cover the construct.  Construct media supplements were also added to prevent 
degradation of the fibrin and to enhance the production of collagen within the constructs, 
respectively.  The stainless steel tees were adjusted so that the suture-to-suture length equalled 
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that of the initial end-to-end construct length, inducing a longitudinal stretch of ~10%.  This 
process was repeated for the three remaining chambers.  Once all constructs were mounted, the 
bioreactor was returned to the incubator and connected to the pressure monitor and pump 
controller. 
6.1.4 Bioreactor culture conditions 
Constructs exposed to only the initial 5 days of compaction in spinner flask culture served as 
time zero (T0) controls and were compared to constructs exposed to an additional: 5 (SF-5 day) 
or 10 (SF-10 day) days of spinner flask culture, 5 days at minimal pressure and flow with (MoT-
5 day) and without (Mo-5 day) TGF-β (10 ng/mL; R&D Systems, Inc, Minneapolis, MN) or 10 
days at minimal pressure and flow with (MoT-10 day) or without (Mo-10 day) TGF-β (Table 
6.1).  Once a day, media samples from each chamber were measured for pH, pCO2, pO2 and 
HCO3- on the ABL-5 (Radiometer Medical A/S, Copenhagen, Denmark).  Twice a day, proximal 
and distal pressure measurements were taken.  Due to the short length of the construct and the 
small inner diameter changes under low pressure, the pressure change should be linear.  
Therefore, the average of the proximal and distal measurements was used as the pressure within 
the construct.  The two daily measurements were averaged and used as the average daily pressure 
within the construct.  Following the experimental culture period, the constructs were assessed for 
mechanical properties, functional properties and cell distribution and phenotype as described in 
Sections 6.1.5, 6.1.6 and 6.1.7, respectively. 
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Table 6.1 Experimental bioreactor culture conditions and experimental number.  SF = spinner flask culture, Mo = 
minimal pressure and flow and T = addition of TGF-β to the culture media.  Time points are indicative of time in 
addition to an initial 5 days of spinner flask culture for compaction of the construct. 
 SF Mo MoT 
5 day n = 3 n = 8 n = 6 
10 day n = 4 n = 7 n = 4 
 
 
To assess the stability of the cellular phenotype following bioreactor culture, a set of 
constructs were subjected to Mo-5 day conditions then removed from the cannulae and placed 
into spinner flask culture for an additional 5 days and referred to as Mo-SF.  Constructs were 
then assessed for cell phenotype as described in Section 6.1.7.1. 
6.1.5 In-Vitro Mechanical Testing 
Following bioreactor culture, constructs were mechanically assessed as described in Section 
2.2.5.  Briefly, constructs were removed from the stainless steel cannulae in the bioreactor, 
mounted onto stainless steel cannulae (the same type used in the bioreactor) in a bathing 
chamber filled with sterile saline and de-aired.  The distal end was clamped, and the construct 
was preconditioned with ten cycles of pressure changes from 0 mmHg to 8 mmHg.  Following 
preconditioning, intraluminal pressure was incrementally increased from 0 mmHg to 20 mmHg 
in 2 mmHg steps.  Outer diameter and intraluminal pressure was recorded at 10 Hz (see Section 
4.2.4).  Immediately following mechanical testing, intraluminal pressure was increased until 
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construct failure.  Constructs were then removed from their cannulae and placed into 4% 
paraformaldehyde. 
6.1.6 In-Vitro Functional Testing 
To assess differentiation of BMPCs to contractile smooth muscle cells following bioreactor 
culture, a select group of constructs, based on SMC maker expression, were subjected to 
functional testing.  Constructs were removed from the bioreactor and mounted into a bathing 
chamber filled with Media 199 (Sigma-Aldrich, St. Louis, MO).  Constructs were sequentially 
subjected to 0 mmHg and 8 mmHg intralumenal pressures, Nω-nitro-L-arginine (100 μM; to 
remove endogenous nitric oxide synthase activity), phenylephrine (40 μM; to assess smooth 
muscle contraction), acetylcholine (5 mM; to assess any striated muscle contraction) and EDTA 
(3 mM; to inhibit muscular response) as previously described in our testing protocols for the 
urethra [141].  Each stimulus was followed by a 15 minute equilibration period, and the outer 
diameter of the middle portion of the urethra was continuously recorded at 10 Hz. 
6.1.7 Assessment of ECM and Cell Distribution 
Constructs were histologically assessed for structure and collagen by H&E, Lillie’s modified 
Masson’s trichrome and picrosirius red (see Section 6.1.7.1).  Differentiation of the BMSCs was 
assessed by immunofluorescence staining (Section 6.1.7.1) and western blotting (Section 
6.1.7.2) for the smooth muscle markers alpha smooth muscle actin (α-SMA), calponin (CALP) 
and myosin heavy chain (MHC). 
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6.1.7.1 Histology and immunofluorescence 
Constructs were processed and stained as described in Section 4.2.5.  Briefly, constructs 
were fixed in 4% paraformaldehyde for 24 hours then transferred to 30% sucrose, cut in half and 
processed for both frozen and paraffin 10 µm sections.  Paraffin sections were dewaxed, 
rehydrated and stained for H&E, Lillie’s modified Masson’s trichrome and PSR.  Sections were 
imaged on a color digital camera (Model 1KH027799; Olympus, Dulles, VA) on a BX45 
Olympus microscope (Olympus, Dulles, VA) using MagnaFire software (version 2.1; Olympus). 
Frozen sections were permeabilized, blocked, and stained with primary antibodies for the 
smooth muscle cell markers α-SMA (clone 1A4; Sigma-Aldrich, St. Louis, MO), (1:250 in 
blocking solution), CALP (DAKO, Glostrup, Denmark), (1:250 in blocking solution) and MHC 
(clone 1C10; DAKO), (1:400 in blocking solution).  Markers were fluorescently tagged with an 
Alexa 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA), (1:500 in blocking 
solution).  All frozen sections were counter-stained with DAPI for nuclear visualization, and 
mounted with gelvatol.  Immunofluorescence was imaged with a color, digital camera 
(QImaging, Surrey, BC, Canada) on an E800 Nikon Eclipse microscope (Nikon, Melville, NY) 
using NIS Elements BR 3.0 software (Nikon, Melville, NY). 
6.1.7.2 Western blotting 
To quantifiy differentiation of the cells to a smooth muscle cell phenotype, western 
blotting was performed.  Following culture, constructs were rinsed with sterile phosphate 
buffered saline and placed into an empty, pre-weighed 1.5mL tube (Bel-Art Products, 
Pequannock, NJ) and were snap frozen in liquid nitrogen followed by storeage in a -80◦C freezer.  
Samples were ground in the micro-tubes with matching pestles (Bel-Art Products) on dry ice.  A 
lysate buffer (1% Triton X-100, 1 M Tris-HCl, 5 M NaCl, 0.05% Brij 35, and 1 M NaN3 in 
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ultrapure water) supplemented with protease inhibitor and EDTA (Roche Diagnostics, Manheim, 
Germany), 2 mM serine protease inhibitor (PMSF; Sigma-Aldrich, St. Louis, MO) and 5 µg/mL 
cystein protease inhibitor in water (E-64; AG Scientific Inc., San Diego, CA) was used to lyse all 
cells within the powdered construct.  Lysates were sonicated and microcentrifuged at 13,000 rpm 
for 10 minutes.  Supernatants were collected and total protein concentrations were determined by 
the BCA assay (Pierce, Rockford, IL). 
Samples were loaded at 16 µg per well and resolved by electrophoresis on 4-15% Tris-
HCl gradient gels (Bio-Rad Laboratories, Hercules, CA) at 200 V.  Total protein was separated 
by SDS-PAGE and electro-transferred to nitrocellulose membranes (Bio-Rad Laboratories, 
Hercules, CA) in a cold Tris-glycine buffer (Pierce) at 100 V for 1 hour.  To ensure equal 
loading, membranes were stained with Ponceau-S for 30 minutes and rinsed with water to 
visualize total protein content.  Membranes were then blocked with non-fat, powdered milk 
blocking buffer (5% v/v) and incubated with primary antibody for the same smooth muscle 
markers (α-SMA (1:1,000), CALP (1:500) or MHC (1:500)) used in immunofluorescence 
(Section 6.1.7.1) overnight at 4◦C.  Membranes were then labeled with horse radish peroxidase 
goat-anti-mouse conjugated secondary antibody (1:10,000, Thermo Scientific, Rockford, IL) at 
room temperature for 1 hour.  Protein bands were detected and imaged using Supersignal West 
Femto Luminal Enhancer Solutions (Thermo Scientific, Rockford, IL) on a Kodak Molecular 
Imaging Station (v.4.5.0, Kodak, Rochester, NY). 
6.1.7.3 Cell counting 
Cell aggregation toward the inner or outer construct surface under our various culture 
conditions was assessed by regional nuclei counts.  Cell counting was performed on DAPI 
images taken with a 10x objective as described in Section 6.1.7.1.  Two fields of view were 
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imaged for each section with four sections stained per primary antibody (12 sections per 
antibody and 24 total fields of view).  Each field of view allowed for visualization of both the 
lumen and outer edge.  Images were imported into ImageJ software (National Institute of Health, 
Bethesda, MD) and thresholded for analysis.  The threshold was adjusted for each image so that 
individual nuclei were clearly visible with minimal background.  The lumen and outer edge of 
the construct were distinguished, and the area to be measured (the outer or lumen half of the 
construct) was outlined.  Automated nuclear counts in the outlined area were obtained by 
specifying the circularity of the pixels (0.83-1.00, as determined by comparing computer and 
hand-counted values for several test sample areas).  All 24 values were averaged for both the 
lumen and outer halves for each experiment and taken as the values for that experiment.  
Averages were used to calculate inner and outer percentages of total cells per field of view.  
Experimental values were averaged for each condition and compared. 
6.1.8 Statistics 
Data is represented as the average ± standard error of the mean.  Statistical comparisons were 
performed using the software package SPSS (version 16.0, SPSS, Inc., Chicago, IL).  For 
comparisons between groups, a one-way ANOVA was used with the factor being either time or 
culture conditions.  Post-hoc testing was performed with a Gabriel or Games-Howell test (for 
normally distributed data), or the Kruskal-Wallis test, followed by a Monte-Carlo test between 
groups (for non-parametric data).  Pressure-diameter data was analyzed using repeated measures 
ANOVA with a post-hoc Bonferroni test to detect overall differences in the curves between 
culture conditions.  Significance was detected at p-values less than 0.05. 
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6.2 RESULTS 
6.2.1 System Stability 
Parameter stability during culture can be seen in Figure 6.3 - Figure 6.7, where dotted lines 
indicate an acceptable parameter range (Appendix E) as determined from ABL-5 readings of 
control media or a target pressure of 5 mmHg.  Pressure values (Figure 6.3) were relatively 
stable over both 5 and 10 day culture durations.  Although some pressures were slightly higher 
than the acceptable pressure range, they were not significantly different than those within the 
range.  The remaining parameters were close to or within their acceptable range for all conditions 
over the culture duration.  There was a significant difference in pH values (Figure 6.4) between 
Mo-5 day and MoT-5 day at day 3 and between Mo-10 day and MoT-10 day at day 2, in pCO2 
values between Mo-10 day and MoT-10 day at day 7 (Figure 6.5); and in HCO3- values between 
Mo-10 day and MoT-10 day at day 0 (Figure 6.7), but all values were within or close to the 
acceptable range for each parameter and not considered biologically significant. 
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Figure 6.3 Intraluminal pressure measurements for constructs cultured under Mo-5 day (n=8), MoT-5 day (n=6), 
Mo-10 day (n=7) and MoT-10 day (n=4) show that all values fall within an acceptable range of 5 ± 2 mmHg (dotted 
lines).  Values shown as average ± SEM.  *p<0.05. 
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Figure 6.4 Environmental pH values for constructs cultured under Mo-5 day (n=8), MoT-5 day (n=6), Mo-10 day 
(n=7) and MoT-10 day (n=4) show that all values fall within an acceptable range (dotted lines).  Values shown as 
average ± SEM.  *p<0.05. 
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Figure 6.5 Environmental pCO2 conditions for constructs cultured under Mo-5 day (n=8), MoT-5 day (n=6), Mo-10 
day (n=7) and MoT-10 day (n=4) show that all values fall within an acceptable range (dotted lines).  Values shown 
as average ± SEM.  *p<0.05. 
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Figure 6.6 Environmental pO2 conditions for constructs cultured under Mo-5 day (n=8), MoT-5 day (n=6), Mo-10 
day (n=7) and MoT-10 day (n=4).  Values shown as average ± SEM.  *p<0.05. 
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Figure 6.7 Environmental HCO3- conditions for constructs cultured under Mo-5 day (n=8), MoT-5 day (n=6), Mo-
10 day (n=7) and MoT-10 day (n=4) show that all values fall within an acceptable range (dotted lines).  Values 
shown as average ± SEM.  *p<0.05. 
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6.2.2 In-Vitro Mechanical Testing 
Pressure-diameter (P-D) results (Figure 6.8) were similar for most groups, with Mo-10 
indicating a decreased compliance from the rest.  There is a visible trend of P-D curves shifting 
to the left (decreased compliance) with increased bioreactor culture duration.  The only 
significant difference was detected at 4 mmHg between Mo-5 day and Mo-10 day and the largest 
variability was seen in SF-5 day and SF-10 day constructs.  No overall significant differences in 
pressure-diameter curves between culture conditions were found.  Step-wise compliance (Figure 
6.9) shows the largest spread in data at low pressures (0-6 mmHg), with 10 day cultures having 
lower compliance values than 5 day cultures, with T0 falling between 5 and 10 day constructs.  
Significant differences were found at 18 mmHg between SF-10 day and Mo-5 day, as well as 
between SF-10 day and Mo-10 day. 
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Figure 6.8 Pressure-diameter curves for constructs cultured under T0 (n=3), SF-5 day (n=3), Mo-5 day (n=8), MoT-
5 day (n=6), SF-10 day (n=4), Mo-10 day (n=7) and MoT-10 day (n=4). Values shown as average ± SEM.  *p<0.05 
between groups at the indicated pressure. 
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Figure 6.9 Step-wise compliance curves for constructs cultured under T0 (n=3), SF-5 day (n=3), Mo-5 day (n=8), 
MoT-5 day (n=6), SF-10 day (n=4), Mo-10 day (n=7) and MoT-10 day (n=4). Values shown as average ± SEM.  
*,+p<0.05 between groups at the indicated pressure. 
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Compliance values calculated over specific pressure ranges (Table 6.2) show that at low 
pressure (0-6 mmHg) TGF-β increases construct compliance.  Culture duration also appears to 
influence the mechanical properties of TGF-β stimulated constructs where 5 day culture 
increases compliance from T0, but 10 day culture decreases it.  There was a significant 
difference between MoT-5 and Mo-10.  Middle pressure (6-12 mmHg) compliance decreased 
with culture duration (10 day < 5 day < T0), but addition of TGF-β increased compliance at both 
5 and 10 days, but with no effect of culture time.  SF-5 and -10 cultures had the highest high 
pressure (12-20 mmHg) compliance at each time point, with MoT-10 having the highest 
compliance, but also the largest variability. 
Beta stiffness values (Table 6.2) increased with increased culture duration, especially 
when cultured in the bioreactor for 10 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 160 
Table 6.2 Compliance (mmHg-1) at various pressure ranges and beta stiffness for constructs cultured under T0 
(n=3), SF-5 day (n=3), Mo-5 day (n=8), MoT-5 day (n=6), SF-10 day (n=4), Mo-10 day (n=7) and MoT-10 day 
(n=4).  Values shown as average ± SEM.  *p<0.05 and values most similar to the native urethra are shaded gray. 
 
Compliance 
x 100 
Low Pressure 
(0-6 mmHg) 
Middle Pressure 
(0-12 mmHg) 
High Pressure 
(12-20 mmHg) 
Overall Pressure 
(0-20 mmHg) 
Beta 
Stiffness 
T0 4.08 ± 0.63 8.31 ± 1.87 2.13 ± 1.50 5.74 ± 0.42 2.42 ± 0.26 
SF-5 day 6.94 ± 4.00 5.50 ± 1.99 4.16 ± 1.35 8.19 ± 3.55 3.68 ± 1.70 
Mo-5 day 7.09 ± 1.73 3.01 ± 0.41 2.49 ± 0.41 5.13 ± 0.86 4.27 ± 0.55 
MoT-5 day 8.44 ± 2.39* 4.96 ± 0.73 2.65 ± 0.33 6.82 ± 1.14 3.19 ± 0.63 
SF-10 day 2.39 ± 1.40 4.06 ± 1.11 4.82 ± 0.99 4.83 ± 1.00 2.88 ± 0.20 
Mo-10 day 0.96 ± 0.55* 2.81 ± 1.02 2.32 ± 0.39 2.33 ± 0.50 5.51 ± 0.94 
MoT-10 day 2.52 ± 1.41 4.22 ± 2.53 4.17 ± 3.24 4.66 ± 2.61 5.95 ± 1.74 
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Burst pressure results (Figure 6.10) showed no significant differences between any 
groups.  Additional SF culture over T0 had no effect on burst pressure.  However, Mo culture 
tended to decrease burst pressure, with increased culture causing larger decreases.  The addition 
of TGF-β (MoT) increased burst pressure over Mo alone at both 5 and 10 days.   
 
 
 
Figure 6.10 Burst pressure for constructs cultured under T0 (n=3), SF-5 day (n=3), Mo-5 day (n=8), MoT-5 day 
(n=6), SF-10 day (n=4), Mo-10 day (n=7) and MoT-10 day (n=4).  Values shown as average ± SEM. 
 
 
 
 
 162 
6.2.3 In-Vitro Functional Testing 
The construct showed an increase in diameter in response to an 8 mmHg increase in pressure, but 
showed no contractile response (decrease in diameter) to any agent added (Figure 6.11).  
Extraneous variations in diameter were due to an accidental bump of the pressure reservoir 
during testing.  There was an increase in diameter between Ach and EDTA, possibly due to the 
long duration of an increased intraluminal pressure or creep failure.  The final diameter increase 
was due to bursting of the construct. 
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Figure 6.11 Outer diameter response of an Mo-5 day construct to various agonists and antagonists (Nω-nitro-L-
arginine (NOSi), phenylephrine (PE), acetylcholine (Ach) and EDTA).  Data was measured at 10 Hz with 15 minute 
equilibrations at each condition.  “Time” represents the seconds into the initiation of the measurements when data 
was obtained.  Outer diameter measurements were normalized to the initial outer diameter at 0 mmHg 
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6.2.4 Histology 
Lillie’s modified Masson’s trichrome (Figure 6.12) and PSR (Figure 6.13) staining showed no 
distinct collagen production within constructs under any culture condition, although Mo-10 
showed very faint positive staining in PSR, which could be collagen or background.  The fibrin 
showed a strong autofluorescence.  Detection of positive staining was based on image 
comparison to a primary delete for each condition for IF analysis, since all culture conditions 
stained positive for α-SMA (Figure 6.14), including the Mo-SF constructs, but none were 
positive for CALP (Figure 6.15).  Only constructs cultured in the bioreactor, with or without 
TGF-β, had some positive staining for MHC (Figure 6.16), with Mo-5 and MoT-10 conditions 
showing a more homogeneous expression.  Although bioreactor culture shows some positive 
MHC staining, it lacks the intensity and structure seen in the native urethra.  The Mo-SF 
construct (Mo-5 day followed by 5 days in SF) was negative for MHC.  A summary of graded 
smooth muscle marker results is available in Table 6.3, showing that constructs culture in the 
bioreactor with or without TGF-β for either 5 or 10 days had the greatest differentiation towards 
a smooth muscle phenotype. 
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Figure 6.12 Representative trichrome staining for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-5 day, 
SF-10 day, Mo-10 day, MoT-10 day, and Mo-SF.  Images taken with a 4x objective and the native urethra served as 
a positive control.  Red = fibrin, blue/green = collagen, black = nuclei. 
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Figure 6.13 Representative picrosirius red staining for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-5 
day, SF-10 day, Mo-10 day, MoT-10 day, and Mo-SF.  Images taken with a 4x objective and the native urethra 
served as a positive control.  Red = organized and mature collagen, green = unorganized or immature collagen.  
Arrows indicate the lumen of the construct. 
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Figure 6.14 Representative α-SMA staining for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-5 day, SF-
10 day, Mo-10 day, MoT-10 day, and dedifferentiation.  Images taken with a 10x objective and the native urethra 
served as a positive control.  Blue = nuclei, green = α-SMA.  Arrows indicate the lumen.  Remaining Sections 
shown in Appendix H. 
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Figure 6.15 Representative CALP staining for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-5 day, SF-
10 day, Mo-10 day, MoT-10 day, and dedifferentiation.  Images taken with a 10x objective and the native urethra 
served as a positive control.  Blue = nuclei, green = CALP.  Arrows indicate the lumen. 
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Figure 6.16 Representative MHC staining for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-5 day, SF-10 
day, Mo-10 day, MoT-10 day, and dedifferentiation.  Images taken with a 10x objective and the native urethra 
served as a positive control.  Blue = nuclei, green = MHC.  Arrows indicate the lumen.  Remaining Sections shown 
in Appendix H. 
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Table 6.3 Graded representation of smooth muscle marker expression for constructs cultured under T0, SF-5 day, 
Mo-5 day, MoT-5 day, SF-10 day, Mo-10 day, MoT-10 day, and dedifferentiation and their comparison to the native 
urethra. 
 SMA CALP MHC 
T0 +++ - - 
SF-5 day +++ - - 
Mo-5 day +++ - + 
MoT-5 day +++ - + 
SF-10 day ++ - - 
Mo-10 day +++ - + 
MoT-10 day +++ - ++ 
Mo-SF +++ - - 
Native Urethra +++ +++ +++ 
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6.2.5 Western Blots 
Although we were able to isolate a large amount of protein from our constructs, it is 
believed that the majority of it is fibrin.  The large amount of fibrin in these constructs made it 
challenging to detect the small amounts (in comparison to fibrin) of α-SMA and MHC that were 
observed in our immunofluorescence results (Section 6.2.4).  Although blots for both α-SMA 
and CALP were blank (Appendix B), an intense band near 75 kDa was visible on MHC blots 
(Figure 6.17). 
 
 
 
Figure 6.17 Western blot stained for MHC (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day, MoT-5 day and Mo-10 day culture conditions. 
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6.2.6 Cell Distribution 
Analysis of cellular distribution indicated that there was a greater aggregation of cells towards 
the outer surface than the lumen for all culture conditions (Figure 6.18).  Only T0 and Mo-5 
conditions had aggregation percentages closest to 50% in each half of the construct.  The 
addition of TGF-β for 5 or 10 days in the bioreactor caused a greater aggregation towards the 
outer edge with Mo-10 having lower percentages than the T0 control.  Although not significantly 
significant, there was a very strong trend (p=0.06) for aggregation towards the outer surface in 
Mo-SF constructs. 
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Figure 6.18 Cell aggregation on inner vs outer portions for constructs cultured under T0, SF-5 day, Mo-5 day, MoT-
5 day, SF-10 day, Mo-10 day, MoT-10 day, and Mo-SF.  Values are shown as experimental average ± SEM.  
*p<0.05 between inner and outer portions within a culture condition. 
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6.3 DISCUSSION 
The bioreactor system was relatively stable over both 5 and 10 day culture durations (Figure 6.3-
Figure 6.7).  Although a few points fell outside of the acceptable range, they were still next to 
the line and not biologically significant.  Pressure-diameter curves indicated that compliance 
decreased with culture duration (shifted to the left of 5 day cultures), with Mo-10 day being the 
least compliant (Figure 6.8).  This is easily seen in Figure 6.9 with 5 day bioreactor cultures 
with and without TGF-β having the highest compliance, with the greatest variation in compliance 
occurring at lower pressures.  Compliance values calculated over low (0-6 mmHg), middle (6-12 
mmHg) and high (12-20 mmHg) pressure ranges showed that compared to T0 conditions, all 5 
day cultures increased low pressure compliance and 10 day cultures decreased it (Table 6.2).  
Although there was no significant difference between groups when tested for burst pressure, 
constructs exposed to bioreactor culture tended to have lower burst pressures than spinner flask 
controls (Figure 6.10).  Constructs cultured with TGF-β showed less of a decrease in burst 
pressure from spinner flask controls than those cultured without it.  Bioreactor culture increased 
differentiation towards a smooth muscle phenotype, staining positive for myosin heavy chain 
(Figure 6.16).  There was an aggregation of cells towards the outer edge of all constructs 
(Figure 6.18), indicating inadequate nutrient diffusion at the luminal surface.  An increased 
luminal flow rate could possibly reduce this outer edge aggregation.  Although there is a 
statistically significant aggregation towards the outer edge, it is only a 10% difference from 
equilibrium, which could arguably be biologically insignificant.  Although cell aggregation could 
have also been assessed along the longitudinal axis, the small size of our construct and division 
of it for both paraffin and frozen sections (Section 6.1.7.1) prevented us from assessing 
aggregation along the longitudinal axis.  Aggregation could have also been assessed in the 
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circumferential direction by dividing the circular cross-section into quadrants.  However, our 
radial assessments were made on images that were ~1/4 of the total cross-sectional area and 
randomly taken around the circumference.  Due to the minimal variability seen in the error bars 
of our radial assessment (Figure 6.18), we feel that there would be only a minimal variation in 
the circumferential assessment as well.  
Although the TEUW is designed to augment, not replace, the diseased urethra, 
mechanical properties that differ greatly from that of a healthy urethra could be detrimental.  A 
TEUW that provides either not enough support to be beneficial or too much, causing urinary 
retention would not provide an ideal treatment.  In comparing the compliance values of our 
constructs to those previously reported for the native urethra [53] we found that T0 was most 
similar to the native urethra at low (0.04 ± 0.01 vs 0.05 ± 0.01 mmHg-1) and high (0.03 ± 0.02 vs 
0.01 ± 0.02 mmHg-1) pressure ranges, while Mo-10 day was most similar to middle (0.02 ± 0.01 
vs 0.01 ± 0.00 mmHg-1) pressure compliance (Table 6.2).  However, there was a lack of collagen 
production in our constructs even with ascorbic acid and TGF-β media supplements (Figure 6.12 
and Figure 6.13).  Previous studies have reported an increase in collagen production in response 
to mechanical stimulation with or without TGF-β [94, 100, 102, 203, 204].  However, these 
reports tend to have longer culture durations (1 to 5 weeks), more rigorous mechanical 
stimulation regimens and many use smooth muscle cells, which tend to readily produce collagen, 
especially in the presence of TGF-β [205].  We do feel that implantation will enhance the 
remodelling of the constructs and initiate collagen production as the body acts as the ultimate 
bioreactor exposing the constructs to many additional stimuli.  An increase in collagen would 
provide more mechanical strength and decrease compliance values. 
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The enhanced differentiation of BMPCs to a smooth muscle cell phenotype, as seen by 
the expression of α-SMA in Figure 6.14 and MHC in Figure 6.16, in the presence of mechanical 
stimulation with or without the addition of TGF-β agrees with work previously reported with the 
same BMPCs cultured in a FlexcellTM Tissue-TrainTM system [102, 203].  These studies showed 
that cells within a micro-scale 3-D environment express the smooth muscle cell markers α-SMA 
and h-calponin when exposed to either mechanical stimulation with [203] or without [102] TGF-
β.  The lack of calponin expression in this work (Figure 6.15) could be a result of a low 
sensitivity of the antibody to the 29 kDa form of calponin found in the lower urinary tract.  
Although we see positive staining in the native urethra (Figure 6.15), it is not as intense or 
uniform as the α-SMA (Figure 6.14) or MHC (Figure 6.16) staining.  Since the constructs only 
express a small amount of MHC, it is likely that the calponin staining is too weak to detect.  
Although we see α-SMC expression under all culture conditions, we only see fully contractile 
smooth muscle cell markers with and without TGF-β at both 5 and 10 days (Table 6.3).  It 
appears that TGF-β has a greater effect on differentiation at longer culture durations.  
Qualitatively there is more positive staining for MHC with TGF-β than without in 10 day 
cultures (Figure 6.16 and Table 6.3), indicating that MoT-10 day shows the greatest degree of 
differentiation towards a SMC phenotype.  However, MHC expression was not confirmed by 
western blot results, which showed only a 75 kDa band and is most likely the product of 
degradation (Figure 6.17).  The lack of contractile response to muscular agonists (Figure 6.11), 
non-homogeneous MHC expression (Figure 6.16) and lack of cell organization (Figure 6.12) 
indicate that while some differentiation of the BMPCs to contractile SMCs has occurred, it was 
not sufficient to create a fully contractile TEUW.  While the contribution of TGF-β to smooth 
muscle differentiation has been reported [123, 126, 203], it has also been shown to increase 
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mechanical properties [94, 100, 204].  As we saw with a trend towards an increase in burst 
pressure in the presence of TGF-β (Figure 6.10), others have reported an increased modulus 
[100, 204] and tensile strength [100]. 
While this work shows the benefit of bioreactor culture with and without TGF-β to 
enhance BMPC differentiation towards a smooth muscle cell phenotype, further analyses are 
necessary.  This study focussed on minimal mechanical stimulation with and without TGF-β, but 
additional studies assessing the effects of mechanical stimuli more similar to that seen by the 
native urethra (steps to gradually increase pressure or short bursts of increased pressure) would 
also be beneficial.  Perhaps a more rigorous stimulus would decrease the loss of MHC seen in 
immunofluorescence following Mo-SF culture (Figure 6.16), enhance cell orientation in the 
circumferential direction and increase functional response to contractile agonists.  Pre-
conditioning of BMPCs in mono-layer with mechanical stimulation prior to incorporation within 
the TEUW could also benefit the mechanical properties and differentiation caused by the 
bioreactor.  The use of different pressure transducers designed for a low pressure environment 
would also reduce the variability seen in Figure 6.3.  A more rigorous control system which 
continuously measures and records media composition and intraluminal pressures would provide 
a more thorough assessment of system stability.  Also, the inclusion of a feedback loop and/or 
pressure relief valves would provide more control over the mechanical stimulation and prevent 
variations due to unexpected pressure increases during culture.  An increase n value for several 
groups could also aid in changing the trends to significant differences.  Although we were unable 
to confirm the expression of our smooth muscle markers by western blot, further studies utilizing 
immuno-precipitate may concentrate the amounts of α-SMA and MHC enough for detection. 
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This study has laid the groundwork for differentiation of BMPCs within a fibrin matrix 
by a bioreactor for urethral augmentation.  We show how bioreactor culture enhances smooth 
muscle cell maker expression while maintaining mechanical integrity.  We believe that further 
studies will enhance the work presented here and lead to a new, mechanical and functional 
support for the diseased urethra. 
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7.0  EFFECTS OF IMPLANTATION OF A TEUW ON THE MECHANICAL AND 
STRUCTURAL CHARACTERISTICS OF THE NATIVE URETHRA IN A RAT MODEL 
OF SUI 
SUI is an emotionally and physically debilitating disease that affects millions of women annually 
[2], with a large number of un-diagnosed women due to the embarrassing nature of the disease.  
While the development and onset of SUI can be caused by many factors including increased age, 
vaginal delivery, prolonged stages of labor and menopause, the main mechanisms of SUI are 
inadequate support of the urethra by surrounding tissues/structures and/or a neuromuscular 
defect [38, 206], which lead to an ineffective closure mechanism.  Although numerous 
treatments for SUI are available, most require strict patient compliance, dissipate over time, or 
are accompanied by additional complications [29, 38]. 
While tissue engineering has explored various treatments for urethral repair (refer to 
Section 1.3), most have focused on the replacement of a non-functional portion of the tissue in a 
male animal model.  The most promising results have developed from the injection of MDSCs 
into the urethra for treatment of SUI [80, 81, 85, 175].  Although the MDSCs have shown 
improvements in LPP and contraction [80, 81, 85, 157, 175], no long-term assessments of their 
location following injection have been performed.  Several studies have shown in a rat model of 
SUI that in addition to a damaged muscular component, the ECM is also damaged [35, 51] 
(Chapter 2.0 ).  Therefore, we believe that a 3-D, cell-based therapy could provide both a 
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mechanical and functional support to the diseased urethra to repair both the damaged muscle and 
ECM components.  Placement of a TEUW around the proximal portion of the urethra could 
provide both a mechanical support, to prevent overdistension of the diseased urethra during 
increases in intraluminal pressures, as well as a functional component via cells to aid in urethral 
contraction to maintain continence, providing relief from SUI. 
7.1 METHODS 
7.1.1 Animals 
Adult female Lewis and SD rats (250-300 g) (Hilltop Lab Animals, Inc., Scottdale, PA) were 
used in this study.  Animals were housed at the University of Pittsburgh under the supervision of 
the Department of Laboratory Animal Resources.  The policies and procedures for the animal 
studies are in accordance with those detailed in the Guide for the Care and Use of Laboratory 
Animals, published by the US Department of Health and Human Services.  Procedural protocols 
were approved by the University of Pittsburgh’s Institutional Animal Care and Use Committee. 
7.1.2 Surgical Procedures 
Animals were divided into three groups per strain: sham continent (SC), sham SUI (SS) and rat 
TEUW (RT) (Figure 7.1).  All initial (day 0) procedures were performed under 4% isoflurane 
anaesthetic.  SC animals received a midline incision and separation of the proximal urethra from 
the underlying vagina (Figure 7.2A).  Separation of the urethra and the vagina on both sides was 
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initiated by using cautery (Bovie® AARON Medical, St. Petersburg, FL).  A pair of Moria Iris 
Forceps (Fine Science Tools, Foster City, CA) was then used to completely separate the tissues, 
creating a 5 mm long separation (Figure 7.2A). 
SS animals received the incision, separation of urethra and vagina as well as a bilateral 
pudendal nerve transection as described in Section 3.1.3 to induce SUI. 
RT animals received the tissue separation and nerve transection, but also received 
placement of a TEUW composed of 5 x 106 BMPCs embedded in rat fibrin around the proximal 
portion of the urethra (Figure 7.2B-C).  TEUWs were fabricated as described in Section 4.2.2, 
but were made with rat fibrinogen (3 mg/mL; Sigma-Aldrich, St. Louis, Mo) instead of bovine 
fibrinogen to decrease an acute inflammatory response seen in preliminary studies (Appendix 
F).  Following fabrication, constructs were cultured in a spinner flask for 5 days prior to 
implantation (Section 4.2.2).  For implantation, constructs were cut to a length of 5 mm and 
opened along the longitudinal axis.  The construct was then wrapped around the proximal portion 
of the urethra in a cuff-like fashion (Figure 7.2B) and closed around the urethra with 10-0 nylon 
suture (ARO-Surgical) (Figure 7.2C). 
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Figure 7.1 Schematic of the test groups and procedures each receives. 
 
 
 
Three weeks following initial procedures, SD rats were assessed for V-LPP (see Section 
3.1.4) and urethral ex-vivo functional properties (see Section 3.1.8).  Lewis rats were assessed 
for urethral ex-vivo mechanical properties (see Section 2.2.5), histology and western blotting.  
Studies were divided between the two rat strains due to differences reported in Chapter 3.0 and 
the preliminary work that had been performed in Lewis rats (Appendix F). 
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Figure 7.2 Images of one representative implantation of a TEUW showing tissue separation (A), placement of 
TEUW around the proximal urethra (B) and TEUW sutured around the urethra (C).  Scale in centimeters, arrows 
indicate 10-0 suture locations. 
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7.1.3 Assessment for V-LPP and Ex-Vivo Functional Properties in SD rats 
7.1.3.1 V-LPP 
Three weeks following procedures, SD rats were assessed for V-LPP as described in 
Section 3.1.4.  Briefly, V-LPP was assessed by transecting the spinal cord at the T9-T10 level, 
ligating both ureters and clearing the colon of feces.  A catheter was implanted into the bladder 
dome and attached to both a pressure reservoir and pressure transducer.  Animals were mounted 
in the vertical position and intravescicle pressure was increased incrementally until leakage from 
the urethral orifice was visible [64]. 
7.1.3.2 Ex-vivo functional testing 
Following V-LPP, urethras were excised and mounted into a bathing chamber as 
described in Section 2.2.5.  Functional testing was performed as described in Section 3.1.8.  
Briefly, urethras were exposed sequentially to 0 mmHg and 8 mmHg intralumenal pressures, 
Nω-nitro-L-arginine (100 μM; to remove endogenous nitric oxide synthase activity), 
phenylephrine (40 μM; to assess smooth muscle contraction), acetylcholine (5 mM; to assess 
striated muscle contraction) and EDTA (3 mM; to inhibit muscular response) while measuring 
the outer diameter of the middle portion of the urethra [141]. 
7.1.4 Assessment for Ex-Vivo Mechanical Properties and Composition in Lewis rats 
7.1.4.1 Ex-vivo mechanical testing 
Ex-vivo mechanical testing was performed as described in Section 3.1.7.  Briefly, the 
urethra was isolated and mounted into our ex-vivo testing system.  The tissue was preconditioned 
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at 0 to 8 mmHg to remove viscoelastic effects and then subjected to incremental increases in 
intraluminal pressure from 0 to 20 mmHg, while measuring outer diameter [54, 142].  The tissue 
was assessed at various positions (proximal, middle and distal) along its length.  After testing, 
tissues were assessed for histology as described in Section 7.1.4.2 
7.1.4.2 Histology 
The tissue was processed and stained as described in Section 3.1.9.  Briefly, the tissue 
was fixed in 4% paraformaldehyde for 24 hours then transferred to 30% sucrose, and cut into 
proximal, middle and distal segments.  Each segment was cut in half and processed for both 
frozen and paraffin 10 µm sections.  Paraffin sections were dewaxed, rehydrated and stained for 
H&E, Lillie’s modified Masson’s trichrome and PSR.  Sections were imaged on a color digital 
camera (Olympus, Dulles, VA) on a BX45 Olympus microscope (Olympus, Dulles, VA) using 
MagnaFire software (Olympus, Dulles, VA). 
Frozen sections, assessed for IF, were permeabilized, blocked, and stained with primary 
antibodies for the smooth muscle cell markers α-SMA (clone 1A4; Sigma-Aldrich, St. Louis, 
MO), (1:250 in blocking solution), CALP (DAKO, Glostrup, Denmark), (1:250 in blocking 
solution) and MHC (clone 1C10; DAKO), (1:400 in blocking solution) followed by Alexa 488-
conjugated secondary antibody (Invitrogen, Carlsbad, CA) (1:500 in blocking solution).  All 
frozen sections were counter-stained with DAPI for nuclear visualization, and mounted with 
gelvatol.  Immunofluorescence was imaged with a color, digital camera (QImaging, Surrey, BC, 
Canada) on an E800 Nikon Eclipse microscope (Nikon, Melville, NY) using NIS Elements BR 
3.0 software (Nikon, Melville, NY). 
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7.1.4.3 Western blotting 
To quantify changes in protein levels due to treatment, western blotting was performed as 
described in Section 6.1.7.2.  Briefly, urethras were isolated and rinsed with sterile phosphate 
buffered saline.  Urethras were then separated into proximal, middle and distal segments and 
each was placed into a pre-weighed tube and snap frozen.  Samples were ground on dry ice and a 
lysed in buffer (see Section 6.1.7.2).  Lysates were sonicated and microcentrifuged, then 
supernatants were collected.  Total protein concentrations were determined by the BCA assay 
(Pierce, Rockford, IL).  Samples were loaded at 16 µg per well and resolved by electrophoresis 
on 4-15% Tris-HCl gradient gels (Bio-Rad Laboratories, Hercules, CA) at 200 V.  Total protein 
was separated by SDS-PAGE and electro-transferred to nitrocellulose membranes (Bio-Rad 
Laboratories).  To ensure equal loading, membranes were stained with Ponceau-S to visualize 
total protein content.  Membranes were then blocked with milk blocking buffer and incubated 
with primary antibody for the same smooth muscle markers (α-SMA (1:1,000), CALP (1:500) 
and MHC (1:500)) used in immunofluorescence (Section 6.1.7.1) as well as PGP 9.5 (1:1,000), 
which is a general neuronal maker, overnight at 4◦C.  Smooth muscle marker membranes were 
then labeled with horse radish peroxidase goat-anti-mouse conjugated secondary antibody 
(1:10,000, Thermo Scientific, Rockford, IL) and PGP 9.5 membranes were labeled with horse 
radish peroxidase goat-anti-rabbit conjugated secondary antibody (1:10,000, Thermo Scientific, 
Rockford, IL) at room temperature for 1 hour.  Protein bands were detected and imaged using 
Supersignal West Femto Luminal Enhancer Solutions (Thermo Scientific, Rockford, IL) and the 
Kodak Molecular Imaging Station (v.4.5.0, Kodak, Rochester, NY).  All three urethral portions 
from each experimental condition were run together on each gel.  Densitometry results were 
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analyzed within each gel as a fold difference from the respective portion of the sham continent 
group. 
7.1.5 Statistics 
Data is presented as the average ± standard error of the mean.  Statistical comparisons were 
performed using the software package SPSS (version 16.0, SPSS, Inc., Chicago, IL).  For 
comparisons between groups, a one-way ANOVA was used.  Post-hoc testing was performed 
with a Gabriel or Games-Howell test (for normally distributed data), or the Kruskal-Wallis test, 
followed by a Monte-Carlo test between groups (for non-parametric data).  Pressure-diameter 
data was analyzed using repeated measures ANOVA with a post-hoc Bonferroni test to detect 
overall differences in the curves between experimental conditions.  Significance was detected at 
p-values less than 0.05. 
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7.2 RESULTS 
7.2.1 Assessment of V-LPP and Ex-Vivo Functional Properties for SD Rats 
7.2.1.1 V-LPP 
SD V-LPP values (Figure 7.3) show a trend of pudendal nerve transection lowering LPP 
in the SS group compared to SC.  A similar decrease is visible in the RT group, indicating the 
neither pudendal nerve transection nor placement of the TEUW had a significant effect on LPP. 
 
 
 
Figure 7.3 SD leak point pressure values for sham continent (SC), sham SUI (SS) and rat TEUW (RT) groups.  
Values shown as average ± SEM. 
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7.2.1.2 Ex-vivo functional testing 
All urethras showed a distinct response to the initial increase in pressure and to each 
chemical agent, excluding Nω-nitro-L-arginine [199] (Figure 7.4).  Each response was 
quantified with respect to the equilibrated diameter at both 8 mmHg and the prior condition 
(Figure 7.5).  With respect to 8 mmHg (Figure 7.5A), it appears that the rat TEUW group had 
responses more similar to the sham continent group than did the sham SUI group for all stimuli 
except EDTA.  The sham SUI group had a significantly greater response than sham continent 
animals to phenylephrine (PE), while the rat TEUW response was significantly lower than that of 
the sham SUI group (Figure 7.5A).  Quantification of each response with respect to equilibrium 
prior to each stimulus shows a similar trend with the rat TEUW animals being most similar to 
sham continent animals (Figure 7.5B).  Sham SUI animals had a significantly greater 
contraction in response to PE than sham continent animals. 
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Figure 7.4 Representative sprague-dawley outer diameter reponse of the middle urethra of sham continent (A), 
sham SUI (B) and rat TEUW (C) groups to various agonists and antagonists (NOSi, PE, Ach and EDTA).  Data was 
measured at 1 Hz with 30 minute equilibrations at each condition.  Outer diameter measurements were normalized 
to the initial outer diameter at 0 mmHg.  All plots are available in Appendix G. 
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Figure 7.5 Outer diameter change of the middle urethra for SD rats of sham continent (SC, n=6), sham SUI (SS, 
n=6) and rat TEUW (RT, n=4) groups to various agonists and antagonists (NOSi, PE, Ach and EDTA) with respect 
to 8 mmHg (A) and the equilibrated previous condition (A).  Data was measured at 1 Hz with 30 minute 
equilibrations at each condition.  Outer diameter measurements were normalized to the initial outer diameter at 0 
mmHg.  Values shown as average ± SEM.  *,¥p<0.05 compared to SC. 
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7.2.2 Assessment of Ex-Vivo Mechanical Properties and Composition for Lewis Rats 
7.2.2.1 Ex-vivo mechanical testing 
Pressure-diameter curves showed a left to right gradient from treatment to control groups 
in the proximal and middle portions of the urethra under both baseline (Figure 7.6) and passive 
(Figure 7.7) conditions, indicating an increase a lower compliance in treatment groups.  The rat 
TEUW curve lying to the left of the control groups indicates that it is less compliant than both 
the sham SUI and sham continent groups in both the proximal and middle portions.  Both 
baseline (Figure 7.8) and passive (Figure 7.9) step-wise compliance curves show the greatest 
difference between groups occurs at low pressures (0, 2 and 4 mmHg). 
SC rats have the greatest proximal compliance at all pressure ranges in both the baseline 
(Figure 7.10A) and passive (Figure 7.11A) states.  The proximal urethra of the SC group was 
significantly more compliance than the RT group at the overall pressure (0-20 mmHg) range in 
the baseline state (Figure 7.10A) and at both the low (0-6 mmHg) and overall ranges in the 
passive state (Figure 7.11A).  Middle urethral compliance values were highest in the SS group at 
low and overall pressure ranges in both baseline (Figure 7.10B) and passive (Figure 7.11B) 
conditions, but the SC group was significantly greater than both the SS and RT groups at high 
(12-20 mHg) pressures in the baseline state (Figure 7.10B).  Distal urethral compliance is 
greatest in the SS group at low and overall pressures, but in SC at middle and high pressures in 
the baseline state (Figure 7.10C).  The RT compliance is most similar to that of the SC group at 
both low and overall pressure ranges in the baseline state (Figure 7.10C) and middle and high 
pressures in the passive state (Figure 7.11C).  Distal passive compliance decreases from SC to 
RT in both low and overall pressure ranges (Figure 7.11C), similar to passive proximal 
compliance. 
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Figure 7.6 Baseline pressure-diameter curves for the proximal, middle and distal urethra of sham continent (SC; 
n=5), sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM. 
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Figure 7.7 Passive pressure-diameter curves for the proximal, middle and distal urethra of sham continent (SC; 
n=5), sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM, *,+p<0.05 compared to 
Sham Continent. 
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Figure 7.8 Baseline step-wise compliance curves for the proximal, middle and distal urethra of sham continent (SC; 
n=5), sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM, *,+p<0.05 compared to 
Sham Continent and $p<0.05 compared to Sham SUI at the designated pressure. 
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Figure 7.9 Passive step-wise compliance curves for the proximal, middle and distal urethra of sham continent (SC; 
n=5), sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM, *,+p<0.05 compared to 
Sham Continent at the designated pressure. 
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Figure 7.10 Baseline compliance values for the proximal, middle and distal urethra of sham continent (SC; n=5), 
sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM, *,+p<0.05 compared to Sham 
Continent. 
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Figure 7.11 Passive compliance values for the proximal, middle and distal urethra of sham continent (SC; n=5), 
sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Data shown as average ± SEM, *,+p<0.05 compared to Sham 
Continent. 
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Beta stiffness values calculated over the entire pressure range (0 to 20 mmHg), show SC 
animals to have the lowest stiffness in all three urethral portions in both the baseline and passive 
states (Figure 7.12).  SS animals had the greatest stiffness in middle urethra in both the baseline 
(Figure 7.12A) and passive (Figure 7.12B) states and in the baseline proximal portion.  RT 
stiffness values tended to fall between the SC and SS values in the proximal and middle portions 
of the urethra, indicating that it may be returning the urethra to healthy values.  However, RT 
values were slightly higher than both SS and SC groups in the distal portion in both baseline and 
passive states. 
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Figure 7.12 Baseline and passive beta stiffness values for the proximal, middle and distal urethra of sham continent 
(SC; n=5), sham SUI (SS; n=6) and rat TEUW (RT; n=7) groups.  Values shown as average ± SEM. 
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7.2.2.2 Histology 
Trichrome staining indicated a large degree of muscle (red staining) in both the proximal 
and middle portions of all three groups, with a greater degree of collagen (blue/green staining) in 
the distal portions (Figure 7.13).  The rat TEUW appeared to be completely degraded and/or 
remodeled, as the fibrin, which typically stains red/pink (recall Figure 6.12), was no longer 
visible and had been replaced by a layer of collagen on the vaginal side of the proximal urethra 
(Figure 7.13). 
PSR staining, which shows the maturity of collagen fibers, showed a strong red signal, 
indicative of mature and oriented collagen fibers, throughout most of the proximal and middle 
urethral cross-sections, with more yellow to green staining, indicative of immature and less 
oriented collagen fibers, in the distal portion (Figure 7.14).  The area surrounding the proximal 
urethra in the RT group shows a strong yellow staining where the TEUW had been placed.  The 
middle portion of the RT group qualitatively has a larger amount of green and yellow staining 
than both the SC and SS groups, although there appears to be more in the SS group than the SC 
group, indicating that both the SS and RT groups have some remodeling occurring in the mid-
uerthra.  
Smooth muscle alpha actin staining was faint for SC and RT groups, but intense for SS 
urethral portions (Figure 7.15), while the greatest calponin expression occurred in the RT group 
(Figure 7.16).  MHC expression was present in all portions of all groups, with some faint 
positive staining in the area surrounding the proximal portion of the RT group where the TEUW 
was placed (Figure 7.17). 
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Figure 7.13 Representative trichrome staining for proximal, middle and distal portions of sham continent (SC), 
sham SUI (SS) and rat TEUW (RT) urethras.  Images taken with a 4x objective.  Red = muscle, blue/green = 
collagen, black = nuclei.  The vagina is located with a V, where visible.  All images are available in Appendix H. 
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Figure 7.14 Representative picrosirius red staining for proximal, middle and distal portions of sham continent (SC), 
sham SUI (SS) and rat TEUW (RT) urethras.  Images taken with a 4x objective.  Red = mature collagen, green = 
immature collagen.  All images are available in Appendix H. 
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Figure 7.15 Representative α-smooth muscle actin staining for proximal, middle and distal portions of sham 
continent (SC), sham SUI (SS) and rat TEUW (RT) urethras.  Images taken with a 4x objective.  Green = calponin, 
blue = nuclei.  All images are available in Appendix H 
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Figure 7.16 Representative calponin staining for proximal, middle and distal portions of sham continent (SC), sham 
SUI (SS) and rat TEUW (RT) urethras.  Images taken with a 4x objective.  Green = calponin, blue = nuclei.  All 
images are available in Appendix H 
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Figure 7.17 Representative myosin heavy chain staining for proximal, middle and distal portions of sham continent 
(SC), sham SUI (SS) and rat TEUW (RT) urethras.  Images taken with a 4x objective.  Green = MHC, blue = nuclei.  
All images are available in Appendix H 
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7.2.2.3 Western blots 
Quantification of α-SMA western blots (Figure 7.18A) shows a decreasing trend from 
proximal to distal portions in all conditions (Figure 7.18B).  Between groups, the largest 
difference is observed in the proximal portion, where sham SUI animals appear to have a greater 
amount of α-SMA than those which received a TEUW.  This trend is seen for both gels, although 
at different fold changes.  No large difference or consistent trend is seen in α-SMA within the 
middle or distal portions. 
 
 
 
Figure 7.18 Western blot results for α-SMA.  Blots from n=2 rats per group (A) were quantified by densitometry 
and reported as changes in α-SMA levels in urethral portion (P=proximal, M=middle, D=distal) relative to sham 
continent (SC) animals (B).  The dotted line in (B) represents no change. 
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Calponin (molecular weight in the lower urinary tract is 29 kDa [207]) was weakly 
expressed compared to h1-calponin (molecular weight of vascular calponin is 34 kDa [208]) 
(Figure 7.19A).  Calponin, like α-SMA, trends towards decreasing from proximal to distal 
urethral portions for all conditions.  Except for the proximal portion of SS-2, the presence of 
calponin appears to be relatively consistent in each portion regardless of experimental group 
(Figure 7.19B), indicating no damage to the SMC component of the urethra by placement of the 
TEUW.  With the exception of SS-2 (Figure 7.19), all proximal urethral portions have 
unchanged urethral calponin levels relative to SC. 
 
 
 
Figure 7.19 Western blot results for calponin.  Blots from n=2 rats per group (A) were quantified by densitometry 
and reported as changes in calponin levels in urethral portion (P=proximal, M=middle, D=distal) relative to sham 
continent (SC) animals (B).  The dotted line in (B) represents no change. 
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Myosin heavy chain appears as a doublet (Figure 7.20A) with western blotting, with 
bands at 136 and 121 kDa, as determined by a relative mobility assay (see Appendix C).  The 
top band shows a decrease from proximal to middle portions and an increase from middle to 
distal portions for groups from Animal 2 and the reverse for groups in Animal 1 (Figure 7.20B).  
It appears that the SS animals have a greater amount of MHC than both RT and SC animals for 
the top band and less than SC for the bottom band, while RT animals have less MHC than SC 
animals for both bands (Figure 7.20B).  The bottom band shows an increase in expression from 
proximal to middle portions and a decrease from middle to distal portions in 75% of the animals 
(Figure 7.20B).  The presence of a doublet (at these molecular weights) is thought to be the 
result of a site-specific enzymatic cleavage of the MHC molecule. 
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Figure 7.20 Western blot results for MHC.  Blots from n=2 rats per group (A) were quantified by densitometry and 
reported as changes in MHC levels in urethral portion (P=proximal, M=middle, D=distal) relative to sham continent 
(SC) animals (B).  The dotted line in (B) represents no change. 
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PGP 9.5, a general neuronal marker, is decreased for the middle portion of both SS (50%) 
and RT (100%) groups as expected, since they both received bilateral pudendal nerve 
transections (Figure 7.21).  We see a trend of SS animals having a greater fold change in PGP 
9.5 expression than RT animals.  SS animals show an up-regulation of PGP 9.5, indicating an 
increase in innervation of the proximal portion.  RT animals were either unchanged or down-
regulated relative to SC controls. 
 
 
 
Figure 7.21 Western blot results for PGP 9.5.  Blots from n=2 rats per group (A) were quantified by densitometry 
and reported as changes in PGP 9.5 levels in urethral portion (P=proximal, M=middle, D=distal) relative to sham 
continent (SC) animals (B).  The dotted line in (B) represents no change. 
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7.3 DISCUSSION 
V-LPP was not significantly affected by pudendal nerve transection with or without placement of 
a TEUW in SD rats (Figure 7.3).  A trend towards a decreased LPP in both SS and RT groups 
compared to SC was observed (Figure 7.3).  Mid-urethral functional response was most similar 
between SC and RT groups (Figure 7.5), with SS animals having a significantly larger 
contraction than SC (Figure 7.5A-B) and RT (Figure 7.5A) animals in response to 
phenylephrine, which causes contraction of smooth muscle.  Ex-vivo mechanical testing showed 
that SS animals had the highest low and overall compliance in the middle and distal urethra 
(Figure 7.10 and Figure 7.11).  TEUW placement provided support to the diseased urethra, 
decreasing compliance values in the proximal urethra compared to SS and showed downstream 
effects, producing low and overall compliance values similar to those of control SC animals 
(Figure 7.10 and Figure 7.11).  RT and SS beta stiffness values (Figure 7.12) were greater than 
SC in both the baseline and passive states.  However, the RT values were closer to SC values 
proximal baseline and middle baseline and passive states, when compared to SS values (Figure 
7.12). 
Current treatments for SUI have proven ineffective or result in additional complications 
[25, 38].  The TEUW approach to treating urethral dysfunction is adapted from cellular therapy 
such as the injection of muscle derived stem cells, which has shown promising results [80].  The 
TEUW is designed to provide immediate mechanical support to the urethra via the tubular fibrin 
matrix, but also provides a cellular therapy as the fibrin degrades, the cells can become 
incorporated with the native tissue and provide functional support as well.  The matrix 
component of the TEUW limits the migration of cells from the implant area, localizing their 
effects to the implantation site. 
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While previous studies have shown that treatments such as the injection of MDSCs 
increases LPP in a model of ISD [81], our current study shows neither a decrease in LPP with 
pudendal nerve transection or an increase following treatment with the TEUW (Figure 7.3).   
Previous studies, including our own work (Figure 3.1) have shown that pudendal nerve 
transection causes a decrease in leak point pressure of SD rats [47, 56, 61].  While damage to the 
middle urethra was confirmed by the decreased expression of PGP 9.5 seen in the middle and 
distal portions of the urethra in both SS and RT groups (Figure 7.21) there was a lack of 
response seen in LPP.  The absence of a significant decrease in LPP in response to pudendal 
nerve transection (Figure 7.3) could be due to the separation of the proximal portion of the 
urethra from the vagina, which was performed in all groups.  This separation could cause 
remodeling or scar formation, which may provide support to the urethra and bladder neck 
preventing leakage.  One anatomical study showed that there is a large degree of vascular and 
neural innervations within the connective tissue between the urethra and the underlying vagina 
from the bladder neck to the middle urethra [209].  It has been also been reported that SUI 
treatments involving the separation of these tissues at the proximal urethra, such as sling 
placement, may worsen a pre-existing condition over time, leading to intrinsic sphincter 
deficiency [209, 210], which could explain why all of our groups have similar LPP values.  
Some bladder distension in our model was evident upon urethral isolation which could be due to 
manipulation of the bladder area during tissue separation.  However, it has been reported that 
urethral denervation can cause bladder distension [58]. 
SS animals had a larger contractile response to phenylephrine (a smooth muscle 
contractile agent) than both SC and RT groups (Figure 7.5).  However, SS urethras contracted 
less than SC and RT groups in response to the striated muscle agonist, acetylcholine (Figure 
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7.5B) when assessing the effects of each individual agent.  The increased response of the SS 
group to PE could be a result of a smooth muscle compensation for the damaged striated 
sphincter, caused by the nerve transection and evident by the decreased response to Ach (a 
striated muscle agonist; Figure 7.5B) and the decreased expression of PGP 9.5 (Figure 7.21) in 
the middle urethra.  This idea of smooth muscle compensation in the SS group is further 
supported by the increased positive staining of both α-SMA (Figure 7.16) and MHC (Figure 
7.17) and the greater than one fold increase shown in western blot results for α-SMA (Figure 
7.18) and PGP-9.5 (Figure 7.21).  The RT group has a similar response to both PE and Ach as 
the SC group (Figure 7.5B), as well as PGP 9.5 fold differences close to one (Figure 7.21B) 
indicating that the TEUW is aiding the urethra in maintaining a healthy contractile response and 
eliminates the need for smooth muscle compensation. 
SUI induced by vaginal distension has been reported to increase low pressure proximal 
compliance in both the baseline and passive states in a rat model [53, 54].  While, our current 
work indicates that SUI, caused by pudendal nerve transection, causes an increase in low and 
overall compliance in the middle and distal portions, it also shows a decreased compliance from 
SC animals in the proximal urethra, and significantly at the middle and high pressure ranges in 
the middle urethra (Figure 7.10).  This variability from previously reported compliance values 
[53, 54] could be largely due to the difference in strain.  While our histology was performed on 
the Lewis urethra, previous studies which focused on the SD urethra [53] qualitatively indicate 
that the SD rat has a greater muscularity than the Lewis rat in both the proximal and middle 
portions than the Lewis urethra. 
Although we expected changes in the mechanical properties of the middle urethra, since 
the pudendal nerve innervates the striated sphincter located there (Section 1.1.2), we did not 
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expect to see a decrease in compliance due to pudendal nerve transection.  This decrease seen in 
proximal compliance lends further support to the idea of SMC compensation in the SS group.  
With the exception of the middle portion in the baseline state, we show minimal differences 
between all groups at middle and high pressures, which agree with results seen in the vaginal 
distension model [53, 54].  Although there was no change in V-LPP with placement of the 
TEUW, it is seen that the TEUW group is less compliant than the SS group at low and overall 
pressure ranges in all urethral portions (Figure 7.10 and Figure 7.11).  This decrease in 
compliance could be due to the additional layer of collagen surrounding the proximal urethra of 
the RT group (Figure 7.13 and Figure 7.14).  The TEUW also provides urethral compliance 
values most similar to SC controls at low and overall pressure ranges. 
Although we report on changes in MHC in Figure 7.20, we expected to see strong 
banding of the main forms of MHC present in smooth muscle at 200 kDa [211], but instead saw 
banding at 136 and 121 kDa.  These lower molecular weight bands are thought to be the result of 
a site-specific cleavage of MHC by a particular enzyme.  Because we are seeing a doublet, at 136 
and 121 kDa, and we used a monoclonal antibody, it is unlikely that these bands are from the 
same MHC molecule.  It is likely that some molecules were cleaved twice (121 kDa), while 
others were cleaved only once (136 kDa), creating these two particular bands, which still possess 
the specific sequence that this antibody binds.  A thorough literature search did not reveal any 
reports of MHC at the molecular weights detected here in the rat urethra or anywhere else. 
While this work has provided encouraging results which support the TEUW providing 
both mechanical and functional support to the native urethra, further analyses should be 
performed.  The division of endpoints between two rat strains, which have shown to have 
different urethral characteristics (Chapter 3.0 ), is the main limitation of this work.  Mechanical 
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testing as well as both histological and protein analyses should be repeated in the SD rat, which 
is more commonly used in lower urinary tract studies to confirm the trends seen in the Lewis rat.  
The low n value for protein work (n=2) should be increased to determine if the large degree of 
variability is consistent in this model.  The MHC protein work could be further analyzed by 
sequencing of the bands or running a more concentrated analysis such as immuno-precipitate.  
Further analyses should be performed to assess any remodeling, hypoxia or nerve damage that 
may occur due to tissue separation or TEUW placement by histology.  These assessments should 
be performed on urethras that remained intact with the vagina for better assessment of scar 
formation and remodeling.  Our current isolation method separates these tissues and prevents 
assessment of scar formation between them.  This stripping away of the vagina and possible scar 
tissue could also explain discrepancies between our in-vivo LPP and ex-vivo mechanical data. 
This work provides a novel approach to the treatment of stress urinary incontinence.  We 
have shown that a TEUW composed of fibrin and bone marrow progenitor cells can provide 
support to the diseased urethra, giving it characteristics more similar to that of a healthy urethra.  
While further analyses are warranted, we have provided the groundwork for a new, long-term 
treatment for type-III SUI. 
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8.0  DISCUSSION  
We have developed a novel approach for the treatment of urethral dysfunction with a tissue 
engineered urethral wrap.  To summarize this work, a brief description of each focus area will be 
followed by a discussion of the clinical relevance.  Finally, limitations and future work will be 
addressed. 
8.1 SUMMARY OF RESULTS 
8.1.1 The Effects of Disease (Chapter 2.0) and Rat Strain (Chapter 3.0) on Urethral 
Function 
In order to develop an effective treatment for urethral dysfunction, it is important to understand 
how the tissue changes in response to various risk factors and to assess it in an appropriate 
animal model.  We evaluated the effects of estrogen deficiency through ovariectomy, 
denervation of the urethra through bilateral pudendal nerve transection and the effect of in-bred 
vs out-bred strain on the urethral response of rats.  We found that ovariectomy caused a 
significantly lower middle urethral response to stress and baseline pressure than both control and 
sham animals, indicating a change in both the striated and smooth muscle components of the 
urethra and causing SUI in ~63% of Ov animals.  This altered urethral response was supported 
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by ex-vivo mechanical testing, which showed a higher baseline compliance following Ov in both 
the proximal and middle portions of the urethra, although not significantly.  Proximal and middle 
urethral compliance values were also higher in the passive state of Ov animals, indicating that 
there may be changes to the urethral ECM in addition to the muscular components.  These results 
indicated that estrogen plays an important role in the continence mechanism and proper urethral 
function. 
Denervation of the urethra assessed in both out-bred (SD) and in-bred (Lewis) rat strains 
revealed that bilateral pudendal nerve transection significantly decreased LPP in SD rats, but had 
no effect on Lewis rats.  However, Lewis rats had a significantly lower LPP than SD rats.  We 
found that there was a greater contribution of the striated sphincter to the in-vivo maintenance of 
continence in the SD rat, and a significantly lower UBP in the Lewis rat.  Ex-vivo mechanical 
testing supported the observed in-vivo differences in striated sphincter contribution to continence 
with higher compliance of the middle urethra in Lewis rats compared to SD rats in both the 
baseline and passive states and in the Lewis proximal urethra in the passive state.  Further 
evidence of differences in muscular function was seen by a larger diameter change to increased 
pressure (inability to resist deformation) and lower contractile responses to both smooth (PE) and 
striated (Ach) muscle agonists of the Lewis middle urethra.  Quantification of the cross-sectional 
muscle components revealed that the Lewis urethra is composed of a greater percentage of 
smooth muscle, while the SD urethra is composed of a greater percent of striated muscle and has 
a significantly larger cross-sectional area than the Lewis urethra, showing that the SD urethra has 
a greater overall muscular component than the Lewis urethra. 
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8.1.2 The Development (Chapters 4.0 and 5.0) and Implementation (Chapter 6.0) of a 
Novel Bioreactor 
In order for the proposed differentiation studies to progress, we needed to develop a bioreactor 
for the simultaneous culture of multiple constructs under minimal pressure and flow.  We 
designed and fabricated a compact bioreactor capable of culturing four constructs simultaneously 
and independently within a standard cell culture incubator and versatile to accommodate various 
length and inner diameter constructs.  The bioreactor was designed for easy monitoring of the 
environmental culture conditions of each chamber, which remained stable over both 5 and 10 
day culture periods.  Constructs subjected to bioreactor culture tended to be less compliant than 
their respective SF controls at middle, high and overall pressure ranges and lower burst 
pressures.  The addition of TGF-β resulted in higher compliance values and burst pressures than 
bioreactor culture without it at both 5 and 10 days.  Although no culture condition stimulated 
collagen production, bioreactor culture with or without TGF-β for 5 or 10 days stimulated 
expression of MHC, a smooth muscle cell contractile marker, indicating differentiation towards a 
smooth muscle phenotype. 
8.1.3 Application of a TEUW for Treatment of SUI (Chapter 7.0)  
We demonstrated ex-vivo the feasibility of application and resulting decreased urethral 
compliance when a TEUW is placed around a denervated urethra.  These proof-of-concept 
studies were followed by an extensive assessment of the in-vivo and ex-vivo effects of 
implantation of a TEUW in a pudendal nerve transection model of SUI in both SD and Lewis 
rats, respectively.  Denervation of the SS and RT groups was confirmed by a decreased 
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expression of PGP 9.5 in the middle urethra compared to SC animals by WB.  Although there 
appeared to be no effect of SUI or TEUW placement on SD LPP, SUI altered mid-urethral 
response to Ach (decreased striated muscle contraction) and significantly to PE (increased 
smooth muscle contraction) indicating a possible compensation of smooth muscle for the 
damaged striated muscle.  This is supported by an increased expression of α-SMA in the 
proximal portion of SS animals compared to both RT and SC groups seen in both IF and WB 
analyses.  Placement of the TEUW maintained urethral responses to PE and Ach at similar levels 
to controls.  TEUW placement provided mechanical support to the Lewis urethra, causing higher 
beta stiffness values in the proximal and middle urethral portions.  However, surgical procedures 
did cause bladder distension and even stone formation in the ureters and/or bladder.  These 
problems occurred in a small percentage of all experimental groups and are therefore, most likely 
the result of the separation of the urethra from the underlying vagina.  The lack of differences 
between LPP values could also be a result of this tissue separation, which may cause scar 
formation.  Due to the separation of the urethra from the surrounding tissues for ex-vivo 
assessment, we were unable to assess if scar tissue had developed. 
8.2 CLINICAL RELEVANCE 
Urinary incontinence (urge, mixed and stress) is highly predominant in the female population 
and affects one third of all women in some degree (moderate to severe) [38].  With current 
treatments being inadequate due to dissipation over time, patient non-compliance or association 
with additional complications such as vaginal erosion [25, 38], the goal of this research was to 
develop a long-term, autologous treatment for urethral dysfunctions such as urinary 
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incontinence.  Our results have revealed how risk factors, such as estrogen deficiency and 
pudendal nerve damage, contribute to dysfunctions such as urinary incontinence.  We have 
shown how ovariectomy and pudendal nerve transection decreased LPP and increased proximal 
and middle compliance over controls through alterations in both muscle and ECM components.  
Knowledge of which urethral components are damaged as a result of various factors can aid in 
the development of both preventative and post-development treatments.  These results coincide 
with previous studies which showed similar damage following vaginal distension [53, 54] and 
diabetes mellitus [101].  These studies indicate that a treatment which provides both mechanical 
and functional support to the urethra would be most beneficial. 
Our TEUW focused on the use of BMPCs, which can easily be isolated from a bone 
marrow aspirate of the iliac crest and provide an autologous cell source and minimizing rejection 
of the implant, and fibrin.  Fibrin was chosen as it is a natural biomaterial comprised of 
fibrinogen and thrombin, which are produced and degraded in the body and can be isolated from 
the blood, yielding an autologous matrix.  The development of a completely autologous 
treatment, such as the one described here, decreases incidents of rejection and eliminates the 
need for immunosuppressants, making it more clinically desirable.  As both the muscle and ECM 
can be compromised in urethral dysfunction, the TEUW provides both a structural and cellular 
component to provide both mechanical and functional support to the urethra.  Since fibrin allows 
cells to freely migrate and produce their own collagen matrix as it degrades [95], the remaining 
cells and collagen can easily integrate with the ECM surrounding the proximal portion of the 
native urethra to provide long-term support as indicated by our 3 week in-vivo studies in a rat 
model.  Our TEUW allows for treatment of the urethra while keeping the cells localized to the 
proximal urethra with matrix, unlike injection therapies [80], which can migrate over time.  As 
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shown in this work, TEUWs that were implanted after 5 days of compaction in spinner flask 
culture expressed α-SMA, an early smooth muscle maker.  However, for a truly functional 
therapy, cells within the TEUW should express MHC.  Due to the numerous studies which show 
differentiation towards a smooth muscle phenotype with mechanical and/or chemical stimulation 
[102-104, 111, 119, 124, 212, 213], we developed and implemented a bioreactor for the 
differentiation of BMPCs to a smooth muscle phenotype within a tubular structure.  Our results 
indicate that even minimal mechanical stimulation with or without TGF-β enhanced 
differentiation towards a contractile smooth muscle phenotype.  Showing that conditioning of 
these cells can enhance smooth muscle markers and provide cells more capable of providing 
functional support to the native urethra.  Implantation of a functional TEUW would provide an 
immediate increase to urethral response and thus improve continence. 
8.3 LIMITATIONS OF METHODOLOGY 
The BMPCs used in this study were composed of a heterogeneous population of cells.  
Therefore, our reports of the effects of bioreactor culture on the differentiation of these cells may 
be skewed as the stimulation may have only affected a sub-population of the cells seeded within 
the constructs.  However, we did find that mechanical stimulation with and without TGF-β plays 
an important role in the up-regulation of contractile smooth muscle cell markers and has efficacy 
for urethral tissue engineering. 
A major limitation of most 3-D tissue engineering work is an appropriate assay to detect 
cell viability and proliferation.  Our initial fabrication assays utilized the MTT assay, which 
measures metabolic activity.  However, this assay was designed for monolayer culture and 
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requires an assumption that all cells have the same metabolic activity.  This is a large assumption 
to make since many things can contribute to an increase or decrease in metabolic activity, 
making it unrealistic to say that an increased result from MTT is directly proportional to an 
increase in cell number.  Although other assays were investigated including the LIVE/DEAD® 
assay (Invitrogen, Carlsbad, CA), a lactate dehydrogenase (LDH) assay (CytoTox96® Non-
Radioactive Cytotoxicity Assay, Promega Corporation, Madison, WI) and assessment of cells 
following fibrinolysis of the constructs, each had its own downfalls.  The LIVE/DEAD assay 
utilizes calcein AM and ethidium homodimer to assess intracellular esterase activity and plasma 
membrane integrity, respectively, by diffusion of the probes into an un-fixed sample.  Therefore, 
dense tissues prevent adequate diffusion of these molecules to all cells.  LDH assays work by 
measuring the levels of LDH released from cells with compromised cell membranes into the 
surrounding environment.  This assay required a concentration of the ~125mL of media from the 
bioreactor chambers or spinner flasks, which presented a challenge due to the 15% serum used in 
our cell culture media.  While we also attempted to isolate the cells from the fibrin constructs 
following culture, the fibrinolysis protocol itself, which involved trypsin, could also lead to cell 
death, making it difficult to assess if cell numbers were truly based on death during culture.  
Early studies utilized a pathologist’s examination of H&E stained slides, which resulted in no 
obvious indications of cell death within the constructs.  This with the differential expression of 
smooth muscle cell markers under various culture conditions led us to believe that the cells 
remained viable throughout culture. 
A limitation of our molecular work was our protein assessment through western blots.  
Due to the time required for ex-vivo testing, we anticipated protein degradation during 
mechanical assessment.  Separate animals were assessed for protein analysis.  This increased the 
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total number of animals, which resulted in a small n value (n=2 per group) for protein analysis.  
Another limiting factor of our protein assessment was the amount of protein isolated from the 
urethra.  The size of the rat urethra (length = ~25 mm, OD = ~1.25 mm) provides a limited 
amount of protein.  Division of the urethra into proximal, middle and distal portions further 
decreased our total amount of protein per sample, and it was felt that pooling samples could 
introduce a large degree of variability.  Although we used a strong protease inhibitor cocktail 
during our protein isolation, our inability to isolate the 200 kDa form of MHC limited our 
evidence of an increased smooth muscle cell contribution in the SS group.  While an extensive 
literature search provided no evidence of either 121 or 136 kDa isoforms of MHC within the rat 
urethra, or anywhere else, we are led to believe that these bands are the result of a site-specific 
enzymatic cleavage of the MHC molecule due to the tight banding observed or non-specific 
binding of the antibody to other proteins.  This enzymatic cleavage may be a result of the 
surgical dissection of the proximal urethra from the vagina, which activated a wound-healing 
response.  As healing and remodeling activate numerous enzymes, it is possible that it activated 
some that our protease inhibitor cocktail was not designed to inhibit.  Although we were able to 
isolate a large amount of protein from our bioreactor studies, the large amount of fibrin in the 
constructs made it challenging to detect the small amount of α-SMA and MHC that may have 
been present as in our immunofluorescence results.  There was the presence of a ~75 kDa band 
in the MHC blot, which is also most likely the product of degradation.  This inhibited our 
confirmation of differentiation of the BMPCs to smooth muscle cells within the bioreactor. 
Data variability is a large limitation of many studies.  We found that the Lewis rat had a 
large degree of intrinsic variability, creating many trends but little significance in our studies.  
While the majority of our SD data had very tight error bars, the corresponding Lewis values had 
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a large degree of variability.  Evidence of this is easily observed in the ex-vivo functional testing, 
where each Lewis urethra tested responded in a different manner.  Although increasing n values 
can reduce variability, a power analysis of pressure-diameter data results in values of n=12 to 
over 30 in order to show significance.  The same variability in ex-vivo data was observed in the 
ovariectomized animals.  Although 10 urethras were tested, the data variability remains large, 
preventing significance.  This variability was also seen in-vivo with only 62.5% of animals 
becoming incontinent.  Although this increased variability with some of our experimental models 
proved inconvenient for our studies, it is representative of what happens in humans, where not all 
women develop SUI following menopause.  Although not significant in all instances, our work 
does show several trends, which indicate alterations of urethral characteristics which can provide 
further insight into appropriate urethral therapies or animal models for urethral studies. 
The damage inflicted by the tissue dissection needed for placement of our wrap is a 
limitation of this treatment.  Although other treatments for, such as sling placement or cystocele 
repair, require the same tissue separation, an increased risk of intrinsic sphincter dysfunction or 
worsening of perineal neuropathy has been associated with procedures that involve dissection of 
these tissues [209, 210].  The proximal urethra and vagina are attached by loose connective 
tissue containing blood vessels and nerve fibers [209], so disruption of this area can cause 
significant trauma and damage to the vascular and neural innervations of the urethra.  
Additionally, the separation could cause remodeling, which could result in scar formation, which 
could contribute to alterations in the urethral properties.  All groups in this work assessed 
animals that had received separation of the tissues.  However, they should be compared to 
untouched animals to determine the effects of the tissue separation on both in-vivo functionality 
and ex-vivo mechanical properties. 
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8.4 FUTURE WORK 
The results of this work have laid the groundwork for continued studies in several areas.  First, 
further assessment of a variety of culture conditions for the differentiation of BMPCs to 
contractile smooth muscle cells could be performed.  While this work focused on the effects of 
minimal pressure and flow with and without the addition of TGF-β, additional studies assessing 
increased mechanical stimulation may produce a more differentiated phenotype and increase 
orientation, which could contribute to construct contractility.  Previous studies have reported 
alignment of cells and upregulation of smooth muscle cell markers under rigorous mechanical 
stimulation with or without growth factors [102-105, 111, 126, 203], indicating that a larger 
degree of mechanical stimulation via increased intraluminal pressures may cause increased 
alignment and differentiation, making a more functional TEUW.  Although we chose to explore 
the differentiation potential of TGF-β on our BMPCs due to its role in smooth muscle cell 
differentiation [122-126], other biochemical factors could also be explored.  The literature has 
numerous reports on the differentiating capabilities of a variety of factors including: ascorbic 
acid [212], β-mercaptoethanol [117, 214], PDGF [119-122] and VEGF [127, 128].  All of which 
have shown positive results towards the differentiation of cells towards a smooth muscle cell 
phenotype and may be more effective on the differentiation of the BMPCs used. 
 Second, although our studies focused on the use of BMPCs, additional work utilizing 
different cell sources could be performed.  One example would be MDSCs, which have already 
shown much promise for the treatment of SUI when injected directly into the urethra [80, 81].  
Utilization of these cells within a TEUW could possibly provide additional benefits as the 
TEUW could prevent them from migrating away from the injection site.  These cells may also be 
more responsive to mechanical and/or chemical stimulation within the bioreactor. 
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Third, due to the trends found for altered LPP and mechanical properties following 
estrogen depletion in virgin rats, it would be interesting to increase n values to see if the trends 
can become significant.  Since, many women experience short term SUI following vaginal 
delivery, but true onset generally follows menopause [37, 49, 50], an assessment of the role 
estrogen deficiency on urethral mechanical properties in retired breeders or following vaginal 
distension would lend insight into the synergistic effects of estrogen and birth trauma on the 
mechanical characteristics of the urethra and how changes in them can lead to the development 
and onset of SUI.  Such studies could aid in the determination of the role of estrogen in 
continence compensation following birth trauma and lead to better preventative therapies for 
SUI. 
 Fourth, further exploration of the differences between the urethral function of Lewis and 
SD rats could be explored.  Limited explorations of differences in urethral LPP, muscular 
composition and function have already been performed in this work.  Continued studies 
assessing innervation along the length of the urethra may provide additional insight to the 
observed differences.  Further investigation may determine if the Lewis rat may be an 
appropriate model for other urethral studies.  Measurement of urethral response to agonists at the 
proximal portion may also indicate a more predominant role of the smooth muscle internal 
urethral sphincter to continence in the Lewis rat.  A comparison of the Lewis urethra to other 
SUI or lower urinary tract disorder models may support the hypothesis that the Lewis rat could 
serve as a natural disease model for future studies.  Since the Lewis rat has an intrinsically low 
LPP, higher compliance values and lower muscle contribution, which have been observed in 
various models of SUI [43, 48, 51, 53, 54, 56], it may be able to serve as a non-surgical model of 
SUI, upon validation.  The low UBP and high baseline compliance of the Lewis urethra indicate 
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a decreased basal tone, which has been previously reported in a vaginal distension model of SUI 
[53]. 
 Fifth, effects of the tissue dissection on urethral functional and mechanical properties 
could be assessed.  While preliminary studies comparing SC and untouched controls one week 
following procedures indicated no severe damage to the urethra following separation, the focus 
of this work was 3 weeks, which may have allowed enough time for scar formation to alter LPP 
and mechanical properties of the urethra.  Due to the isolation of the urethra for mechanical 
testing, it was separated from the vagina.  Studies assessing the interface between the two tissues 
could provide evidence for or against scar formation and possibly explain the lack of difference 
in LPP between experimental groups.  If the tissue separation proves to not be detrimental, 
further studies utilizing constructs cultured within the bioreactor system could be implanted for 
assessment of further benefits in returning the dysfunctional urethra back to a healthy state. 
 Lastly, an alternate use for the TEUW could be for the localized delivery of drugs or 
biological agents to the urethra, or other tubular structures.  Fibrin has previously been used for 
the controlled release of both genes [215] and growth factors [216]. The fabrication method of 
the TEUW, gelling of a liquid solution during the reaction of fibrinogen and thrombin, makes it 
ideal for the addition of various agents.  During fabrication, additional factors such as drugs, 
growth factors, microbeads, etc., could be added to the fibrinogen solution prior to the addition 
of thrombin.  Upon implantation, the fibrin would degrade and deliver its contents to the 
surrounding area.  Fibrin gel porosity and fiber size [76], and therefore degradation rate, can be 
finely tuned by altering the fibrinogen and thrombin concentrations, allowing for a controlled 
time release of the factor of interest.  
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APPENDIX A 
PROPAGATION OF ERROR ASSOCIATED WITH PRESSURE AND OUTER 
DIAMETER MEASUREMENTS 
Previous studies [217, 218] developed the following error analysis.  Uncertainty in measured 
parameters used to calculate quantities must first be assessed in order to assess the propagation 
of error of the calculated values. 
The ex-vivo testing system was set up as described in Section 2.2.5 with a piece of 
Penrose drain tube tied to the cannulae.  A hydrostatic pressure reservoir filled with water was 
used to apply each pressure step while outer diameter was read with a He-Ne laser micrometer.  
This was repeated four times.  Values for both pressure and diameter were averaged and standard 
deviations were calculated.  The uncertainty was taken as two standard deviations for 95% 
confidence limits and given by [217]: 
σ = 2 * 1.96 * σmeasured      (A. 1) 
where σ is the uncertainty value and σmeasured is the standard deviation of the measured 
component (i.e., pressure or outer diameter).  The resulting uncertainty values are provided in 
Table A.1. 
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Table A.1 Uncertainty values for pressure and diameter measurements used to calculate mechanical characteristics 
 Pressure (mmHg) Diameter (mm) 
 0 6 12 20 0 6 12 20 
σ 0.012 0.038 0.030 0.065 0.008 0.014 0.018 0.018 
 
 
With the uncertainty values in Table A .1, the propagation of error could be calculated for 
compliance and beta stiffness as follows: 
σ∆P= √(σPmax+ σPmin )      (A.2) 
σ∆D= √(σDmax+ σDmin )      (A.3) 
%σ∆C= √((%σ∆D)
2+ (%σ∆P)
2+ (%σDmin)
2     (A.4) 
%σP,D= √((%σP)
2 + (%σD)
2)      (A.5) 
%σβ= √((%σP,D0mmHg)
2+ (%σP,D6mmHg)
2+ (%σP,D12mmHg)
2 + (%σP,D20mmHg)
2)    (A.6) 
 
Uncertainties were calculated for pressure and diameter differences (σΔP, σΔD, respectively) using 
Equation A.2 and Equation A.3.  This was calculated for low (0-6 mmHg), middle (6-12 
mmHg) and high (12-20 mmHg) pressure compliance values, where σPmax and σPmin are the 
uncertainty values for the maximum and minimum pressures and σDmax and σDmin are the 
maximum and minimum outer diameters in each range.  The percentage of error was calculated 
for each parameter by dividing the uncertainty value by the actual measured difference or 
measured value (i.e., %σΔP = %σΔP/ΔP, %σΔD = %σΔD/ΔD).  Results for the propagation of error 
are in Table A.2. 
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Table A.2 Percentage of propagated error derived from uncertainty values for low, middle and high pressure 
compliance (C). 
 
Propagation of Error 
σlowC σmiddleC σhighC σβ 
1.83% 4.81% 6.38% 0.40% 
 
 
 232 
APPENDIX B 
WESTERN BLOT IMAGES 
BIOREACTOR STUDIES 
 
Figure B.1 Western blot stained for α-SMA (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day, MoT-5 day and Mo-10 day culture conditions. 
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Figure B.2 Western blot stained for α-SMA (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day and MoT-5 day culture conditions. 
 
 
 
Figure B. 3 Western blot stained for CALP (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day, MoT-5 day and Mo-10 day culture conditions. 
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Figure B.4 Western blot stained for CALP (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day and MoT-5 day culture conditions. 
 
 
 
Figure B.5 Western blot stained for MHC (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day, MoT-5 day and Mo-10 day culture conditions. 
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Figure B.6 Western blot stained for MHC (A) and the white light molecular weight standard (B) for constructs 
cultured under T0, SF-5 day, SF-10 day, Mo-5 day and MoT-5 day culture conditions. 
 
 
 
Figure B.7 Ponceau S stained gels from MHC blots for constructs cultured under T0, SF-5 day, SF-10 day, Mo-5 
day, MoT-5 day, and Mo-10 day culture conditions. 
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Figure B.8 Ponceau S stained gels from MHC blots for constructs cultured under T0, SF-5 day, SF-10 day, Mo-5 
day, MoT-5 day, and Mo-10 day culture conditions. 
 
 
 
Figure B.9 Ponceau S stained gels from MHC blots for constructs cultured under T0, SF-5 day, SF-10 day, Mo-5 
day, MoT-5 day, and Mo-10 day culture conditions. 
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IN-VIVO STUDIES 
 
Figure B.10 Western blot stained for α-SMA (A) and the white light molecular weight standard (B) for animal-1 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
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Figure B.11 Western blot stained for α-SMA (A) and the white light molecular weight standard (B) for animal-2 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
 
 
 
Figure B.12 Western blot stained for calponin (A) and the white light molecular weight standard (B) for animal-1 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
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Figure B.13 Western blot stained for calponin (A) and the white light molecular weight standard (B) for animal-2 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
 
 
 
Figure B.14 Western blot stained for MHC (A) and the white light molecular weight standard (B) for animal-1 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
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Figure B.15 Western blot stained for MHC (A) and the white light molecular weight standard (B) for animal-2 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
 
 
 
Figure B.16 Western blot stained for PGP 9.5 (A) and the white light molecular weight standard (B) for animal-1 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
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Figure B.17 Western blot stained for PGP 9.5 (A) and the white light molecular weight standard (B) for animal-2 of 
each condition.  SC = sham continent, SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle 
and distal portions of the urethra. 
 
 
 
Figure B.18 Ponceau S stained gels from calponin blots for Animal 1 (A) and Animal 2 (B).  SC = sham continent, 
SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle and distal portions of the urethra. 
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Figure B.19 Ponceau S stained gels from MHC blots for Animal 1 (A) and Animal 2 (B).  SC = sham continent, SS 
= sham SUI, RT = rat TEUW and P, M and D are the proximal, middle and distal portions of the urethra. 
 
 
 
Figure B.20 Ponceau S stained gels from α-SMA blots for Animal 1 (A) and Animal 2 (B).  SC = sham continent, 
SS = sham SUI, RT = rat TEUW and P, M and D are the proximal, middle and distal portions of the urethra. 
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APPENDIX C 
RELATIVE MOBILITY ASSAY FOR DETERMINATION OF PROTEIN MOLECULAR 
WEIGHT IN A WESTERN BLOT 
Intense banding at unexpected molecular weights was assessed by using relative mobility plot in 
order to determine the molecular weight of the protein detected according to the methods of 
Weber et al. [219].  Briefly, the distance for a fixed point to the bottom of each molecular weight 
standard band was measured.  The log of the molecular weights for the standards was plotted 
versus the relative mobility of each standard band through the gel and the equation of the line 
was found (Figure C.1).  The distance from the fixed point to the bottom of the band of interest 
was then measured, and the equation from the standards was used to calculate the molecular 
weight of the band of interest (Table C.1 and Table C.2).  The average across all conditions was 
calculated for the top and bottom bands in each gel, resulting in molecular weights of 136 kDa 
and ~121 kDa, respectively (Table C. 3).  
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Figure C.1 Relative mobility plots for two different western blots. 
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Table C.1 Relative mobility distances and calculated molecular weights based on standard curves for each gel for 
the top MHC band seen in in-vivo studies. 
Animal -1 Top Band 
 SC-P SC-M SC-D SS-P SS-M SS-D RT-P RT-M RT-D 
Distance 
(mm) 
61 62 61 62 62 62 62 61 61 
MW 
(kDa) 
133 138 133 138 138 138 138 133 133 
Animal -2 Top Band 
 SC-P SC-M SC-D SS-P SS-M SS-D RT-P RT-M RT-D 
Distance 
(mm) 
62 62 62 61 61 62 61 63 62 
MW 
(kDa) 
137 137 137 132 132 137 132 143 137 
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Table C.2 Relative mobility distances and calculated molecular weights based on standard curves for each gel for 
the bottom MHC band seen in in-vivo studies. 
Animal -1 Bottom Band 
 SC-P SC-M SC-D SS-P SS-M SS-D RT-P RT-M RT-D 
Distance 
(mm) 
58 60 59 59 59 59 58 59 58 
MW 
(kDa) 
133 133 133 133 133 133 133 133 133 
Animal -2 Bottom Band 
 SC-P SC-M SC-D SS-P SS-M SS-D RT-P RT-M RT-D 
Distance 
(mm) 
62 62 62 62 62 62 62 62 62 
MW 
(kDa) 
122 122 122 117 117 122 117 122 122 
 
 
Table C. 3 Average molecular weight across all conditions of proteins of interest from in-vivo MHC blots. 
 Animal-1 
Average M W 
Animal-2 
Average M W 
Top Band 136 kDa 136 kDa 
Bottom Band 122 kDa 120 kDa 
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APPENDIX D 
ASSESSMENT OF COMPACTION FOR TEUWS 
TEUW compaction was calculated as a percentage of the original volume of the construct.  
Initial TEUW volume and dimensions were determined from the mold dimensions and volume 
of fibrin-cell solution added to it.  Following culture, construct length was measured with 
calipers, the unloaded diameter by a laser micrometer, and the inner diameter by histology as 
described in Section 4.2.5.  The values for construct length, outer diameter and inner diameter 
following culture can be found in Table D .1, Table D.4 and Table D.5, respectively.  These 
values were used to calculate post-culture construct volume (V) as: 
  Vouter = πRoL      (D.1) 
Vinner = πRiL      (D.2) 
   Vtube = πRo
2L – πRi
2L     (D.3) 
where Ro is the outer radius and Ri is the inner radius and L is the construct length.  If 
 Ri = Ro - t      (D.4) 
where t is the thickness of the wall (Table D. 2), Equation D.3 simplifies to: 
  Vtube = πL(2Ro - t
2)       (D.5) 
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To put into terms of inner diameter, we can express Ro as: 
 Ro = (ID+2t)/2      (D.6) 
where ID is the inner diameter of the construct.  Substituting Equation D.6 into Equation D.5, 
and allowing Vtube to equal V, we have: 
V = πLt(ID + t)       (D.7) 
Volumes for all experiments are in Table D.6.  Compaction [69] as a percentage of the initial 
volume (Vo), which was 5 mL for all constructs, was calculated by Equation D.8 and can be 
seen in Table D.7. 
Cm = (V/Vo) * 100     (D.8) 
 
 
 
 
 
 
Table D.1 Measured lengths (mm) from constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 cells/mL and 
cultured for 3 or 5 days in spinner flask. 
Culture cells/mL Experiment 1 Experiment 2 Experiment 3 Experiment 4 
 
3 days 
0.75 x 106 14 17 13  
1.00 x 106 15 17 18  
1.25 x 106 15 17 16  
 
5 days 
0.75 x 106 14 16 11 15 
1.00 x 106 12 18 14 14 
1.25 x 106 12 10 14 12 
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Table D. 2 Thickness variability for Experiments 1 and 2.  Measured thickness values for each section from each 
experiment for constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 cells/mL and cultured for 3 or 5 days in 
spinner flask. 
Experiment 1 
Culture cells/mL Section 1 Section 2 Section 3 Section 4 
 
3 days 
0.75 x 106 1.2218 ± 0.0368 1.2307 ± 0.0341 1.0884 ± 0.0253 1.0793 ± 0.0271 
1.00 x 106 1.2937 ± 0.0198 1.2308 ± 0.0208 1.1782 ± 0.0101 1.3029 ± 0.0169 
1.25 x 106 1.0685 ± 0.0156 1.0732 ± 0.0178 1.0616 ± 0.0171 1.0898 ± 0.0173 
 
5 days 
0.75 x 106 1.0669 ± 0.0198 1.0705 ± 0.0165 1.0524 ± 0.0172 0.9618 ± 0.0176 
1.00 x 106 1.1313 ± 0.0084 1.1459 ± 0.0079 1.1194 ± 0.0271 1.1176 ± 0.0095 
1.25 x 106 1.1438 ± 0.0232 1.1032 ± 0.0261 1.1187 ± 0.0266 1.1492 ± 0.0235 
Experiment 2 
Culture cells/mL Section 1 Section 2 Section 3 Section 4 
 
3 days 
0.75 x 106 1.0185 ± 0.0287 1.0989 ± 0.0169 1.1005 ± 0.0213  
1.00 x 106 0.7453 ± 0.0079 0.6832 ± 0.0071   
1.25 x 106 0.7336 ± 0.0375 0.9584 ± 0.0394   
 
5 days 
0.75 x 106 1.0158 ± 0.0273 1.0042 ± 0.0241 1.0575 ± 0.0290  
1.00 x 106 1.1908 ± 0.0279 1.2088 ± 0.0279 1.1348 ± 0.0378  
1.25 x 106 1.1817 ± 0.0341 1.0504 ± 0.0361 1.1450 ± 0.0547  
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Table D. 3 Thickness variability for Experiments 3 and 4.  Measured thickness values for each section from each 
experiment for constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 cells/mL and cultured for 3 or 5 days in 
spinner flask. 
Experiment 3 
Culture cells/mL Section 1 Section 2 Section 3 Section 4 
 
3 days 
0.75 x 106 0.8561 ± 0.0387 0.9138 ± 0.337 0.8066 ± 0.374  
1.00 x 106 0.7618 ± 0.0249 0.6850 ± 0.0294 0.8221 ± 0.0266  
1.25 x 106 1.1230 ± 0.0285 1.0622 ± 0.0363 0.9587 ± 0.0440  
 
5 days 
0.75 x 106 0.8891 ± 0.0322 0.9044 ± 0.0329 0.9344 ± 0.0334 0.8912 ± 0.0346 
1.00 x 106 1.0811 ± 0.0186 0.9222 ± 0.0331 1.0221 ± 0.0388  
1.25 x 106 1.0811 ± 0.0186 1.1176 ± 0.0267 1.0185 ± 0.0356  
Experiment 4 
Culture cells/mL Section 1 Section 2 Section 3 Section 4 
 
5 days 
0.75 x 106 0.8640 ± 0.0159 0.8555 ± 0.0183 0.9228 ± 0.0192 0.8833 ± 0.0125 
1.00 x 106 0.9101 ± 0.0093 0.8662 ± 0.0079 0.8115 ± 0.0086 0.8210 ± 0.0090 
1.25 x 106 0.9235 ± 0.0173 0.9125 ± 0.0149 0.9456 ± 0.0178 0.9051 ± 0.0147 
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Table D.4 Average measured thickness (mm) values from constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 
106 cells/mL and cultured for 3 or 5 days in spinner flask. 
Culture cells/mL Experiment 1 Experiment 2 Experiment 3 Experiment 4 
 
3 days 
0.75 x 106 1.1551 1.0726 0.8588  
1.00 x 106 1.2514 0.7142 0.7563  
1.25 x 106 1.0733 0.8460 1.0480  
 
5 days 
0.75 x 106 1.0379 1.0258 0.9013 0.8805 
1.00 x 106 1.1286 1.1781 1.0085 0.8522 
1.25 x 106 1.1287 1.1257 1.0724 0.9217 
 
 
 
 
 
 
Table D.5 Calculated inner diameter (mm) values from constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 
cells/mL and cultured for 3 or 5 days in spinner flask. 
Culture cells/mL Experiment 1 Experiment 2 Experiment 3 Experiment 4 
 
3 days 
0.75 x 106 0.6469 1.6029 1.2752  
1.00 x 106 0.3187 1.7780 1.5052  
1.25 x 106 1.0019 1.8702 0.5236  
 
5 days 
0.75 x 106 0.2658 1.2549 0.4144 0.5687 
1.00 x 106 2.7790 0.5239 0.6979 0.7631 
1.25 x 106 0.3693 0.4144 0.6482 0.6495 
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Table D.6 Calculated volumes (mm3) from constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 cells/mL and 
cultured for 3 or 5 days in spinner flask. 
Culture cells/mL Experiment 1 Experiment 2 Experiment 3 Experiment 4 
 
3 days 
0.75 x 106 91.55 153.27 74.85  
1.00 x 106 92.59 95.07 96.72  
1.25 x 106 104.96 122.72 82.79  
 
5 days 
0.75 x 106 59.51 117.60 40.98 60.13 
1.00 x 106 166.25 113.39 75.69 60.54 
1.25 x 106 63.74 54.46 81.15 54.59 
 
 
 
 
 
Table D.7 Calculated compaction values from constructs seeded with 0.75 x 106, 1.00 x 106 or 1.25 x 106 cells/mL 
and cultured for 3 or 5 days in spinner flask. 
Culture cells/mL Experiment 1 Experiment 2 Experiment 3 Experiment 4 
 
3 days 
0.75 x 106 1.83 3.07 1.50  
1.00 x 106 1.85 1.90 1.93  
1.25 x 106 2.10 2.45 1.66  
 
5 days 
0.75 x 106 1.19 2.35 0.82 1.20 
1.00 x 106 3.32 2.27 1.51 1.21 
1.25 x 106 1.27 1.09 1.62 1.09 
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APPENDIX E 
DETERMINATION OF AN ACCEPTABLE RANGE FOR BIOREACTOR 
ENVIRONMENTAL PARAMETERS 
The acceptable range for pressure measurements was based on the error (± 2 mmHg) of the 
pressure transducers used.  Since our ideal pressure was 5 mmHg, the acceptable range was 3 
mmHg to 7 mmHg.  Acceptable ranges for media parameters were based on readings from 
control media and previously published work.  One chamber of the bioreactor was filled with 
only media and readings were recorded over a 5 day period as shown in Table E.1. 
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Table E.1 Recorded values for environmental conditions of control media cultured in the bioreactor for 5 days. 
 Day 0 Day 1 Day 2 Day 3 Day 4  Day 5 
pH 7.28 7.27 7.30 7.28 7.27 7.29 
pCO2 (mmHg) 37 39 36 38 38 37 
pO2 (mmHg) 150 151 136 138 138 137 
HCO3- (mmol/L) 17 17 17 17 17 17 
 
 
The acceptable range for pCO2 was taken as ± 5 mmHg [220], HCO3- as ± 2 mmol/L [220] and 
pO2 ± 15 mmHg [220] of average control media readings.  These ranges are those generally 
reported for these parameters in the blood [220], which seemed acceptable for our system as 
well.  The pH range was based on the bicarbonate concentrations as: 
pH = pK + log ([HCO3
-]/[H2CO3])    (E.1) 
where pK = 6.10 and H2CO3 is in equilibrium with CO2.  Substitutions lead to: 
pH = 6.10 + log ([HCO3
-]/[CO2])      (E.2) 
The solubility coefficient of CO2 = 0.0301, so we then have: 
pH = 6.10 + log ([HCO3
-]/(0.0301*[pCO2]))   (E.3) 
Therefore, the acceptable ranges for all parameters can be seen in Table E. 2. 
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Table E. 2 Acceptable range values for pH pCO2 and HCO3-. 
 Low High 
pH 7.22 7.34 
pCO2 (mmHg) 32.5 42.5 
pO2 (mmHg) 126 156 
HCO3- (mmol/L) 15 19 
 256 
APPENDIX F 
PRELIMINARY ASSESSMENT OF THE IMPLANTATION OF A TEUW 
Preliminary assessments of the effects of a TEUW on LPP and the mechanical and structural 
properties of the urethra were made at 1 (Lewis and SD rats) and 4 (Lewis rats) weeks following 
initial procedures according to Chapter 7.0.  Although rat fibrinogen was the logical matrix 
choice to reduce rejection by our animal model, implantation of bovine fibrinogen (used in 
bioreactor work Chapters 4.0 and 6.0 was also explored as its use is more economical.  In 
addition to the SC, SS and RT groups listed in Chapter 7.0 a SUI group, which received only 
bilateral pudendal nerve transection, and an untouched control (Cont) group were assessed.  
Animals were assessed for V-LPP, ex-vivo mechanical testing and trichrome staining as 
described in Chapter 7.0  
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RESULTS 
Leak Point Pressure 
V-LPP values at 1 week (Figure F.1) show that SD rats have higher LPP values than Lewis rats 
for all conditions and significantly for SUI and continent groups.  Lewis LPP appears to be 
independent of experimental condition remaining constant across them.  SD control groups 
receiving tissue separation (SC and SS) have LPP values higher than their non-separated 
equivalents.  SS and RT both appear to have an effect in SD animals, with an n=1 in each group. 
 
 
 
Figure F.1 One week LPP values for Lewis and SD rats.  Values shown as average ± SEM.  *p<0.05. 
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Assessment of Lewis LPP values across all time points (Figure F. 2), including the 3 
week studies described in Chapter 7.0 show relatively constant values across all conditions at all 
time points, with the SUI group having values slightly higher than controls. 
 
 
 
Figure F.2 Lewis LPP values for 1, 3 and 4 week studies.  Values shown as average ± SEM.  *p<0.05 and n values 
are indicated on the bars. 
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Ex-Vivo Assessment of One Week Studies 
Pressure-diameter curves show that TEUW placement (bovine and/or rat) did have an effect on 
urethral mechanical properties in both Lewis (Figure F.4 and Figure F.5) and SD (Figure F.4 
and Figure F. 6) rats.  In both strains, the TEUW group(s) had curve shifted to the left of the 
other conditions in the proximal portion, indicating a decreased compliance due to the wrap.  It is 
also visible that in Lewis rats, SUI caused a shift to the right from Cont, indicative of an increase 
in compliance, in the proximal portion, while the SD rats showed this shift in the middle portion 
of the urethra.  Lewis SC, SS and RT groups showed little variation at the middle urethra, with 
all being shifted to the left, indicative of decreased compliance, than Cont.  SD rats showed a 
rightward shift of the SUI curve from other groups in the distal portion, but no other differences, 
while Lewis rats showed a rightward shift of the RT, SUI and BT curves from Cont, indicating a 
significant downstream effect. 
The trends in compliance for the Lewis (Figure F.7 and Figure F.9) and SD (Figure F.8 
and Figure F.10) groups are more easily seen in the stepwise compliance curves.  Both Lewis 
and SD animals showed the greatest spread in data at low pressures, with increased resistance 
(decreased compliance) with increased pressure.  The effects of SUI on proximal (Lewis) and 
middle (SD) urethral portions appear to be more predominant in the SD rat, with a greater 
variation between SUI and Cont.  TEUWs show little deformation at low pressures, giving 
support to the native urethra.  Distal properties are dependent upon experimental group in the 
Lewis rat, but only show an increased compliance at 0 mmHg in the SD rat. 
Beta stiffness values for Lewis rats (Figure F.11), were increased above SUI for SC, SUI 
and RT groups in the baseline state but similar to SUI in the passive state.  SC, BT and SUI 
groups all had higher beta stiffness values than Cont in SD rats. 
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Figure F. 3 Average baseline pressure-diameter curves for 1 week Lewis studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.4 Average baseline pressure-diameter curves for 1 week SD studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.5 Average passive pressure-diameter curves for 1 week Lewis studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
 263 
 
Figure F.6 Average passive pressure-diameter curves for 1 week SD studies.  SC = sham continent, SS = sham SUI, 
RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.7 Average baseline step-wise compliance curves for 1 week Lewis studies.  SC = sham continent, SS = 
sham SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.8 Average baseline step-wise compliance curves for 1 week SD studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.9 Average passive step-wise compliance curves for 1 week Lewis studies.  SC = sham continent, SS = 
sham SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
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Figure F.10 Average passive step-wise compliance curves for 1 week SD studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
 268 
 
Figure F.11 Beta stiffness values for 1 week Lewis studies.  SC = sham continent, SS = sham SUI, RT = rat TEUW, 
BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM for n=2, where n=1 for all 
other groups. 
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Figure F.12 Beta stiffness values for 1 week SD studies.  SC = sham continent, SS = sham SUI, RT = rat TEUW, 
BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM for n=2, where n=1 for all 
other groups. 
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Ex-Vivo Assessment of Four Week Studies 
Four weeks following implantation, TEUWs appear to still be providing support to the proximal 
urethra, with curves shifted to the left of the others in both the baseline and passive states 
(Figure F.13A and Figure F.14A).  SC shows a proximal P-D curve similar to Cont animals, 
however it is shifted to the left of Cont in the middle urethra.  SUI shows a middle curve similar 
to RT in the baseline state (Figure F.13B), both of which are shifted to the left of the Cont curve.  
In the distal urethra, SUI shows the only effect, shifting the curve to the right of all others in both 
baseline and passive states (Figure F.13C and Figure F.14C). 
Step-wise compliance curves (Figure F. 15 and Figure F .16) show that the greatest 
spread in data between groups occurs at low pressures (0-6 mmHg), with the highest compliance 
values generally occurring at 0 and 2 mmHg.  These plots more clearly show the lowest 
compliance in the RT and BT groups in the proximal urethra and the Cont group showing the 
greatest compliance at low pressures in both the proximal and middle urethra in the baseline state 
(Figure F.15A-B). 
Beta stiffness values were similar for all urethral portions in SS and Cont groups in both 
the baseline and passive states (Figure F. 17).  SC and SUI greatly increased middle stiffness, 
while RT increased proximal values from Cont.  Distal baseline stiffness values appeared 
independent of experimental group, but SC and RT were much greater than Cont in the passive 
state. 
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Figure F.13 Average baseline pressure-diameter curves for 4 week Lewis studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM. 
 272 
 
Figure F.14 Average passive pressure-diameter curves for 4 week Lewis studies.  SC = sham continent, SS = sham 
SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM for 
n=2, where all other groups are n=1. 
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Figure F.15 Average baseline step-wise compliance curves for 4 week Lewis studies.  SC = sham continent, SS = 
sham SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM 
for n=2, where n=1 for all other groups. 
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Figure F.16 Average passive step-wise compliance curves for 4 week Lewis studies.  SC = sham continent, SS = 
sham SUI, RT = rat TEUW, BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM 
for n=2, where n=1 for all other groups. 
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Figure F.17 Beta stiffness values for 4 week Lewis studies.  SC = sham continent, SS = sham SUI, RT = rat TEUW, 
BT = bovine TEUW, and Cont = untouched continent.  Data shown as average ± SEM for n=2, where n=1 for all 
other groups. 
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Histology 
Histology in the Lewis urethra (Figure F.18) showed a large cellular infiltration of the BT at 1 
week, but remodeling and collagen production within the RT at the same time point.  Both 
TEUWs degraded over time and were replaced with collagen.  By 4 weeks the TEUW had 
completely degraded.  No large variations under other experimental conditions were ovserved. 
Summary 
These preliminary studies indicate that SUI, as a result of pudendal nerve transection, affects the 
urethra of Lewis and SD rats differently.  Lewis rats showed no change in LPP values, while SD 
rats showed a decreased LPP in the presence of SUI.  Although Lewis rats showed no changes in 
LPP over all experimental conditions, SD rats showed an increasing trend in LPP with TEUW 
treatment, bringing LPP values closer to that of SC controls.  Lewis rats also appeared to show 
more of a proximal urethra response (increased compliance), while SD rats showed a mid-
urethral response to SUI.  Both groups indicate that TEUW placement provides support to the 
proximal urethra as seen in the resistance pressure increases.  It does appear that separation of 
the urethra from the vagina may cause increases in urethral resistance due to the increased LPP 
values of SC, SS and BT groups in the SD model, but the low n value and lack of response seen 
in Lewis values did not confirmation of this trend.  Histology indicates that rat fibrinogen 
provides a better remodeling and decreased inflammatory response when compared to bovine 
fibrinogen and was therefore used for the remaining in-vivo studies. 
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Figure F.18 Representative trichrome staining of 1, 3, and 4 week Lewis rat studies.  SC = sham continent, SS = 
sham SUI, RT = rat TEUW, BT = bovine TEUW.  Red = muscle/fibrin, blue/green = collagen, black = nuclei, where 
U = urethra and W = TEUW.  Images taken with a 4x objective.  All images can be found in Appendix H. 
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APPENDIX G 
 
IN-VIVO PRESSURE-DIAMETER CURVES 
1 WEEK LEWIS BASELINE 
 
Figure G.1 Baseline pressure-diameter curves for 1 week, Lewis SC proximal, middle and distal segments. 
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Figure G.2 Baseline pressure-diameter curves for 1 week, Lewis SS proximal, middle and distal segments. 
 
Figure G.3 Baseline pressure-diameter curves for 1 week, Lewis RT proximal, middle and distal segments. 
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Figure G.4 Baseline pressure-diameter curves for 1 week, Lewis BT proximal, middle and distal segments. 
 
Figure G.5 Baseline pressure-diameter curves for 1 week, Lewis SUI proximal, middle and distal segments. 
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Figure G.6 Baseline pressure-diameter curves for 1 week, Lewis Cont proximal, middle and distal segments. 
1 WEEK LEWIS PASSIVE 
 
Figure G. 7 Passive pressure-diameter curves for 1 week, Lewis SC proximal, middle and distal segments. 
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Figure G. 8 Passive pressure-diameter curves for 1 week, Lewis SS proximal, middle and distal segments. 
 
 
Figure G.9 Passive pressure-diameter curves for 1 week, Lewis RT and BT proximal, middle and distal segments. 
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Figure G.10 Passive pressure-diameter curves for 1 week, Lewis SUI proximal, middle and distal segments. 
1 WEEK SD BASELINE 
 
Figure G.11 Baseline pressure-diameter curves for 1 week, SD BT, Cont and SC proximal, middle and distal 
segments. 
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Figure G.12 Baseline pressure-diameter curves for 1 week, SD SUI proximal, middle and distal segments. 
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1 WEEK SD PASSIVE 
 
Figure G.13 Passive pressure-diameter curves for 1 week, SD SC, Cont and BT proximal, middle and distal 
segments. 
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Figure G.14 Passive pressure-diameter curves for 1 week, SD SUI proximal, middle and distal segments. 
4 WEEK LEWIS BASELINE 
 
Figure G.15 Baseline pressure-diameter curves for 4 week, Lewis SC proximal, middle and distal segments. 
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Figure G.16 Baseline pressure-diameter curves for 4 week, Lewis SS and SUI proximal, middle and distal 
segments. 
 
 
Figure G.17 Baseline pressure-diameter curves for 4 week, Lewis Cont, RT and BT proximal, middle and distal 
segments. 
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4 WEEK LEWIS PASSIVE 
 
Figure G.18 Passive pressure-diameter curves for 4 week, Lewis Cont, RT and BT proximal, middle and distal 
segments. 
 
 
Figure G.19 Passive pressure-diameter curves for 4 week, Lewis SC proximal, middle and distal segments. 
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Figure G. 20 Passive pressure-diameter curves for 4 week, Lewis SS and SUI proximal, middle and distal segments. 
3 WEEK LEWIS BASELINE 
 
Figure G. 21 Baseline pressure-diameter curves for 3 week, Lewis SC proximal, middle and distal segments. 
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Figure G.22 Baseline pressure-diameter curves for 3 week, Lewis SC and SS proximal, middle and distal segments. 
 
 
Figure G.23 Baseline pressure-diameter curves for 3 week, Lewis SS proximal, middle and distal segments. 
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Figure G.24 Baseline pressure-diameter curves for 3 week, Lewis RT proximal, middle and distal segments. 
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Figure G.25 Baseline pressure-diameter curves for 3 week, Lewis RT and BT proximal, middle and distal segments. 
LEWIS 3 WEEK PASSIVE 
 
Figure G.26 Passive pressure-diameter curves for 3 week, Lewis SC proximal, middle and distal segments. 
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Figure G.27 Passive pressure-diameter curves for 3 week, Lewis SS proximal, middle and distal segments. 
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Figure G.28 Passive pressure-diameter curves for 3 week, Lewis RT proximal, middle and distal segments. 
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Figure G.29 Passive pressure-diameter curves for 3 week, Lewis SC, RT, BT proximal, middle and distal segments. 
OVARIECTOMY BASELINE 
 
Figure G.30 Baseline pressure-diameter curves for control proximal, middle and distal segments. 
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Figure G.31 Baseline pressure-diameter curves for control proximal, middle and distal segments. 
 
 
Figure G.32 Baseline pressure-diameter curves for sham Ov proximal, middle and distal segments. 
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Figure G.33 Baseline pressure-diameter curves for sham Ov proximal, middle and distal segments. 
 
 
 
Figure G.34 Baseline pressure-diameter curves for Ov proximal, middle and distal segments. 
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Figure G.35 Baseline pressure-diameter curves for Ov proximal, middle and distal segments. 
 
 
 
Figure G.36 Baseline pressure-diameter curves for Ov proximal, middle and distal segments. 
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Figure G.37 Baseline pressure-diameter curves for Ov proximal, middle and distal segments. 
OVARIECTOMY PASSIVE 
 
Figure G.38 Passive pressure-diameter curves for control proximal, middle and distal segments. 
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Figure G.39 Passive pressure-diameter curves for control proximal, middle and distal segments. 
 
 
Figure G.40 Passive pressure-diameter curves for sham Ov proximal, middle and distal segments. 
 301 
 
Figure G. 41 Passive pressure-diameter curves for Ov proximal, middle and distal segments. 
 302 
 
Figure G.42 Passive pressure-diameter curves for Ov proximal, middle and distal segments. 
ALPHABUNGAROTOXIN BASELINE 
 
Figure G.43 Baseline pressure-diameter curves for Lewis alphabungarotoxin proximal, middle and distal segments. 
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Figure G.44 Baseline pressure-diameter curves for Lewis alphabungarotoxin proximal, middle and distal segments. 
 
 
 
Figure G.45 Baseline pressure-diameter curves for SD alphabungarotoxin proximal, middle and distal segments. 
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Figure G.46 Baseline pressure-diameter curves for SD alphabungarotoxin proximal, middle and distal segments. 
ALPHABUNGAROTOXIN PASSIVE 
 
Figure G. 47 Passive pressure-diameter curves for Lewis alphabungarotoxin proximal, middle and distal segments. 
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Figure G.48 Passive pressure-diameter curves for SD alphabungarotoxin proximal, middle and distal segments. 
 306 
3 WEEK SD ACTIVE 
 
 
Figure G.49 Active curves for SC middle segment. 
 307 
 
 
Figure G.50 Active curves for SS middle segment. 
 308 
 
Figure G.51 Active curves for RT middle segment. 
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APPENDIX H 
HISTOLOGY 
1 WEEK TRICHROME 
 
Figure H.1 Representative Masson’s Trichrome for 1 week RT, SC and SS. 
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Figure H.2 Representative Masson’s Trichrome for 1 week Lewis Cont, SC, RT and SUI. 
 311 
 
Figure H. 3 Representative Masson’s Trichrome for 1 week Cont, SUI, and BT. 
 312 
 
Figure H. 4 Representative Masson’s Trichrome for 1 week BT and SUI. 
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3 WEEK LEWIS TRICHROME 
 
Figure H.5 Representative Masson’s Trichrome for 3 week SC. 
 314 
 
Figure H.6 Representative Masson’s Trichrome for 3 week SC and SS. 
 315 
 
Figure H.7 Representative Masson’s Trichrome for 3 week SC and RT. 
 316 
 
Figure H.8 Representative Masson’s Trichrome for 3 week RT. 
 317 
 
Figure H.9 Representative Masson’s Trichrome for 3 week RT and BT. 
 318 
 
Figure H.10 Representative Masson’s Trichrome for 3 week SC and SS. 
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3 WEEK SD TRICHROME 
 
Figure H.11 Representative Masson’s Trichrome for 3 week RT and SS. 
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Figure H.12 Representative Masson’s Trichrome for 3 week RT and SS. 
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Figure H.13 Representative Masson’s Trichrome for 3 week Cont, RT and SS. 
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4 WEEK TRICHROME 
 
Figure H.14 Representative Masson’s Trichrome for 4 week RT, SC and SUI. 
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Figure H.15 Representative Masson’s Trichrome for 4 week BT, Cont, SC and SUI. 
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3 WEEK IN-VIVO PICROSIRIUS RED 
 
Figure H. 16 Representative PSR for 3 week SC and SS experiments. 
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Figure H.17 Representative PSR for 3 week SC and RT experiments. 
 326 
 
Figure H. 18 Representative PSR for 3 week SS and RT experiments. 
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BIOREACTOR IMMUNOFLUROESCENCE 
 
Figure H.19 Representative MHC and SMA staining for Mo, MoT and T0 bioreactor conditions. 
 328 
 
Figure H.20 Representative MHC and SMA staining for Mo, MoT and SF bioreactor conditions. 
 329 
 
Figure H.21 Representative MHC and SMA staining for Mo, T0 and SF bioreactor conditions. 
 330 
 
Figure H.22 Representative MHC and SMA staining for MoT, T0 and SF bioreactor conditions. 
 331 
 
Figure H.23 Representative MHC and SMA staining for Mo and MoT bioreactor conditions. 
 332 
 
Figure H.24 Representative MHC and SMA staining for Mo and MoT bioreactor conditions. 
 333 
IN-VIVO IMMUNOFLUROESCENCE 
 
Figure H.25 Representative SMA staining for RT, SC and SS 3 week studies. 
 334 
 
Figure H.26 Representative CALP staining for RT, SC and SS 3 week studies. 
 335 
 
Figure H.27 Representative CALP staining for RT, SC and SS 3 week studies. 
 336 
 
Figure H.28 Representative MHC staining for RT 3 week studies. 
 337 
 
Figure H.29 Representative MHC staining for RT, SC and SS 3 week studies. 
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